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Abstract 
The SEURAT-1 methods are here collected together and reported in the format of the 
database service that ensures OECD compliant descriptions. The information provided 
for each method is provided as reported and publicly available in the EURL ECVAM 
DataBase service on Alternative Methods (DB-ALM) developed and maintained by the 
Commission's Joint Research Centre (http://ecvam-dbalm.jrc.ec.europa.eu). 
The aim of the FP7 SEURAT-1 Research Initiative is the development of a long-term 
research strategy leading to pathway-based human safety assessments in the field of 
repeated dose systemic toxicity testing of chemicals. The overall goal is to develop 
complementary theoretical, computational and experimental (in vitro) models that 
predict quantitative points of departure needed for human safety assessment and 
replace currently used animal testing. 
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Introduction 
One of the most valuable outputs of SEURAT-1 is the portfolio of cutting-edge 
computational and in vitro tools and methods that will underpin new animal-free 
approaches to the safety assessment. Several of them were already being applied in the 
SEURAT-1 case studies to demonstrate their utility in predicting toxicity and supporting 
decision making.  
The idea is that the SEURAT-1 Tools & Methods Catalogue only includes non-confidential 
information in a summarised and easy to read format – something that anyone can pick 
up and consult to see what is available. If there is interest in a particular method then 
more detailed information and generated data can be retrieved from the ToxBank Data 
Warehouse (http://toxbank.net/).  
The SEURAT-1 Scientific Expert Panel agreed the catalogued SEURAT-1 methods should 
be disseminated via the public EURL ECVAM DataBase service on Alternative Methods, 
(DB-ALM) developed and maintained by the Commission's Joint Research Centre.  
The DB-ALM is an online service (http://ecvam-dbalm.jrc.ec.europa.eu/) and provides 
standardised curated descriptions of over 250 alternative methods intended for use both 
in biomedical research and regulatory safety assessment and already includes 
information on methods developed and evaluated in other EU sponsored projects.  
The SEURAT-1 methods are collected together and reported in the format of the 
database service that ensures OECD compliant descriptions. All methods included in the 
database, can be updated at any time, also after the projects are finalized. It is also 
assumed that the currently provided collection of methods is not the final outcome but 
that there still will be additional methods to be included originating from SEURAT -1. 
Some SEURAT-1 partners were rather reluctant to submit their methods to be included 
in the catalogue, partly due to the interest to publish methods and related outcome in 
peer-reviewed papers without pre-emptying the results through the catalogue or any 
other publicly accessible database, but also because of the additional effort to provide 
summarised descriptions of the method. 
In this report we have included the SEURAT-1 overview and the methods currently 
available in the Seurat-1 Catalogue.  
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SEURAT-1 Tools & Methods Catalogue 
SEURAT-1 methods are intended for online dissemination through the DB-ALM as soon 
as new information is made available. An extract of the current status as of 
15th September 2016 is included hereafter.  
The compilation consists of method descriptions, contributed by each project. The 
dissemination medium are individual datasheets in pdf fromat, reviewed and compiled 
according to the harmonised content criteria, lay out and graphic style of the service.  
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Research Initiative - SEURAT-1 - Towards the Replacement of In Vivo Repeated Dose Systemic
Toxicity Testing (2011 - 2016)
Systemic Toxicity
Study goal
The aim of the SEURAT-1 Research Initiative is the development of a long-term research strategy leading
to pathway-based human safety assessments in the field of repeated dose systemic toxicity testing of
chemicals. The overall goal is to develop complementary theoretical, computational and experimental
( in vitro) models that predict quantitative points of departure needed for human safety assessment and
replace currently used animal testing.
Background
‘Safety Evaluation Ultimately Replacing Animal Testing’ (SEURAT) was presented as the target for
chemical testing in the Seventh Framework Programme (FP7) under the Health team in 2008. The
SEURAT Research Initiative started in January 2011 and is co-funded by the European Commission
Directorate-General for Research & Innovation through FP7, and Cosmetics Europe with a total budget of
EUR 50 million. The initiative was called SEURAT-1, indicating that this would be the first step in the
specific area of repeated dose systemic toxicity addressing the global long-term strategic target of
SEURAT to fundamentally change the way we assess the safety of chemicals, by superseding traditional
animal experiments with a predictive toxicology that is based on a comprehensive understanding of how
chemicals can cause adverse effects in humans.
Objectives
Formulate and implement a research strategy based on generating and applying knowledge of
mode-of-action.
1.
Develop highly innovative tools and methodology that can ultimately support regulatory safety
assessment.
2.
Demonstrate proof-of-concept at multiple levels, from theory to application.3.
Provide the blueprint for expanding the applicability domains - chemical, toxicological and
regulatory.
4.
Description
The SEURAT-1 Research Initiative is designed as a coordinated cluster of five research projects,
supported by a ‘data handling and servicing’ project (ToxBank) and a ‘coordination and support’ project
(COACH). Detailed and updated information on the research initiative is available at 
http://www.seurat-1.eu/.
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The projects of the cluster were:
Task: Stem cell differentiation for providing human-based organ specific target cells
to assay toxicity pathways in vitro.
Coordinator: Marc Peschanski, INSERM / i-STEM, France
Website: www.scrtox.eu
Task: Development of a hepatic microfluidic bioreactor mimicking the complex
structure and function of the human liver.
Coordinator: Catherine Verfaillie, KU LEUVEN, Belgium
Website: www.hemibio.eu
Task: Identification and investigation of human biomarkers in cellular models for
repeated dose in vitro testing.
Coordinator: Jürgen Hescheler, Klinikum der Universität Köln, Germany
Website: www.detect-iv-e.eu
Task: Development of systems biological tools for organotypic human cell cultures
suitable for long term toxicity testing and the identification and analysis of pathways
of toxicological relevance.
Coordinator: Elmar Heinzle, Universität des Saarlandes, Germany
Website: www.notox-sb.eu
Task: Delivery of an integrated suite of computational tools to predict the effects of
long-term exposure to chemicals in humans based on in silico calculations and
estimation techniques.
Coordinator: Mark Cronin, Liverpool John Moores University, UK
Website: www.cosmos-tox.eu
Task: Supporting integrated data analysis and servicing of alternative testing
methods in toxicology.
Coordinator: Barry Hardy, Douglas Connect, Switzerland
Website: http://toxbank.net/
Task: The coordination action, set up to optimise cooperation between the cluster
projects and to pave the way for future research.
Coordinator: Bruno Cucinelli, ARTTIC, France
Each project had an individual Description of Work and a list of deliverables to fulfil. These deliverables
are primarily contributing to the second SEURAT-1 objective on the development of new tools and
methods.
SEURAT1 identified a set of standard reference compounds (‘Gold Compounds’). They were chosen
based on their rich database and known mode-of-action. They are divided in groups based on the target
organ long-term toxicity. The three major groups being: hepatoxtoxic, cardiotoxic and renal toxic. More
information on the compounds has been collected by ToxBank at the Gold compounds wiki pages.
SEURAT-1 is also performing a series of proof-of-concept case studies on three different levels:
theoretical (Adverse Outcome Pathways constructs), systems (developing integrated systems of testing
methods to predict toxicity) and application (develop a quantitative safety assessment based on
SEURAT-1 methods).
For more information on SEURAT-1, an annual report is issued each year of the research initiative
(SEURAT-1, 2011-2016), which is downloadable at http://www.seurat-1.eu/ or you can request a copy by
writing to coach-office@eurtd.com.
Outcome
A valuable and easy accessible overview of the outcome of the SEURAT-1 projects will be collected in
DB-ALM, searchable as the SEURAT-1 tools and methods catalogue. 
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Status
The SEURAT-1 started in 2011 and will be finalised at the end of 2016. The research activities were
finalised at the end of 2015.
Remarks
Any updates of the SEURAT-1 tools and methods reported in DB-ALM will also be possible by SEURAT-1
partners after the end of the projects. Therefore, the documentation here collected is live and will not be
finalised by the end of 2016, but will constitute a permanent source of continuously developed and
refined alternative methods and related information for public access.
Sponsors
EUR 25 million funding are provided by the European Commission through FP7 HEALTH theme (DG for
Research & Innovation) and EUR 25 million by Cosmetics Europe.
Contact
COACH office: ARTTIC, Sara Vinklatova (coach-office@eurtd.com)
Member of the COACH team at JRC: Elisabet Berggren, DG JRC (elisabet.berggren@ec.europa.eu).
Main References
SEURAT-1 Annual Report, Eds. T. Gocht and M. Schwarz, Vol. 1, 2011.
SEURAT-1 Annual Report, Eds. T. Gocht and M. Schwarz, Vol. 2, 2012.
SEURAT-1 Annual Report, Eds. T. Gocht and M. Schwarz, Vol. 3, 2013.
SEURAT-1 Annual Report, Eds. T. Gocht and M. Schwarz, Vol. 4, 2014.
SEURAT-1 Annual Report, Eds. T. Gocht and M. Schwarz, Vol. 5, 2015.
HIgh resolution copies of the anaual reports can be downloaded from the project's website:
http://www.seurat-1.eu/pages/library/seurat-1-annual-report.php
Last update: 19 May 2016
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JRC 
 
 
HepaRG repeated and single dose exposure study for mitochondrial health 
and lipid accumulation 
This procedure was developed at JRC and evaluated in the Seurat-1 Research 
Initiative, launched by Cosmetics Europe and the European Commission with the 
long-term goal of achieving "Safety Evaluation Ultimately Replacing Animal Testing". 
It is a high throughput assay in 96-well plate format. It detects changes in 
mitochondrial membrane potential and lipid accumulation in of HepaRG cells, 
following repeated and single exposure to chemicals. High content imaging system 
was used for automated capture of fluorescence images and quantitative analysis. A 
detailed protocol is available as JRC Technical Report Nr 98147. 
Method Summary no 167……………………….…………………………………………15 
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DB-ALM Method summary n° 167 : HepaRG repeated dose exposure in vitro assay of
mitochondrial health and steatosis
Systemic Toxicity, Hepatotoxicity / Metabolism-mediated Toxicity
This high throughput experimental procedure detects changes in mitochondrial membrane potential and
lipid accumulation in of HepaRG cells, following repeated and single exposure to chemicals.
Fluorescently labeled live and fixed cells are analysed with high content imaging instrument. The
procedure was developed as a part of the EU Integrated Project Seurat-1.
1. General Information
Corresponding author(s):
EURL ECVAM, European Commission - Joint Research Centre Italy
Date of data sheet creation: 27 April 2016
Last version number: 1
Last update: 27 April 2016
Assay Throughput:
High Throughput Assay in 96-well plate format. Platforms used: Microlab STARlet , Microlab Star
(Hamilton, US), Cellomics ArrayScan® VTI (Thermo Scientific).
Status
Known Laboratory Use:
JRC (Italy)
Participation in Evaluation Studies:
This procedure was developed at JRC and evaluated in the Seurat-1 Research Initiative, launched by
Cosmetics Europe and the European Commission with the long-term goal of achieving "Safety
Evaluation Ultimately Replacing Animal Testing". More specifically, it is part of a SEURAT-1 Level 2 Proof
of Concept case study, formalized with a research contract between Cosmetics Europe and the European
Commission's Joint Research Centre (Contract No. 32485-COLIPA-2011-T1CD ISP).
2. Method Definition
Purpose of the Method
TYPE OF TESTING : Screening, Part of an integrated testing strategy
LEVEL OF TOXICITY ASSESSMENT : Hazard identification, Toxic potential
PURPOSE OF TESTING : Screen or priority setting, Mechanistic studies
Context of use
This procedure was created for the SEURAT-1 Project to address liver toxicity endpoints relevant for the
acute and repeated dose toxicity studies. Liver Adverse Outcome Pathways (AOPs) and their Key Events
(reviewed in detail by Landesmann, 2015; and Vincken, 2015) have been used as guidance in selection of
the most relevant endpoint assays. Selected assays were then adapted to the HTS platform to screen a set
of reference chemicals across the selected endpoints. The ultimate goal of the study is to provide input
data for high order analysis and modeling using cumulative data generated in the course of the Seurat-1
project.
Scientific Principle of the Method
Knowledge regarding molecular pathways leading to development of liver fibrosis, steatosis and
cholestasis was used to carefully to select the endpoints indicative of potential liver toxicity in this assay.
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These endpoints reflect either general organ (including liver) - toxic effects (such as cytotoxicity,
mitochondrial damage, apoptosis) or liver-specific ones (such as accumulation of lipid droplets
(steatosis)).
Human primary hepatocytes were used to study Cytochrome P450(CYP)-mediated metabolism and
induction following exposure to new drugs in humans in vitro. However, their usage is limited by the
restricted availability of liver tissue, their early phenotypic changes and their limited life-span.
Furthermore, primary hepatocytes exhibit large variability at the level of CYP activities and the
magnitude of induction after incubation with prototypical inducers - often greater than seen in vivo
situation (Guillouzo et al., 1993). Therefore, for high throughput studies an established hepatic cell line
woudl be more suitable. 
The human hepatoma cell line HepaRG displays hepatocyte-like functions and expresses drug
detoxifying enzymes at a relatively high levels drug transporter proteins and nuclear receptors, when
compared to cell lines like HepG2 (Kanebratt et Andersson, 2008). HepaRG cells were obtained from a
liver tumor of a female patient suffering from hepatocarcinoma and hepatitis C infection (Gripon et al.,
2002). Undifferentiated bipotent proliferating HepaRG progenitor cells start to differentiate towards
hepatocyte-like and biliary-like cells at confluence. If hepatocyte-like cells are selectively isolated and
cultured at high cell density, they proliferate only slightly, while still preserving their differentiation
status. However, when plated at low density, they transdifferentiate into hepatocyte and biliary lineages
through a bipotent progenitor stage (Cerec et al., 2007)
High content cell imaging can be used to detect changes in mitochondrial membrane potential and lipid
accumulation following the exposure of HepaRG cells in a wide range of treatments on a high
throughtput platform. The treatment scheme includes both single and repeated exposure scenarios to
approximate the effects of sub-chronic chemical exposure.
The assay is designed to observe cells that are still viable, (and therefore attached to the surface of the
well), but undergoing physiological changes due to chemical exposure. To achieve this, a combination of
four fluorescent molecular probes with non-overplapping excitation and emission spectra are used.
Procedure Description
Biological Endpoint and Measurement:
The method assesses four biologically relevant endpoints:
MITOCHONDRIAL FUNCTION is evaluated with the Mitochondrial Health Kit (Invitrogen, H10295),
measuring depolarization of mitochondrial membrane potential, which is considered a good indicator
of mitochondrial dysfunction.
CELL VIABILITY is evaluated with the Image-iT DEAD Green viability stain, which is included in the
Mitochondrial Health Kit. The stain is a marker of membrane permeability and its purpose is to
differentiate between healthy cells and those whose physiology due to toxic exposure has already been
slightly compromised.
LIPID ACCUMULATION is quantified with the LipidTOX Deep Red neutral lipid stain (Molecular
probes, H34477) which has an extremely high affinity for neutral lipid droplets, considered indicators
of chemically induced steatosis in HepaRG cells.
CELL NUMBER in each well is estimated by counterstaining fixed cells with Hoechst 33342 nucleic acid
stain. The fluoresce is directly proportional to the number of nuclei in the sample.
Endpoint Value:
SIGNAL TO NOISE RATIO (S/N) is calculated for each chemical and each concentration tested
TRESHOLD value is used to assess the significance of Signal to Noise (S/N) ratio. E.g. threshold of -3 or
less (for downwards effect) and +3 or more (for upwards effect) indicates a significant effect.
EC50 - the half maximal effective concentration of a test substance
Experimental System:
Monolayer culture of human hepatoma cell line HepaRG™. The cells are a human hepatic progenitor
cell line that retains many characteristics of primary human hepatocytes. They are patented
(PCT/FR02/02391 of July 8, 2002) and can only be used under MTA from a licensed distributor.
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Metabolic Competence:
Experimental system is metabolically competent
Exposure regime:
Application type : Repeated dose
Application volume : 85 µl
Dosage : Series of 11 dillutions by factor 1:3. 
Chemical applied once or refreshed every 6 hours 
Min : 0 
Max : 250µM 
Exposure time : Min : 4 hours 
Max : 72 hours 
Controls used:
Positive Controls (PCs):
Cell viability (Dead Green stain) - Valinomycin 7.2 μM
Mitochondrial toxicity (MitoHealth stain)– Valinomycin 165 nM
Lipid droplets formation (LipidTOX stain) – Cyclosporine A 30 μM
Negative Control (NC):
DMSO 0.1 % (added to four wells in every 96-well plate)
Basic procedure:
Main sterp of the procedure are outlined in the Figure 1 below. Briefly: 72 hours after the seeding,
HepaRG cells are exposed to a set of 90 test chemicals and 2 positive controls at 11 concentrations
(dillution 1:3). In each plate, 4 negative control wells (cells treated with only DMSO) are included.
Figure 1: Outline of the main steps of the procedure
The cells are incubated at 37°C, 5% CO2, 100% humidity for 24 or 72 hours. The medium, containing the
chemicals is refreshed every 6h. All the treatment procedures are fully automated using the STAR
platform (Hamilton) and the entire process is managed by Hamilton software.
After the exposure cells are stained with Mitochondrial Health kit for 30 min. Afterwards the cells are
fixed with 4% Formaldehyde and counterstained with Hoechst 33342 for 15 min. After fixation the cells
are washed with PBS once and LipidTox staining solution is added for 30 min. The plates are stored
overnight at +4°C, prior to high content imaging with Cellomic ArrayScan® (Thermo Scientific). The
image acquisition is done using a set of four filters, selective for each fluorophore. Further details are
made available in the JRC Technical Report No. 98147 (Jossens et al., 2015).
Quality/Acceptance Criteria
Culture conditions
All procedures must be carried out under aseptic conditions and in the sterile environment of a laminar
flow cabinet (class II biological hazard standard). All methods and procedures must be adequately
documented and raw data archived for historical reference.
Undifferentiated HepaRG cells are used as starting culture in this assay. The cells must have to be free of
contamination and cannot be passaged more than 20 times. At passage 21 the cells will to go to
senescence.
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Chemical solubility
Poor chemical solubility can significantly affect the results of a toxicological study. To identify potential
solubility issues in an objective and quantitative manner, the JRC procedure uses a nephelometric
analysis (see page 15 of the JRC Technical Report). Highest concentration of a compound in DMSO is 250
mM. If there is precipitation, serial dilutions are preared until no precipitation is observed. These
solutions, and further 1:1000 dilutions in the culture medium are then tested by nephelometer. Solutions
with turbidity level higher than 10 nephelometric turbidity units are regarded as insoluble, and
necesitate further dilluton of both stock and working solutions. For each chemical, the highest soluble
concentration (used for the testing) is recorded in Annex 2 of the JRC Technical Report No. 98147
(Jossens et al., 2015).
Control plates
To ensure the quality of each run several controls are included: solvent control and the positive controls
for the enpoints measured (cell viability, mitochondrial potential and lipid accumulation). For a run to be
considered valid each normalised positive control should produce a clear dose-reponse curve, the
replicate curves shoudl overlap and there is a statistically significant effect at the relevant concentrations.
In particular the cells treated with the Valinomycin dilution range starting form 165 μM should display a
significant decrease of mitochondrial potential but no detectable loss in viability or cell number.
HTS specific issues
In some runs, certain plates showed a position effect i.e. the behaviour of cells depends on the where the
well was located on the plate. In order to remove this effect, an additional mathematical approach can
be applied and it should be documented in the data analysis files. Another approach used at JRC to
counter the positional effects was to randomly rotate the position of the negative control.
Data Interpretation and/or Prediction Models
Data Analysis:
Normalisation 
Raw data of multiple read outs are captured for all 96-well plates containing cells treated with chemicals,
solvent controls and positive controls. Further processing is done in Excel as follows: an averge of the
negative contol per each plate ( NC c ) and stadard deviation of all negative controls across all plates ( SD 
nc ) are calulated and used to normalise the read out for each well.
Interpretation 
For each chemical the normalised data are plotted against the concentration tested and the confidence
interval and the strength of the observed effect is calulated. Note that for the endpoints such as
mitochondrial depolarisation the observed effects for the chemicals tested at the JRC were both positive
and negative.
This part of the assay is still in development and current status is presented in detail in the JRC Technical
Report No. 98147 (Jossens et al., 2015).
Prediction Model (PM):
Not available.
3. Method Performance
Robustness of the Method
Within-laboratory reproducibility:
4 runs with 90 chemicals each were conducted at the JRC. The method was judged by the developers as
highly reproducible. The results are now being analised in the preparation of the final Seurat-1 case
study (Joossens at el., 2015).
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Test Compounds
90 chemicals with well documented mode of action and present or absent hetapatotoxic effects were
tested in the JRC study and were mostly pharmaceuticals (selection was based on the work of O'Brien et
al., 2006; Xu et al., 2008; Gomez-Lechon et al., 2010; Porceddu et al., 2012 and Garside et al., 2014). The
complete list, including the highest soluble concentrations is included in the Annex 2 of the JRC
Technical Report No. 98147 (Jossens et al., 2015).
Applicability:
The method is suitable for testing of pure solid and liquid organic and inorganic chemicals provided that
they are soluble in both DMSO and culture medium to a sufficient extent. It is not suitable for volatile
substances.
4. Discussion
Ethical issues and considerations for 3R’s impact 
The ultimate goal of the Seurat-1 Research Initiative is to develop complementary theoretical,
computational and experimental ( in vitro) models that predict quantitative points of departure needed
for human safety assessment and replace currently used animal testing in the field of repeated dose
systemic toxicity testing of chemicals.
The hepatotoxocity was one the main endpoints chosen by the consortium to study in depths as it is
known to be a major risk in the drug development and prolonged chemical exposure. The predictive
cpacity of the animal models is often limited and the AOP-based testing strategies gain momentum as
evidence-based and sound scientific approaches to the problem (Vinken, 2015).
The "HepaRG repeated dose exposure assay of mitochondrial health and steatosis" uses a well established
human cell line HepaRG which, when differentiated, displays hepatocyte-like characteristics including
morphology, expression of key metabolic enzymes, nuclear receptors and drug transporters (see e.g. 
http://www.heparg.com).
Potential for further development
The "HepaRG repeated dose exposure assay of mitochondrial health and steatosis" was developed with the
aim of providing information that can be used for detection and classification of potential liver toxicity. It
was a first a study of this kind, combining the currently best available in vitro model of liver cells, the high
throughput approach and physiologically relevant endpoints. Preliminary analysis of the data revealed
that whereas the methods is very reproducible and sensitive with the positive controls. However
matching the hepatotoxic effects of reference chemicals with the in vitro test results presented a
challenge. More data are needed from more chemicals or by including information of other relevant
events of the AOP by either expanding the assay with probes specific for other such as oxidative stress,
apoptosis, vesicle transport, or pooling the test results with datasets obtained with another method such
as CYP induction or transcriptiomic studies.
Other methods for assessing hepatotoxicity
In 2008 DB-ALM has compiled a thematic review of "Hepatotoxicity/ metabolism-mediated toxicity",
intended as an overall view about the information content on alternative methods provided at the time
the DB-ALM for the entire topic area (DB-ALM, 2008).
Another recomended extensive overview of the in vitro systems used to predict human hepatotoxicity
has been published by Hengstler et al. (2014). Here the authors disuss main available hepatocyte in vitro
systems and their possibilities as well as limitations in studying hepatotoxicity and ADME.
5. Contact Details
EURL ECVAM
Chemicals Safety and Alternative Methods Unit - European Union Reference Laboratory for Alternatives
to Animal Testing (EURL-ECVAM)
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European Commission - Joint Research Centre
Corresponding author
via E. Fermi 1
Ispra (VA) 21027
Italy
email: ecvam-contact@jrc.ec.europa.eu
telephone: 39 0332 7813527
Elisabeth Joossens
Senior statistitian
Chemicals Safety and Alternative Methods Unit - European Union Reference Laboratory for Alternatives
to Animal Testing (EURL-ECVAM)
European Commission - Joint Research Centre
Method developer / user
Via Enrico Fermi 2749
Ispra 21027
Italy
email: Elisabeth.JOOSSENS@ec.europa.eu
telephone: +39 0332 786785
Dr Tomislav Horvat
Research fellow
Chemicals Safety and Alternative Methods Unit - European Union Reference Laboratory for Alternatives
to Animal Testing (EURL-ECVAM)
European Commission - Joint Research Centre
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6. Abbreviations & Definitions
AOP: Adverse Outcome Pathway
HTS: High Throughput Screening
JRC: Joint Research Center
NC: Negative control
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SEURAT-1: FP7 EU Integrated Project "Safety Evaluation Ultimately Replacing Animal Testing" . The aim
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chemicals. Project Website: http://www.seurat-1.eu/ 
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DB-ALM Method summary n° 165 : Differentiation of induced-pluripotent stem cells into
post-mitotic neurons and glial cells (mixed culture)
Stem cell culture method, Systemic Toxicity, Neurotoxicity
This method describes all the stages of differentiation of human induced-pluripotent stem cells into
neural precursor cells and further into mixed cultures of post-mitotic neurons and glial cells.
1. General Information
Corresponding author(s):
Dr Anna Price, European Commission - Joint Research Centre 
Date of data sheet creation: 05 June 2015
Last version number: 1
Last update: 05 June 2015
Proprietary and/or Confidentiality Issues:
For this method the IMR90 cell line (fetal lung fibroblasts) was reprogrammed towards pluripotency
generating human induced pluripotent stem cells (hiPSCs) by I-Stem (Evry, France) and kindly provided.
On 8th October 2012 a material transfer agreement was signed between I-Stem and JRC where the hiPSC
(IMR90) cell culture has been made available to JRC within the frame of Scr&Tox project, for non-profit
research purposes.
Assay Throughput:
Not applicable
Status
Known Laboratory Use:
EURL ECVAM
Participation in Evaluation Studies:
The neural differentiation protocol for human induced pluripotent stem cells (hiPSCs) has been
developed at the JRC and applied to mechanistic studies of the toxicity pathways triggered by the
exposure to a chemical.
Pistollato et al. (2014) has developed a novel hiPSC-based in vitro model and assay for measuring the
perturbations of the CREB pathway which is crucial in the development of the central nervous system
(CNS), including neuronal survival, neurite outgrowth, precursor proliferation and neuronal
differentiation (Lonze et al., 2002).
The hiPSC-derived neuronal cultures are considered as useful tools to study
chemical-induced effects on developing human neuronal cells, providing a
valuable alternative to the use of animal in vitro cell models, including
cancer cell lines that often do not reproduce physiological cell biology
(Pistollato et al., 2014).
In the course of the Scr&Tox project ( http://www.scrtox.eu/ ) two SOP's were developed for the
expansion and differentiation of the hiPSC-derived neural stem cells (NSCs), available from DB-ALM as:
DB-ALM Protocol n° 165: Standard operating procedure for differentiation of human induced
pluripotent stem cells into post-mitotic neurons and glial cells (mixed culture)
DB-ALM Protocol n° 166: Standard operating procedure for expansion of rosette-derived neural
stem cells
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2. Method Definition
Purpose of the Method
TYPE OF TESTING : Replacement (partial), Part of an integrated testing
strategy
Context of use
Currently the method is used for Non-regulatory purposes, mainly for basic research.
This method summary describes the procedure for differentiation of the hiPSCs into neural precursors
(NSCs) and further into mixed cultures of post-mitotic neuronal and glial cells.
Human pluripotent stem cells (PSCs) offer a unique opportunity to develop a wide variety of human
cell-based test systems because they may be expanded indefinitely and triggered to differentiate into any
cell type. The differentiation of hiPSCs into mixed neuronal/glial culture and the establishment of stem
cell-based assays for neurotoxicology could provide proof of concept on the use of these cell models for
identifying relevant "toxicity pathways" which result in adverse health effects.
Neither the exposure regime nor endpoint measurements are currently defined in both DB-ALM
Protocols n° 165 and 166 and are based on case by case studies (fit for purpose).
Scientific Principle of the Method
hiPSCs are widely used in the areas of basic research, regenerative medicine and toxicology. They are
considered as a powerful tool for drug screening based on in vitro testing strategies. This expertise can be
further applied for the development of new human in vitro tests which address current challenges in
safety assessments. In particular, those related to different susceptibility to toxicants in human
populations as stem cells can be obtained for individuals, leading to personalised medicine and toxicity
studies. It allows avoiding interspecies variations since extrapolation of animal data is not required.
Additionally, hiPSCs might in the future replace human embryonic stem cell-derived cultures, as they do
not represent an ethical and/or legislative challenge for application in modern toxicity assays (Pistollato
et al., 2012; Canovas-Jorda et al., 2014; Grskovic et al., 2014).
A major challenge for the application of stem cell-based models in toxicology and drug discovery is to
demonstrate that they can reproducibly generate a significant range of toxicologically relevant cell types
and that these cells provide characteristics and responses typical of human tissue types (Trosko and
Chang, 2010). The general problem is that cells derived from iPSCs often do not differentiate and, for this
reason, further effort is required to optimise existing differentiation protocols in order to be able to obtain
functionally and terminally differentiated cells (including the neuronal lineage).
Amongst the differentiated cell types that can be obtained from PSCs and used for toxicology studies,
neurons have been the most extensively studied (Kumar et al., 2012). HiPSC cells can be indefinitely
expanded and efficiently differentiated into neuronal derivatives, including different regionalized
neuronal subtypes, glial cells and peripheral neurons.
Neuronal models derived from hiPSCs are particularly suitable for developmental neurotoxicity testing,
including application within a battery of tests for a chemical-induced neural teratogenicity. However
before any testing is performed, these cultures have to be carefully characterized at cellular, molecular
and functional level in order to define how they reflect the functionality of the in vivo central and
peripheral nervous systems (Trosko and Chang, 2010; Pistollato et al., 2012).
The differentiated cell population should be shown to express at an appropriate level specific neural
related markers, such as β-III-tubulin, microtubule-associated protein 2 (MAP2), neurofilament 200
(NF200) and Synapsin-I for mature neurons (Pistollato et al., 2012 and 2014). Once a marker panel has
been selected, specific quality control methods are needed to establish acceptability criteria, which
should also include cell functionality. Moreover, PSC-derived neurons should be proven to be
electro-physiologically active and thus, specific quality control metrics for the functional activity and
threshold levels for a positive phenotype need to be defined in order to properly judge the suitability of
these cells for use in a toxicology assay.
The demonstration of the reliability and relevance of PSC-based in vitro toxicity tests for a given purpose
is mandatory for the use of PSCs in regulatory toxicity testing. A high level of standardisation of the
neuronal differentiation process is required in order to ensure the establishment of robust test systems
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(Pistollato et al., 2012).
Procedure Description
Experimental System:
hiPSs (IMR90-hiPSC culture) - Human induced-pluripotent stem cells (hiPSC) derived from human
foetal lung fibroblast (IMR90), reprogrammed towards pluripotency by retroviral transduction of Oct4
and Sox2, using the pMIG vectors. Created and distributed by I-Stem (Evry, France).
Metabolic Competence:
Not known
Exposure regime:
Application volume : Adjusted for each case study 
Dosage : Adjusted for each case study 
Exposure time : Adjusted for each case study 
Basic procedure:
The current method describes the differentiation of IMR90-hiPSCs into post-mitotic neurons and glia.
The cells are seeded at appropriate density and medium and cultured for 10 days. The cells begin to form
colonies which are cut out and plated on low attachment petri dishes where they form embryoid bodies
(EBs) floating in the medium. In a further stage, EBs are plated on poly-ornithine/laminin-coated plates
and in the presence of the neural induction medium, and begin to generate visible rosettes after 5-8
days. Finally, rosettes are cut out, resuspended in neural differentiation medium and cultured for 21
days, where they generate post-mitotic neuronal and glial cells (see Figure 1 below).
Figure 1: Representative scheme summarizing the described neuronal differentiation protocol.
Quality/Acceptance Criteria
Good Cell Culture Practice (GCCP) principles are recommended (Coecke et al., 2005; Pistollato et al.,
2012).
3. Method Performance
Robustness of the Method
General performance measures:
The current method summary accompanies a robust and relatively rapid protocol: DB-ALM n°165 :
Standard operating procedure for differentiation of human induced pluripotent stem cells into
post-mitotic neurons and glial cells (mixed culture).
The protocol is developed for the neural differentiation of hiPSCs into heterogeneous cultures of mixed
post-mitotic neurons (GABA-ergic, glutamatergic and dopaminergic neurons) and also glial cells
(astrocytes, oligodendrocytes and microglia). The latter are fundamental for myelin formation, for the
physiological functionality of neuronal networks and for neuronal homeostasis (Ghosh et al., 2011).
The reproducible differentiation protocol, yielding heterogenous cultures of relevant cell types, including
progenitors and terminally differentiated cells, is necessary to predict physiological in vivo cellular
responses to toxicant exposure (Trosko and Chang, 2010). Indeed, this cell model could be used to
perform a wider screening of chemicals, toxic not only for neurons.
The obtained neuronal cultures are suitable for studying different neuronal-related signalling pathways,
such as the cyclic AMP response element binding (CREB) protein pathway (Pistollato et al., 2014). When
strong perturbations of these pathways occur as a consequence of toxicant exposures, these pathways
can be considered as "toxicity" pathways. Pathway perturbations can be monitored by mean of
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can be considered as "toxicity" pathways. Pathway perturbations can be monitored by mean of
cell-specific (neuronal and glial) physiological and functional readouts (e.g., immunocytochemical
analysis and high content imaging, qPCR, multi-electrode array (MEA) analysis).
Moreover, there could be an association of the neuronal cultures with chemical perturbations of
signalling pathways that are studied from other research groups in order to evaluate the relevance of
selected “toxicity” pathways in conjunction with cell type specific functional readouts.
Generally, the obtained data should be compared across diverse in vitro models by extrapolation and
further aligned to in vivo available data sets, in order to bridge the gap between in vivo and in vitro
testing and prove the reliability of in vitro results.
Test Compounds
Applicability:
The iPSC-derived neuronal and glia cells have been used for testing CREB pathway perturbations elicited
upon exposure to 25μM 2-napthol-AS-E-phospate (KG-501) (Pistollato et al., 2014). The CREB pathway is
crucial in the development of the central nervous system, including neuronal, survival, neurite
outgrowth, precursor proliferation and neuronal differentiation (Lonze et al., 2002).
KG-501 is a specific CREB signalling inhibitor (used as a positive control), which was administered in a
time-course mode in the hiPSC-derived neuronal/glial cultures. The results have revealed that CREB
pathway is expressed in IMR90-hiPSC-derived neurons and its inhibition is relevant to neurotoxicity
testing. This cellular model might be a useful tool for studying chemical effects on human neuronal cells,
providing a valuable alternative to the use of other in vitro animal models (Pistollato et al., 2014).
4. Discussion
Ethical issues and considerations for 3R’s impact 
The use of hiPSC cultures (derived from adult cells, such as fibroblasts) does not create as many ethical
concerns as those linked to the use of human embryonic stem cells.
The presented method describes a robust and relatively rapid (28 days) protocol for the differentiation of
hiPSCs (IMR90-hiPSCs) into heterogeneous cultures of post-mitotic neurons and glia.
Currently, the use of PSC-derived, and particularly, of hiPSC-derived cells for regulatory toxicity testing
has been taken into great consideration (Kumar et al., 2012). Such test system offer several advantages,
such as the capability to: (i) generate disparate and toxicologically relevant cell types, (ii) avoid the
diverse national legislative policies regulating the use of human embryonic stem cell-derived models
(hESCs), (iii) decrease/replace the use of animal and cancer-derived cell lines by human cell culture, and
(iv) avoid complex extrapolation issues associated with use of animal models.
In this regard, heterogeneous cell derivatives, such as the hiPSC-derived neuronal and glial cultures,
rather than homogenous cell cultures, might better mimic possible toxicological responses of human
tissues in vivo. 
Potential for future development
It would be beneficial to develop a working cell bank of neural stem cells (NSCs) and, when needed,
further differentiate them into neurons and glia instead of direct differentiation of rosettes into mature
neuronal cultures. This could further improve the robustness and reproducibility of the method. The
procedure described in the DB-ALM Protocol n° 166 was developed for that purpose and shows that the
expansion and cryostorage of NSC's is feasible and the cells retain diffrentiation potential.
In order to demonstrate the value of neuronal/glial cell cultures derived from PSCs for toxicology,
establishing and maintaining cell phenotypes over long-term cultures is of pivotal importance, as well as
achieving automated cell production and differentiation. The development of mass cell production of
hiPSC-derived neurons can be a challenging task, although mandatory for the final transfer of an assay
on industrial platforms which could allow the automated screening for potential neurotoxicant.
Related methods
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Related methods
One of the aims of the EU Integrated Project SCR&Tox was to assess the activation of Keap1-Nrf-2-ARE
pathway, which is related to oxidative stress, across different cell types in order to evaluate the relevance
of this pathway as a general (horizontal) “toxicity” pathway in conjunction with cell type specific
functional readouts, including neural cells. In order to address the multiple aspects of neurotoxicity,
three different neuronal models have been established from different stem cell sources:
hiPSC-derived neuroepithelial-like stem cells differentiated into motor neuronsa.
human embryonic stem cells differentiated into post-mitotic neuronsb.
mixed post-mitotic neuronal and glial cultures derived from hiPSCs (JRC's STU approach).c.
One of the advantages of the JRC method is that the hiPSCs can be used for regulatory toxicity testing
without the diverse legislative policies tha are required for the use of human embryonic stem cells.
Another important aspect of this method is that the established differentiation protocol leads to
heterogeneous cultures of post-mitotic neurons together with glial cells (see DB-ALM Protocol No. 165)
which might better mimic toxicological responses of human tissues in vivo, than homogenous neuronal
cultures (without glial cells).
One of the limitations of the DB-ALM Protocol No. 165 was the number of differentiated cells produced
in one experimental run, which might be insufficient for large scale (high-throughput) chemical exposure
studies. To overcome this limitation, an additional protocol has been developed by the JRC, which allows
the expansion of rosette-derived NSCs, before further differentiation is induced (see DB-ALM Protocol
No. 166).
5. Contact Details
Dr Anna Price
Chemicals Safety and Alternative Methods Unit - European Union Reference Laboratory for Alternatives
to Animal Testing (EURL-ECVAM)
European Commission - Joint Research Centre
Corresponding author
via E. Fermi 1
Ispra (VA) 21027
email: Anna.Price@ec.europa.eu
telephone: 39 0332 7813527
last contact update: 30 May 2013
Dr Dimitra Zagoura
Chemicals Safety and Alternative Methods Unit - European Union Reference Laboratory for Alternatives
to Animal Testing (EURL-ECVAM)
European Commission - Joint Research Centre
Method developer / user
via E. Fermi 1
Ispra (VA) 21027
telephone: 39 0332 7813527
Dr David Canovas-Jorda
Chemicals Safety and Alternative Methods Unit - European Union Reference Laboratory for Alternatives
to Animal Testing (EURL-ECVAM)
European Commission - Joint Research Centre
Method developer / user
via E. Fermi 1
Ispra (VA) 21027
telephone: 39 0332 7813527
Dr Francesca Pistollato
Chemicals Safety and Alternative Methods Unit - European Union Reference Laboratory for Alternatives
to Animal Testing (EURL-ECVAM)
European Commission - Joint Research Centre
Method developer / user
via E. Fermi 1
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Ispra (VA) 21027
email: Francesca.PISTOLLATO@ec.europa.eu
telephone: 39 0332 7813527
Ver n° Date Name Type of change
1 05 June 2015 Dr Dimitra Zagoura Datasheet compiled
6. Abbreviations & Definitions
DB-ALM: EURL ECVAM Database Service on Alternative Methods to Animal Experimentation
EURL ECVAM: The European Union Reference Laboratory for alternatives to animal testing
hESC: human embryonic stem cells
hiPSC: human induced pluripotent stem cells
HCI: High Content Imaging
IC: Immunocytochemistry
JRC: Joint Research Center
MEA: Multielectrode Array
ND medium: Neural Differentiation medium
NI medium: Neural Induction medium
NSC: Neural Stem Cell
PSC: Pluripotent Stem Cell
Scr&Tox: EU Integrated project: "Stem cells for relevant efficient extended and normalized toxicology"
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DB-ALM Protocol n° 165 : Standard operating procedure for differentiation of human induced
pluripotent stem cells into post-mitotic neurons and glial cells (mixed culture)
Stem cell culture method, Neurotoxicity, Systemic Toxicity
Detailed differentiation protocol for induced-pluripotent stem cells differentiated into neural precursors
and further into mixed cultures of post-mitotic neurons and glial cells was developed within the 
SCR&Tox EU integrated project (Seurat-1).
Résumé
For background information on the scientific rationale and applications of this method please consult 
DB-ALM Method Summary N°165: Differentiation of induced-pluripotent stem cells into post-mitotic
neurons and glial cells (mixed culture) . 
Experimental Description
Experimental System(s):
hiPSs (IMR90-hiPSC culture) - Human induced-pluripotent stem cells (hiPSC) derived from human
foetal lung fibroblast (IMR90), reprogrammed towards pluripotency by retroviral transduction of Oct4
and Sox2, using the pMIG vectors. Created and distributed by I-Stem (Evry, France).
Basic Procedure
The procedure takes approximately 28 days to complete, with main steps outlined in the Figure 1 (see
page 8). The hiPSC cells are seeded at appropriate density and medium and cultured for 10 days. The
cells begin to form colonies which are cut and plated on low attached petri dishes where they form
embryoid bodies (EBs) floating in the medium. EBs are plated on adherent matrix in the presence of the
neuroepithelial induction medium and begin to create visible neuroepithelial aggregates (rosettes) after
5-8 days. Finally, rosettes are cut, dissociated and the cells plated onto an adherent surface of target
vessel (MEA chip, 96-well plate or a Petri dish) and further cultured in the presence of neural
differentiation medium for 21 days, where they generate mixed (neural/glial) post-mitotic neuronal
cultures.
Status
Known Laboratory Use:
EURL ECVAM
Participation in Evaluation Studies:
The SOP was developed within the frame of the Scr&Tox EU Integrated project:
 http://www.scrtox.eu/ 
Proprietary and/or Confidentiality Issues
For this method the hiPS(IMR90 cell line), created and provided by I-Stem (Evry, France), was used as
induced-pluripotent stem cells. On 8th October 2012 JRC has signed a material transfer agreement with
I-Stem, as a partner of Scr&Tox project. The cells were used for non-profit research purposes.
Abbreviations and Definitions
bFGF: basic Fibroblast Growth Factor
BDNF: Brain-Derived Neurotrophic Factor
BSA: Bovine Serum Albumin
DB-ALM: EURL ECVAM Database Service on Alternative Methods to Animal Experimentation
DPBS: Dulbecco's Phosphate-Buffered Saline
EB: Embryoid body
EURL ECVAM: The European Union Reference Laboratory for alternatives to animal testing
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EURL ECVAM: The European Union Reference Laboratory for alternatives to animal testing
GDNF: Glial-Derived Neurotrophic Factor
hiPSC: human induced Pluripotent Stem Cell
HCI: High Content Imaging
IC: Immunocytochemistry
MEA: Multielectrode Array
ND medium: Complete Neural Differentiation medium
NRI medium: Complete Neuroepithelial Induction Medium
NSC: Neural Stem Cell
P/S: Penicillin/Streptomicine
PSC: Pluripotent Stem Cell
qPCR: Quantitative Real-time PCR
Scr&Tox: EU Integrated project: "Stem cells for relevant efficient extended and normalized toxicology"
SOP: Standard Operating Procedure
Last update: 05 Jun 2015
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PROCEDURE DETAILS, 05 June 2015
Standard operating procedure for differentiation of human induced pluripotent stem cells into post-mitotic neurons and
glial cells (mixed culture)
DB-ALM Protocol n° 165
Unless otherwise stated, all procedures must be carried out under aseptic conditions in a class II laminar
flow cabinet (biological hazard standard). 
Differentiated cells can be analysed using routine analytical techiques such as qPCR, IC, Affymetrix
mircoarrays, HCI system or MEA analysis (these procedures are not included in the protocol). 
Contact Details
Dr Anna Price
System Toxicology Unit - European Union Reference Laboratory for Alternatives to Animal Testing
(EURL-ECVAM)
European Commission - Joint Research Centre
via E. Fermi 1
Ispra (VA) 21027
email: Anna.Price@ec.europa.eu
telephone: 39 0332 7813527
Dr Dimitra Zagoura
System Toxicology Unit - European Union Reference Laboratory for Alternatives to Animal Testing
(EURL-ECVAM)
European Commission - Joint Research Centre
via E. Fermi 1
Ispra (VA) 21027
telephone: 39 0332 7813527
Dr David Canovas-Jorda
System Toxicology Unit - European Union Reference Laboratory for Alternatives to Animal Testing
(EURL-ECVAM)
European Commission - Joint Research Centre
via E. Fermi 1
Ispra (VA) 21027
telephone: 39 0332 7813527
Dr Francesca Pistollato
System Toxicology Unit - European Union Reference Laboratory for Alternatives to Animal Testing
(EURL-ECVAM)
European Commission - Joint Research Centre
via E. Fermi 1
Ispra (VA) 21027
email: Francesca.PISTOLLATO@ec.europa.eu
telephone: 39 0332 7813527
Materials and Preparations
Cell or Test System
hiPSC line: wild type IMR90 (received from I-Stem)
Equipment
Fixed Equipment
Benchtop centrifuge
Countess® Automated Cell Counter
Fridge (4°C)
Freezer (-20°C)
HCI using Cellomics platform
Humidified incubator (37°C, 5% CO2 in air)
Laminar flow hood for sterile atmosphere (type II classified)
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qPCR Sequence Detection System
Optical inverted microscope
Stereoscopic (dissecting) microscope
Micropipettes
Water Bath
Consumables
(Cell culture, plastic ware and disposables)
T-25 or T-75: 25 and 75 cm2 cell culture flasks with filtered cap (Corning, Cat No. 430639 and TPP,
Cat No. 90076, respectively)
15 and 50 ml conical plastic tubes (TPP, Cat No. 91015 and 91050, respectively)
5 and 10 ml plastic pipettes (Dispenser (TPP), Cat No. 94005 and 94010, respectively)
96-well plates (TPP, Cat No. 92096)
Countess Cell Counting Chamber (Invitrogene, Cat No. C10283)
Eppendorf tubes
Gibson 20 and 300 μl dualfilter pipette tips (Eppendorf, Cat No. 022491270 and 022491245,
respectively)
Gibson 20-200 μl filter pipette tips (Diamond, Cat No. GF-F171503)
Low attachment 60 mm petri dishes (Greiner, Cat No. 628102)
MEA chips (single well, Multichannel Systems)
Powder-free Nitrile Gloves (Microflex)
Media, Reagents, Sera, others
30G needle
B27 Serum-Free Supplement (Invitrogen, Cat No. 17504044)
BSA (7.5% solution) (Sigma, Cat No. A8412)
BDNF (Invitrogen, Cat No. PHC7074)
bFGF (Invitrogen, Cat No. 13256-029 or Immunological Sciences, Cat No.GRF-15595)
β-Mercaptoethanol (50 mM) (ThermoFisher, Cat No.31350-010)
DMEM/F12 (Invitrogen, Cat. No. 3133-038)
DPBS no calcium, no magnesium (1X) (Gibco, Cat No. 14190-094)
EGF Recombinant Human Protein, Animal-Origin Free (Invitrogen, PHG6045)
GDNF (Invitrogen, Cat No. PHC7045)
Heparin Grade I-A, ≥180 USP units/mg (Sigma, Cat No. H3149-100KU)
L-Glutamin 200 mM Solution (Gibco, Cat No. 25030-081)
Laminin (Sigma, Cat No. L2020)
Knockout DMEM (Invitrogen, Cat No. 10829-018)
Knockout Serum Replacement (Invitrogen, Cat No. 10828-028)
Matrigel TM hESC-qualified Matrix (Corning, Cat No. 354277)
Matrigel® Basement Membrane Matrix (Corning, Cat No. 354234)
N2 Supplement (Invitrogen, Cat No. 17502-048)
Neurobasal Medium TM (Invitrogen, Cat No. 21103049)
NEAA: Non-Essential Amino Acids (Invitrogen, Cat No. 11140-035)
P/S: Penicillin/Streptomicine (Invitrogen, Cat No. 15140-122)
Poly-L-ornithine 0.01% solution, 50 ml (Sigma, Cat No. P4957)
Sterile-Filtered Water (Sigma, Cat No. W3500)
Trypan blue (Sigma, Cat. No. T8154), for manual cell counting
mTeSR™1 Basal Medium, (Stem Cell Technologies, Cat No. 05851)
mTeSR™1 5X Supplements, (Stem Cell Technologies, Cat No. 05852) 
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Preparations
Media and Endpoint Assay Solutions
BDNF Aliquots
Dissolve 10 μg of BDNF in 1 ml of 0.1% BSA/DPBS
Aliquot in 50 μl (10μg/ml) and store at -20°C.
1.
bFGF Aliquots
Add 10 ml of 0.1 % BSA-DPBS to 100 μg of bFGF for a final concentration of 10 μg /ml
Aliquot bFGF solution in 500 µl and store at -20°C.
2.
0.1 % BSA/DPBS 
Add 1.33 ml BSA (7.5%) to 98.67 ml of DPBS for a final BSA concentration of 0.1%
3.
EGF Aliquots
Dissolve 500 μg of human EGF in 5 ml of 0.1% BSA/DPBS and aliquot in 1 ml (100 μg/ml)
store at -20°C.
Add 9 ml of 0.1% BSA/DPBS to 1 ml (100 μg/ml) for a final concentration of 10 μg/ml.
Aliquots in 500 μl and store at -20°C
4.
L-Glutamin 200 mM5.
Thaw out L-glutamin bottle
Prepare 5 ml aliquots and store at -20°C
Heparin6.
Dissolve heparin in DMEM/F12 medium (1mg/ml)
Aliquot solution (1ml aliquots) and store at -20 °C
Laminin Coating Solution (optional)
Laminin coating solution is freshly prepared before use
7.
Thaw out laminin
Dilute neat laminin (1mg/ml) in DPBS for a final laminin concentration of 10 µg/ml
(1:100 dilution)
MatrigelTM Basement Membrane Matrix / MatrigelTM hESC-Qualified Matrix (recommended)
Thaw out the MatrigelTM Basement Membrane Matrix or MatrigelTM hESC-Qualified
Matrix by placing the matrix vial/bottle on ice until matrix becomes liquid (do not let the
matrix to solidify at temperatures above 10°C by keeping it on ice)
Aliquot matrix in 200 μl and store them at -20°C until use
8.
Penicillin/Streptomycin Aliquots9.
Thaw out P/S bottle
Prepare 2.5 ml aliquots and store at -20°C
GDNF Aliquots
Dissolve 10 μg of GDNF in 1 ml of 0.1% BSA/DPBS, aliquot in 50 μl (10 μg/ml) and store at
-20°C.
10.
Cell Media Preparations
Note: Some media reciepies below include antibiotic Penicillin/Streptomycin mix which is optional.
When hiPSC-derived neuronal cultures will be used particularly for analysis of electrical activity, the
use of P/S mixture should be avoided if possible. It alters the electrophysiological properties of cultured
neurons and may interfere with the MEA analysis (Bahrami and Janahmadi, 2013).
11.
Complete Feeder-Independent Maintenance Medium (for hiPSC expansion)
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Complete Feeder-Independent Maintenance Medium (for hiPSC expansion)
(Complete hiPSC medium) 
Volume 50 ml Volume 500 ml(1)
mTeSR™1 Basal Medium 40 ml 400 ml
10 ml 100 ml
(1) Complete mTeSR™1 is stable when stored at 2 - 8°C for up to 2 weeks or when frozen at -20°C for up to 6
months. Thaw frozen complete medium at room temperature (15 - 25°C) or overnight at 2 - 8°C before use.
(2) 5X Supplements can be dispensed into working aliquots and stored at -20°C. Use frozen aliquots within
3 months. Thawed aliquots should be used within 1 day to prepare complete mTeSR™1 medium.
Complete iPSC EB Medium (for EB formation)
Final Concentration Volume 50 ml Volume 250 ml
Knockout DMEM 1 X 39 ml 195 ml
Knockout Serum Replacement 20% 10 ml 50 ml
NEAA 1 X 500 µl 2.5 ml
Penicillin/Streptomycin 50 U/ml 250 µl 1.25 ml
L-Glutamine 2 mM 500 µl 2.5 ml
β-Mercaptoethanol 50 µM 50 µl 250μl
Complete Neuroepithelial Induction (NRI) Medium (for neuroepithelial cell formation)
Final Concentration Volume 50 ml Volume 500 ml
DMEM/F12 1 X 49 ml 490 ml
NEAA 1 X 500 µl 5 ml
N2 Supplement 1 X 500 µl 5 ml
Penicillin/Streptomycin 50 U/ml 250 µl 2.5 ml
Heparin 2 µg/ml 100 µl 1 ml
bFGF 20 ng/ml 100 µl 1000 µl (3)
(3) bFGF is instable therefore complete NRI medium should be used within 2-3 weeks. 
Complete Neural Differentiation (ND) Medium
Final Concentration Volume 50 ml Volume 500 ml
Neurobasal MediumTM 1 X 50 ml 500 ml
B-27 Supplements (50x) 1 X 1 ml 10 ml
GDNF 1 ng/ml 5 μl 50 μl
BDNF 2.5 ng/ml 12.5 μl 125 μl
Penicillin/Streptomycin 50 U/ml 250 μl 2.5 ml
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Method
Routine Culture Procedure
A. MatrigelTM Basement Membrane Matrix and MatrigelTM hESC-qualified matrix Coating of Culture
Dishes* 
MatrigelTM basement membrane matrix is used for expansion of neural stem cells; 
MatrigelTM hECS-qualified matrix is used for expansion of pluripotent stem cells
Thaw out 200 μl of the appropriate MatrigelTM aliquots (see point 8. in Media and Endpoint Assay
Solutions above) on ice
Dilute 200 μl of MatrigelTM in 20 ml of DMEM/F12 medium
Add 5 ml of MatrigelTM /DMEM/F12 solution to a 60 mm Petri dish and leave it in an incubator at 37
°C for a minimum of 1 hour
Remove MatrigelTM /DMEM/F12 solution before cell plating
* Note : Alternative to the use of MatrigelTM basement membrane matrix, Laminin or
Poly-L-ornithine/Laminin coating can be used. These procedures take longer and the cell attachment is less
strong, however they might be e.g. less likely to interfere with the electrical reading on MEA chips 
Laminin Coating 
Add 4 ml (or 8 ml) of laminin coating solution (see point 7. in Media and Endpoint Assay
Solutions above) to a T-25 (or T-75) flask
Place flask in an incubator at 37 °C for a minimum of 2 hours
Ensure all laminin solution is removed from the flask before adding cells
Poly-L-ornithine/Laminin Coating 
Dilute Poly-L-ornithine (1:6) in DPBS to coat plates and flasks (e.g., 100 μl/well in 96 well plate)
Incubate flasks/plates overnight (or minimum 6 hours) at 37°C
Rinse 3 times with DPBS
Coat with 1:500 laminin coating solution (see point 7. in Media and Endpoint Assay Solutions 
above) for minimum 2 hours
Aspirate laminin before plating the cells
B. Cell Counting (Trypan blue dye) 
Under sterile conditions take 11 μl of your cell suspension into a sterile Eppendorf tube
Add 11 μl of Trypan Blue dye to your 11 μl of cell suspension (1:1), mix and place 11 μl in a Countess
cell counting chamber slide
Place slide in the Countess® Automated Cell Counter to obtain the number of cells per ml
C. Pluripotent Stem Cell Culture and Differentiation 
hiPSC Cell Culture Maintenance 
hiPSC (wild type IMR90) cultures are grown on MatrigelTM hESC-qualified matrix -coated 60 mm
Petri dishes
1.
Coat a 60 mm Petri dish with MatrigelTM hESC-qualified matrix minimum one hour
before passaging cells
Using a phase contrast or a stereoscopic (dissecting) microscope under sterile conditions
(in a laminar flow cabinet) cut stem cell colonies in squares of about 200µm x 200µm
using a 30G needle
Aspirate in and out growth medium using a 200μl pipette to detach colony pieces.
Aspirate detached colony pieces (around 100 pieces) and place them in a fresh
MatrigelTM hESC-qualified matrix -coated Petri dish. Add 3-4 ml of complete hiPSC
medium 
Place Petri dish in an incubator at 37°C, 5% CO2 
Perform total medium change every day 
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Differentiation protocol for post-mitotic neurons from hiPSC cultures 
The neuronal differentiation protocol applied on IMR90 cells has been developed based on the
procedures used by Stummann et al. (2009) and Pistollato et al. (2014) with some modifications
(Figure 1). 
Figure 1: Cartoon summarizing the differentiation protocol for PSC-derived post-mitotic neurons
used at the JRC. 
2.
Formation of PSC aggregates (EBs) (day 0-day 2) 
Day 0: 
Change complete hiPSC medium (with 3ml of medium/60 mm Petri dish)
prior cutting the undifferentiated colonies under sterile conditions
Cut colonies with 30G needle into fragments of approximately 200µm x
200µm
Note: This step requires great manual skill and precision and is critical for the
procedure. The iPSC colony fragments must be of equal size to obtain
homogenous EBs in the next step
Detach fragments very gently using a p200 µl tip
Transfer detached fragments into a 15 ml tubes, rinsing the dish with
additional 2 ml of complete hiPSC medium 
Centrifuge at 800 rpm (112 g) for 1 min
Aspirate supernatant and gently resuspend pellet in 5 ml of complete iPS EB
medium 
Place cell suspension in 60 mm low attachment Petri dish (5 ml per dish)
Leave Petri dish overnight in an incubator at 37°C, 5% CO2 
Note: Normally colonies coming from 1x60 mm Petri dish can be re-plated as
floating aggregates in 1x60mm low-attachment Petri dish. 
Day 1: 
Note: floating EBs should be already visible 
a.
Transfer EBs into a 15 ml tube
Centrifuge EBs at 800 rpm (112 g) for 1 min
Remove cell debris by decanting supernatant (be careful not to decant the
EBs)
Resuspend EBs in 5 ml complete iPS EB medium and transfer them into 60
mm low attachment Petri dish
Return dish to the incubator at 37°C, 5% CO2
Coat 1x60 mm petri-dishes (1 for every 60mm petri dishes containing EBs)
with Matrigel TM Basement Membrane Matrix or laminin (to be used the day
after, day 2) 
page 8 / 12
© EURL ECVAM DB-ALM: Protocol
SEURAT-1 TOOLS & METHODS CATALOGUE PAGE 40
Early neural differentiation: neuroepithelial aggregates (rosettes) formation (day 2-day 7) 
Figure 2: Phase contrast image of IMR90 embryoid bodies before plating (10x
magnification). 
Day 2: 
Remove laminin or Matrigel coating solution from 60 mm Petri dishes and
plate EBs in 4 ml of complete NRI medium (about 50 EBs/60 mm in Petri
dishes)
Perform a total medium change with complete NRI medium every other day,
up to the 7th day
After maximum 5 days (i.e. 7th day) neuroepithelial aggregates (rosettes)
should be visible.
b.
Coat with Matrigel TM Basement Membrane Matrix or laminin at 37°C (or for a
minimum of 2 hours before use) any required 96 well plates (for IC,
100µl/well), 24 well plates (for qPCR, 250µl/well), 12 well plates (for
Affymetrix, 500µl/well), MEA chips (for electrical activity, 1ml/chip), or 60
mm Petri dishes (for NSC expansion) 
page 9 / 12
© EURL ECVAM DB-ALM: Protocol
SEURAT-1 TOOLS & METHODS CATALOGUE PAGE 41
Late neuronal differentiation: 
Cutting of rosettes like structure and post mitotic neurons differentiation (Day 8-Day 28) 
Figure 3: Phase-contrast image of IMR90 rosettes at Day 8, visible as cylindrical
structures (10x magnification). 
Day 8: 
c.
Using a phase contrast or a stereoscopic (dissecting) microscope under
sterile conditions, cut rosettes-like structures in very small fragments from 60
mm Petri dishes using a 30G needle and gently perform fragment
detachment by pipetting up and down medium using a p100 tip
Transfer rosettes-like structures fragments into a 15 ml conical tube and spin
down at 800 rpm (112 g) for 2 min
Remove supernatant and gently resuspend pellet in 1 ml of DPBS (to perform
a partial single cell dissociation)
Add appropriate volume of complete NRI medium 
Count cells with trypan blue (see section B. Cell Counting (Trypan blue dye) 
above, this step may be omitted if cells cannot be brought into a single cell
suspension)
Aspirate the laminin from Petri dishes, 96 well plates and/or MEA chips.
Plate single/partial dissociated cells in complete NRI medium according to
the study plan. For example in some JRC studies a density of approximately
15.000 cells/cm 2 was used. 
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Note: If rosette fragments do not look completely dissociated, in order to reach
a cell plating density of about 15.000 cells/cm 2 , dissociated rosettes fragments
deriving from about 50 EBs/1x60mm Petri dish can be resuspended in 50 ml of
complete NRI medium and plated as follows, depending on the selected plate
format: 
Multiwell
plates/MEA
Growth
area 
(cm2)
Volume of cell
suspension 
to plate per well 
(or MEA chip)
Maximum number of plates that
can be plated 
(with 50 ml of cell suspension)
96 wells 0.3 100 μl 5
48 wells 0.7 220 μl 4
24 wells 2 625 μl 3
12 wells 4 1.25 ml 3
6 wells 10 3.125 ml 2
Single well 
MEA chip
3.5 1.1 ml 45
Additional considerations: 
The selected EBs should be homogenous in size if iPSC colony fragments of
approximately 200µm x 200µm have been generated in step a. Formation of PSC
aggregates (EBs) Day 0 
i.
At this stage the cells can be either further differentiated into a mixed culture of the
post-mitotc neurons and glial cells, or expanded and maintained in the present
state, to be fully differentiated at a later stage. 
The latter procedure is described in the DB-ALM Protocol No. 166: Standard
operating procedure for expansion of rosette-derived neural stem cells 
ii.
Day 10: 
To promote full differentiation of rosette derived cells:
After two days in complete NRI medium , perform a medium change using complete ND
medium 
Day 12 onwards: 
Perform total medium change with complete ND medium every 3-4 days (twice a week)
until day 28
On day 28 process the cells according to the planned readout (using eg.
RNAqueous®-Micro Kit for RNA extraction for qPCR).
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DB-ALM Protocol n° 166 : Standard operating procedure for expansion of rosette-derived
neural stem cells
Stem cell culture method, Neurotoxicity, Systemic Toxicity
Procedure for expansion of rosette-derived neural precursor stem cells, intended for further
differentiation into mixed cultures of post-mitotic neurons and glial cells. Technique developed within
the SCR&Tox EU integrated project (Seurat-1).
Résumé
For background information please consult DB-ALM Method Summary N°165: Differentiation of
induced-pluripotent stem cells into post-mitotic neurons and glial cells (mixed culture).
Experimental Description
Experimental System(s):
hiPSs (IMR90-hiPSC culture) - Human induced-pluripotent stem cells (hiPSC) derived from human
foetal lung fibroblast (IMR90), reprogrammed towards pluripotency by retroviral transduction of Oct4
and Sox2, using the pMIG vectors. Created and distributed by I-Stem (Evry, France).
Basic Procedure
The rosette-derived neural stem cells (NSC) are prepared from the neuroepithelial aggregates (rosettes),
obtained as described in the DB-ALM Protocol N°165 (step c: Late neuronal differentiation: Cutting of
rosettes like structure on Day 8) (DB-ALM, 2016).
The NSC's are seeded at the density of 50,000 cell/cm2 in Complete Neural Induction (NI) Medium and
grown until confluence. Afterwards NSC's are trypsinised, counted, diluted to a desired density and
plated into fresh medium.
Discussion
This procedure was developed as an extension to the DB-ALM Protocol N°165. It can be used to
maintain and expand the rosette-derived NSCs (obtained from hiPS(IMR90) cell line), in an
undifferentiated, proliferative state. In this way an increased number of cells can be obtained for further
differentiation and chemical exposure studies.
Status
Participation in Evaluation Studies:
The SOP was developed within the frame of the Scr&Tox EU Integrated project:
 http://www.scrtox.eu/ 
Proprietary and/or Confidentiality Issues
This procedure is intended for the experiments conducted with the hiPS(IMR90 cell line), created and
provided by I-Stem (Evry, France) and used as iPSCs. On 8th October 2012 JRC has signed a material
transfer agreement with I-Stem, as a partner of Scr&Tox project. The cells were used for non-profit
research purposes.
Abbreviations and Definitions
bFGF: basic Fibroblast Growth Factor 2
BDNF: Brain-Derived Neurotrophic Factor
BSA: Bovine Serum Albumin
DB-ALM: EURL ECVAM Database Service on Alternative Methods to Animal Experimentation
DPBS: Dulbeccos Phosphate-Buffered Saline
EURL ECVAM: The European Union Reference Laboratory for alternatives to animal testing
hiPSC: human induced Pluripotent Stem Cell
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hiPSC: human induced Pluripotent Stem Cell
IC: Immunocytochemistry
NI medium: Complete Neural Induction medium
NRI medium: Complete Neuroepithelial Induction medium
NSC: Neural Stem Cell
P/S: Penicillin/Streptomicine
Scr&Tox: EU Integrated project: "Stem cells for relevant efficient extended and normalized toxicology"
SOP: Standard Operating Procedure
T-25: 25 cm2 cell culture flasks
Last update: 26-02-2016
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PROCEDURE DETAILS, 26 November 2015
Standard operating procedure for expansion of rosette-derived neural stem cells
DB-ALM Protocol n° 166
This procedure is complementary to the DB-ALM Protocol N°165: Standard operating procedure for
differentiation of human induced pluripotent stem cells into post-mitotic neurons and glial cells
(mixed culture).
Unless otherwise stated, all procedures must be carried out under aseptic conditions in a class II laminar
flow cabinet (biological hazard standard).
Contact Details
Dr David Canovas-Jorda
System Toxicology Unit - European Union Reference Laboratory for Alternatives to Animal Testing
(EURL-ECVAM)
European Commission - Joint Research Centre
via E. Fermi 1
Ispra (VA) 21027
telephone: 39 0332 7813527
Dr Anna Price
System Toxicology Unit - European Union Reference Laboratory for Alternatives to Animal Testing
(EURL-ECVAM)
European Commission - Joint Research Centre
via E. Fermi 1
Ispra (VA) 21027
email: Anna.Price@ec.europa.eu
telephone: 39 0332 7813527
Materials and Preparations
Cell or Test System
The rosette-derived neural stem cells (NSC) are prepared from the neuroepithelial aggregates (rosettes),
obtained from the hiPS(IMR90 cell line), follwing the procedure described in the DB-ALM Protocol
N°165 , till step c: Late neuronal differentiation: Cutting of rosettes like structure and post mitotic neurons
differentiation (day 8) (DB-ALM, 2016). 
Equipment
Fixed Equipment
Benchtop centrifuge
Countess® Automated Cell Counter
Fridge (4°C)
Humidified incubator (37°C, 5% CO2 in air)
Ice machine
Laminar flow hood for sterile atmosphere (type II classified)
Liquid nitrogen storage
Micropipettes
Milli-Q water dispenser
Mr. FrostyTM freezing container
pH meter
Stereoscopic (dissecting) microscope
Water Bath
Consumables
(Cell culture, plastic ware and disposables)
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15 and 50 ml conical plastic tubes (TPP, Cat No. 91015 and 91050, respectively)
25 cm2 cell culture flasks with filtered cap (T-25) (Corning, Cat No. 430639)
5 and 10 ml plastic pipettes (Dispenser) (TPP, Cat No. 94005 and 94010, respectively)
60 mm Petri dishes (TPP, Cat No. 93060)
Countess Cell Counting Chamber (Invitrogene, Cat No. C10283)
Cryovials Nalgene® (Sigma Cat No. V5007-500EA)
Gibson 20 and 300 μl dualfilter pipette tips (Eppendorf, Cat No. 022491270 and 022491245,
respectively)
Gibson 20-200 μl filter pipette tips (Diamond, Cat No. GF-F171503)
Powder-free Nitrile Gloves (Microflex)
Media, Reagents, Sera, others
B27 Serum-Free Supplement (Invitrogen, Cat No. 17504044)
BDNF (Invitrogen, Cat No. PHC7074)
BSA (7.5% solution) (Sigma, Cat No. A8412)
bFGF (Immunological Sciences, Cat No.GRF-15595)
Defined Trypsin Inhibitor (Invitrogen, Cat No. R-007-100)
DMEM/F12 (Invitrogen, Cat. No. 3133-038)
DMSO
EGF Recombinant Human Protein, Animal-Origin Free (Invitrogen, PHG6045)
Heparin Grade I-A, ≥180 USP units/mg (Sigma, Cat No. H3149-100KU)
L-Glutamin 200 mM Solution (Gibco, Cat No. 25030-081)
Matrigel® Basement Membrane Matrix (Corning, Cat No. 354234)
N2 Supplement (Invitrogen, Cat No. 17502-048)
NEAA: Non-Essential Amino Acids (Invitrogen, Cat No. 11140-035)
2-Propanol (Sigma, Cat No. 190764)
P/S: Penicillin/Streptomicine (Invitrogen, Cat No. 15140-122)
Sterile-Filtered Water (Sigma, Cat No. W3500)
Trypan blue (Sigma, Cat No. T8154)
Trypsin-EDTA (0.5%), no phenol red (Gibco, Cat No. 15400-054)
mTeSR™1 Basal Medium, (Stem Cell Technologies, Cat No. 05851)
mTeSR™1 5X Supplements, (Stem Cell Technologies, Cat No. 05852)
Preparations
Media and Endpoint Assay Solutions
 bFGF Aliquots 1.
Add 10 ml of 0.1% BSA/DPBS to 100 μg of bFGF for a final concentration of 10 μg/ml
Aliquot bFGF solution in 500 µl aliquots and store at 4°C.
 0.1 % BSA/ DPBS 2.
Add 1.33 ml BSA (7.5%) to 98.67 ml of DPBS for a final BSA concentration of 0.1%
 BDNF Aliquots 
Dissolve 10 μg of BDNF in 1 ml of 0.1% BSA/DPBS , aliquot in 50 μl (10μg/ml) and store at
-20°C.
3.
 EGF Aliquots 4.
Dissolve 500 μg of human EGF in 5 ml of sterile water.
Aliquot in 1 ml (100 μg/ml) and store at -20°C.
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Add 9 ml of 0.1% BSA/DPBS to 1 ml (100 μg/ml) for a final concentration of 10 μg/ml.
Aliquot in 500 μl and store at -20°C . 
Heparin 5.
Dissolve heparin in DMEM/F12 medium (1mg/ml)
Aliquot solution (1ml aliquots) and store at -20 °C
 L-Glutamin 200 mM 6.
Thaw out L-glutamin bottle
Prepare 5 ml aliquots and store at -20°C
 Matrigel® Basement Membrane Matrix 7.
Thaw out Matrigel by placing Matrigel vial/bottle on ice until Matrigel becomes liquid 
(NOTE: do not let Matrigel to solidify at temperatures above 10°C by keeping it on ice)
Aliquot Matrigel in 200 μl portions and store at -20°C until use
 Penicillin/Streptomycin Aliquots 8.
Thaw out P/S bottle
Prepare 2.5 ml aliquots and store at -20°C
 Trypsin-EDTA (0.5%) 9.
Trypsin is diluted in DPBS to a final concentration of 0.05% (1:10 dilution)
 Cell Medium Preparation 10.
Complete Neural Induction (NI) Medium 
Final Concentration Volume 50 ml Volume 500 ml
DMEM/F12 1 X 49 ml 490 ml
NEAA 1 X 500 µl 5 ml
N2 Supplement 1 X 500 µl 5 ml
Penicillin/Streptomycin 50 U/ml 250 µl 2.5 ml
Heparin 2 µg/ml 100 µl 1 ml
bFGF (1) 10 ng/ml 50 µl 500 µl
L-Glutamine 2 mM 500 μl 5 ml
EGF (1) 10 ng/ml 50 µl 500 µl
BDNF (1) 2.5 ng/ml 12.5 µl 125 µl
B-27 Supplements (50x) 1X 1 ml 10 ml
(1) bFGF is unstable and therefore the complete NI medium should be used within 2-3 weeks.
Alternatively, NI medium containing all other medium supplements except bFGF, EGF and BDNF can be
prepared and divided in 50 ml aliquots to which bFGF, EGF and BDNF are added just before use.
 Freezing medium 
Final Concentration Volume 10 ml
mTeSR™1 Basal Medium 
containing mTeSR™1 supplements and 50mg/ml BSA
50% 5 ml
Complete NI medium 40% 4 ml
DMSO 10% 1 ml
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Method
Test System Procurement
Follow the procedure as described in the DB-ALM Protocol N°165 until step c, Day 8: Cutting of rosettes
like structures (DB-ALM, 2016). 
Routine Culture Procedure
Matrigel® Basement Membrane Matrix Coating of Culture Dishes
Thaw out 200 μl Matrigel on ice1.
Dilute 200 μl of Matrigel in 20 ml of DMEM/F12 medium2.
Add 5 ml of Matrigel DMEM/F12 solution to a 60 mm Petri dish/T-25 and leave it in an incubator at
37 °C for a minimum of 1 hour
3.
Remove solution before cell plating4.
Neural Stem Cell Expansion 
The neuronal stem cell expansion protocol applied on IMR90 cells is based on the protocol supplied by
the cell provider (I-Stem, Evry (France)) with slightly modifications.
Spin down rosettes-like structures fragments in a conical 15ml tube at 800 rpm (112 g) for 2 min and
gently resuspend the pellet in NI medium
1.
Gently dissociate fragments by pipetting and transfer cells onto a MatrigelTM basement membrane
matrix pre-coated 60 mm Petri dish/T-25 flask
2.
Culture rosette-derived neural stem cells in NI medium performing medium change every other day
until they reach confluence, as illustrated in Figure 1.
3.
Figure 1: Phase-contrast image of confluent IMR90 neural stem cells (10x magnification) (10x
magnification).
Neural Stem Cell Passage
Remove medium1.
Wash cells gently with warmed DPBS2.
Add 1.2-1.5 ml of warmed 0.05% Trypsin-EDTA to the dish containing the cells and place it in the
incubator for 1 minute
3.
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incubator for 1 minute
Check cell under the microscope and help cells to detach by gently tapping the flask4.
Add 1.2-1.5 ml of Defined Trypsin Inhibitor. Transfer cells into a 15 ml tubes5.
Wash Petri dish/T-25 flask by adding equal NI medium volume (i.e. 1.2-1.5 ml) and place it in the 15
ml tube containing the cells
6.
Centrifuge the cells for 3 min at 130 g7.
Ensure that all Matrigel solution is removed from the new flask. Avoid Matrigel drying by adding a
few ml of  NI medium to wet the bottom of the flask.
8.
Remove supernatant leaving around 100-200 μl to avoid removing the cells pellet9.
Dissociate cell pellet by resuspending cells in NI medium (e.g 500 μl) and gently mixing cell
suspension
10.
Add appropriate volume of NI medium to cell suspension (e.g. 3.5 ml)11.
Perform cell counting, see step Cell Counting (Trypan blue dye) below12.
Plate cells at density of about 50,000 cells/cm2. During the first passages (1-4) it is recommended to
seed cells at densities of at least 75,000 cells/cm2
13.
Perform a total medium change every other day14.
Cell Counting (Trypan Blue dye) 
Under sterile conditions take 11 μl of your cell suspension into a sterile Eppendorf tube1.
Add 11 μl of Trypan Blue dye to your 11 μl of cell suspension (1:1), mix and place 11 μl in a Countess
cell counting chamber slide
2.
Place slide in the Countess® Automated Cell Counter to obtain the number of cells per ml3.
Cyropreservation of NCS
Harvest the cells at point 7. of the Neural Stem Cell Passage procedure1.
Resuspend the cells in Freezing Medium, to achieve a cell concentration of 3x10*6 cells/ml2.
Aliquot 0.5-0.53 ml of cell suspension, contaning 1.5-1.6 x10*6 cells per cryovial. The higher cell
numer will reach confluence faster when defrosted.
3.
Place cryovials in Mr. Frosty™ Freezing Container (containing 2-propanol to achieve a rate of cooling
very close to -1°C/minute)
4.
Place Mr. Frosty™ Freezing Container at -80°C for minimum 2 hours and up to 2 weeks5.
Rapidly transfer cryovials into vapour phase of liquid nitrogen6.
Thawing of Cryopreserved NCS
Prepare one Matrigel® Basement Membrane Matrix-coated Petri dish to thaw one cryovial1.
Retrieve cryovial from the vapour phase of the liquid nitrogen tank and place immediately in warm
water bath (37°C) for about 30-60 seconds
2.
Transfer thawed cell solution in a 15 ml conical tube containing 6 ml of warmed NI medium3.
Centrifuge cells to remove DMSO for 4 min at 850 rpm4.
Carefully remove supernatant and very gently resuspend the cells in 1 ml NI medium (using 1 ml
pipette tip)
5.
Add 4 ml of NI medium into the 60 mm-Petri dish and carefully add 1 ml of cell suspension on top6.
Culture cells in the incubator7.
Refresh medium after 48 hours8.
When cells reach confluence, split them following the Neural Stem Cell Passage procedure 9.
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DNA methylation analysis using HumanMethylation450 microarray 
Epigenomic data on the DNA methylation can be obtained, assessed and 
comparatively evaluated with the untreated controls using Illumina 450K BeadChip 
Array. It covers up to 485.000 CpGs spread over the genome (mostly in promoters 
and gene bodies). The method is cheap (~250 €/sample) and easy to perform. One 
of the known limitations is the the limited coverage of CpGs (repetitive elements are 
missing). This is one of the methods applied in the Large Scale Multi-omics VPA 
Case Study investigated by the NOTOX project. The researchers provided a detailed 
protocol for sample preparation when conducting epigenomic evaluations for all 
scientists interested in rough epigenetic profiling. 
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Analysis of histone modifications via chromatin immunoprecipitation and 
sequencing (ChIP-seq) 
ChIP-seq is the current state of the art regarding histone modification profiling, as it 
provides genome-wide data. There is a wide range of commercially available 
antibodies validated for ChIP-seq allowing a deep characterization of histone 
modification landscapes. This is one of the methods applied in the Large Scale Multi-
omics VPA Case Study investigated by the NOTOX project. The genome-wide 
histone modifications of treated and control samples were studied using chromatin 
immunoprecipitation followed by deep sequencing. ChIP-seq data yield valuable 
information for the characterization of regulatory genomic regions. 
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DB-ALM Method Summary n° 170 : DNA methylation analysis using HumanMethylation450k
microarray
Mechanistic Studies, Systemic Toxicity, Cancer Research
Genome-wide DNA methylation profiles can be obtained, assessed and comparatively evaluated across
different human human cells, tissues, and treatments using Illumina 450K BeadChip Array. The results
can be used in the assessment of the xenobiotic effects on epigemone.
1. General Information
Corresponding author(s):
Bioinformatician Pavlo Lutsik, Saarland University 
Dr. Sascha Tierling, Saarland University 
Prof. Dr. Jörn Walter, Saarland University 
Date of data sheet creation : 14 January 2016
Last version number : 1
Last update : 14 January 2016
Proprietary and/or Confidentiality Issues:
The method is based on the Illumina 450K BeadChip kit, which is developed, manufactured and
commercially distributed for research use only by Illumina, Inc. All main method components including
the BeadChip Array, iScan or HiScan array scanners and GenomeStudio software are registered
trademarks of Illumina, Inc.
Assay Throughput:
Maximum 72 samples can be processed in 3 days.
Status
Known Laboratory Use:
The HumanMethylation450k Microarray method is widely accepted by the scientific community
because of its representative character and its cost efficiency. It is one of the most popular techniques for
genome-wide profiling of DNA methylation, with thousands of references to its various applications in
the scientific literature and public repositories (on 17 Feb 2016 Google Scholar, queried with "Illumina
DNA Methylation 450k Array" counted 1,870 results; EBI-EMBL ArrayExpress contained processed data
from 464 studies, uploaded since 2011).
Participation in Evaluation Studies:
The performance of the HumanMethylation450k Microarray was evaluated in comparison with (i) an
ealier generation of the HumanMethylation27 Microarray, (ii) reduced representation- and (iii) 
whole-genome bisulfite sequencing. In all cases a very good correlation was reported (Bibikova et al.,
2011; Sandoval et al., 2011; Dedeurwaerder et al., 2011).
The potential of the HumanMethylation450k Microarray for hepatotoxicity
profiling was evaluated in the 7th European Framework Programme NOTOX
project ( notox-sb.eu ). HepaRG cells were treated with acetaminophen and
valproic acid, DNA was isolated and profiled on 450K BeadChip arrays.
Comparative studies including statistics were performed. The method was
considered very suitable for such representative comparative studies.
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2. Method Definition
Purpose of the Method
TYPE OF TESTING : Part of an integrated testing strategy
LEVEL OF TOXICITY
ASSESSMENT
: Risk assessment
PURPOSE OF TESTING : Mechanistic studies, Screen or priority setting
Context of use
Currently the method is used for Non-regulatory purposes, mainly in basic research: systems biology
studies of human cancers and their biomarkers, cell differentiation and pathology (Sandoval et al.,
2011). 
Within the NOTOX project the method was used to profile primary liver cells and related cell lines
(HepaRG, HepG2), as potential candidate to be included in the integrated testing strategy for systemic
toxicity. This method summary focuses only on the DNA sample analysis. Neither the cell culture or
exposure are considered. 
Scientific Principle of the Method
DNA methylation is an essential element of the genome maintenance, global regulation of gene
expression. It defines cell identity, development and epigenetic memory (Bird, 2002). Molecular systems
which introduce and maintain methylation of specific cytosine residues in the DNA are both dynamic
and essential in most organisms. The CpG sequences are targeted most frequently and it is estimated
that up to 80% of all CpGs are methylated in an adult mammalian genome (Ziller at al., 2013). The
changes in the methylation patterns are observed both during normal development and disease
(especially cancer) and can be interpreted as a general marker of a perturbation of a biological system
(Roberts, 2005). 
Whole genome sequencing of mammalian genomes to identify epigenetic methylation marks is very
cost- and labour-intensive. The presented method is based on a multiplexed primer extension approach
on approx. 485.000 CpG dinucleotides (~2% of all CpGs in the genome) to catch the information of the
most relevant epigenetically regulated regions (promoters, enhancers; mostly obtained from cancer
studies). Fluorescence-based signals are detected and compared to obtain a relative methylation beta
value for each CpG position providing single-base methylation data.
Comparative analysis between samples can be done using the RnBeads software package developed in
the group of Dr. Tierling at Saarland University.
Procedure Description
Biological Endpoint and Measurement:
Biologically, CpG methylation is detected from 485.000 CpGs distributed throughout the genome
(predominantly promoters, enhancers).
The measurement is based on fluorescence signals, one for methylated DNA, one for unmethylated
DNA. Relative comparison of both signals from approx.. 485.000 CpG positions is output as
methylation beta value.
Endpoint Value:
BETA VALUE (β) uses the ratio of intensities between methylated and unmethylated alleles to estimate
the methylation level of the CpG locus.
Experimental System:
The Infinium HumanMethylation450 BeadChip array containing predefined oligonucleotides bound to
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beads. Bisulfite-treated DNA binds to the complementary oligos on the array. Subsequently hybridised
oligos are extended in a methylation-dependent manner by one single, fluorophore-marked
nucleotide.
Metabolic Competence:
Not present in the experimental setup. Related to the source material from which DNA samples are
obtained.
Basic procedure:
Genomic DNA is extracted form the source material (eg. chemical-treated or intreated HepaRG or HepG2
cells). DNA is checked for purity and integrity, quantified and treated with bisulfite. Bisulfite-treated
DNA is analysed with the Infinium HumanMethylation450 BeadChip array, according to the
manufacturer's instructions (Bibikova et al., 2011). Afterwards, high resolution images of
fluorecent-labeled arrays are caputerd with an array scanner and analysed with dedicated software. 
Quality/Acceptance Criteria
The quality control steps and acceptance criteria for a valid experimental run are defined by the
developer of Infinium HumanMethylation450 BeadChip array and made available with a purchased kit
and dedicated analytical equipment and software. They include checks of the purity and integrity of
sample DNA, bisulfite treatment efficiancy and internal controls for the performance of the BeadChip
array (hybridisation, readout and normalisation steps) (Bibikova et al., 2011; Assenov et al., 2014).
Quality of the results mostly dependends on input DNA quality and bisulfite treatment efficiancy.
Data Interpretation and/or Prediction Models
Data Analysis:
The assay readout is the methylation beta-value, calculated for each of the 485,577 potential methylation
sites, represented on the array as beads carrying probes specific for the methylated and the
unmethylated alleles.
β = intensity of the Methylated allele (M) / [intensity of the Unmethylated allele (U) + intensity of the
Methylated allele (M) + 100]
The assay is designed in such way that the oligonucleotide probes for methylated and unmethylated
alleles are either located on (i) two different beads and labeled with one fluorescent dye (Infinium I
BeadChip) or (ii) on one bead and labeled with two different fluorescent dyes (Infinium II BeadChip)
(Dedeuwaerder et al., 2011). In both cases the intensity of the fluorescence is directly proportional to the
amount of sample DNA bound to the probe. Hence the unmethylated CpG's will have β=0,
hemi-methylated β≈0.5, methylated β=1.
Data analysis process consists of several steps: image processing to identify the location and identity of
the individual beads, matching their probe sequences (array internal controls or genomic loci),
correction for background, positional and batch effects, signal normalisation, calculation of β value for
each allele pair, and finally the differential analysis of DNA methylation patterns across arrays. This can
be accomplished with the Methylation Module of the GenomeStudio software, developed and
distributed by Illumina Inc.
Alternatively, the RnBeads software package can be used, developed for the open source R software
environment for statistical computing (Assenov et al., 2014). Raw data from Infinium 450K experiments
can be imported directly into RnBeads to conduct preprocessing, normalization, quality check and
differential methylation analysis. In addition theRnBeads can be used to analyse DNA methylation data
for diffrent platforms: bisulfate sequencing experiments and HumanMethylation27 Microarray. It
enables differential methylation analysis with publicly available DNA methylation datasets, eg. deposited
in the Gene Expression Omnibus (GEO) database (Assenov et al., 2014).
Prediction Model (PM):
Not applicable.
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3. Method Performance
Robustness of the Method
Within-laboratory reproducibility:
The within-laboratory reproducibility is considered very high. The reported average correlation of
β-values between technical replicates ranges from R2=0.992 to R2=0.998 (Bibikova et al., 2011;
Dedeurwaerder et al., 2011).
Between-laboratory transferability and reproducibility:
Formal between-laboratory transferability studies, as defined in the ECVAM's modular approach to
validation (OECD, 2005), have never been conducted for the use of the Infinium HumanMethylation450
BeadChip array. However, since its introduction in 2011, the method has been adopted in dozens of
laboratories worldwide and became a widely accepted standard in the DNA methylation profiling.
Standardised array design, high quality manufacturing and extensive data analysis process allow for
combining various datasets even if the were obtained in different experiments and by different
laboratories. 
One of the largest multilaboratory intitiatives of its kind is the The Cancer Genome Atlas (TCGA), a
coordinated effort to accelerate the understanding of the molecular basis of cancer through the
application of genome analysis technologies, including large-scale genome sequencing and epigenetic
profiling. The consortium has generated a large collection of cancer methylomes using the Infinium 450k
assay, performed in different batches and in different laboratories. The RnBeads analysis of 4034 blood,
breast, intestinal and brain cancer samples showed data consistency across the dataset and the
feasibility of re-assessing combined results from different studies for a new purpose (Assenov et al., 2011).
Test Compounds
Predictive capacity:
Not applicable
Applicability:
Any eventual limitations woudl be related to the experimental design and specific cell or tissue type
tested, which are beyond scope of this summary. 
4. Discussion
Known experimental strengths and/or limitations of the method
Strengths:
The method is fast, reproducible and cost-effective (app. 250 €/sample) and easy to perform, when
compared to alternatives, such as bisulfite sequencing. Only 250ng of DNA is required and no
amplification is needed. Large user base and many data sets from various studies are publicly
available for all common cell lines, tissues and many cancers. They can be re-used as reference set,
in hypothesis testing or aid in planning of a new experiments.
Limitations:
Initial investment needed in an array scanner, computational resources and training. 
The probe coverage of the Infinium HumanMethylation450 BeadChip is not exhaustive. Only
approximately 485.000 CpGs are evaluated, out of 28 million estimated possible methylation sites in
the genome (Assenov et al., 2011). Some elements, known to be methylated in the human genome
(eg. repetitive elements) are not included, so that some important epigenetic information might not
be detected.
Technical requirements
250 ng of genomic DNA is needed
BeadChips have to be purchased from Illumina
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iScan or HiScan machine has to be purchased from Illumina
Potential for future development
The method is undergoing continuous development. New EPIC array is already released by Illumina
now covering 850.000 CpG positions. It has been show to be highly reproducible at the 450K CpG sites
and consistent among technical replicates while offering additional coverage of 333,265 CpGs located in
enhancer regions identified by the ENCODE and FANTOM5 projects (Moran et al., 2016).
Comparisons to other methods
Validation of 450K BeadChip array results using local deep sequencing revealed high confidence of 450K
data. It is considered as one of the best established techniques for DNA methylation analysis. For a more
general review of other techniques refer to eg. a recently published comparative review by Kurdyukov
and Bullock (2016).
5. Contact Details
Bioinformatician Pavlo Lutsik
PhD student
FR8.3 Life Sciences, Genetics/Epigenetics
Saarland University
Function: Corresponding author, Method developer / user
Campus, Bld. A2 4
Saarbrücken D-66123
email: p.lutsik@mx.uni-saarland.de
telephone: +49 681 302 2881
Dr. Sascha Tierling
Post-Doc, Biologist
FR8.3 Life Sciences, Genetics/Epigenetics
Saarland University
Function: Corresponding author, Method developer / user
Campus, Bld. A2 4
Saarbrücken D-66123
email: s.tierling@mx.uni-saarland.de
telephone: Tel: +49 681 302 3295
Prof. Dr. Jörn Walter
FR8.3 Life Sciences, Genetics/Epigenetics
Saarland University
Function: Corresponding author
Campus, Bld. A2 4
Saarbrücken D-66123
email: j.walter@mx.uni-saarland.de
telephone: +49 (0) 681 302 4367
Ver n° Date Name Type of change
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6. Abbreviations & Definitions
450K BeadChip Array: Microarray technology developed and distributed by Illumina
BETA VALUE (β): β = intensity of the Methylated allele (M) / [intensity of the Unmethylated allele (U) +
intensity of the Methylated allele (M) + 100]
CpG: cytosine and guanine separated by a phosphate group
DNA: Deoxyribonucleic acid
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DNA: Deoxyribonucleic acid
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DB-ALM Protocol n° 170 : DNA methylation analysis using HumanMethylation450 microarray
Mechanistic Studies
A detailed protocol for sample preparation when conducting epigenomic evaluations for all scientists
interested in rough epigenetic profiling. The data are obtained, assessed and comparatively evaluated
with the untreated controls using Illumina 450K BeadChip Array.
Résumé
Epigenomic data are obtained, assessed and comparatively evaluated with the untreated controls using
Illumina 450K BeadChip Array. With this primer extension-based array up to 485.000 CpG positions can
be scanned covering promoters and gene body regions. The described method is ideal for rough
estimations about DNA methylation changes between two or more samples. DNA methylation of treated
and control samples is studied on a genome-wide representative microarray. Epigenomic evaluation is
performed on the Illumina 450K BeadChip array. It covers up to 485.000 CpGs spread over the genome
(mostly in promoters and gene bodies). The method is cheap (~250 €/sample) and easy to perform. The
limitations are the limited coverage of CpGs (repetitive elements are missing).
More information about the method is included in the DB-ALM Method summary n° 170 : DNA
methylation analysis using HumanMethylation450k microarray.
Experimental Description
Endpoint and Endpoint Measurement:
Biologically, CpG methylation is detected from 485.000 CpGs distributed throughout the genome
(predominantly promoters, enhancers).
The measurement is based on fluorescence signals, one for methylated DNA, one for unmethylated
DNA. Relative comparison of both signals from approx.. 485.000 CpG positions is output as
methylation beta value.
Endpoint Value:
BETA VALUE (β) uses the ratio of intensities between methylated and unmethylated alleles to estimate
the methylation level of the CpG locus.
Experimental System(s):
The Infinium HumanMethylation450 BeadChip array containing predefined oligonucleotides bound to
beads. Bisulfite-treated DNA binds to the complementary oligos on the array. Subsequently hybridised
oligos are extended in a methylation-dependent manner by one single, fluorophore-marked
nucleotide.
Health and Safety Issues
General Precautions
Sodium bisulfite is potentially inducing mutations in DNA – please wear gloves when performing
bisulfite treatments with DNA. During the microarray a formamide-containing solution is used, which is
potentially toxic and, in case of improper handling, can be harmful. Therefore, all the operations
involving formamide should be carried out with all necessary precautions by specially trained staff.
Abbreviations and Definitions
450K BeadChip Array: Microarray technology developed and distributed by Illumina Inc.
BETA VALUE (β): β = intensity of the Methylated allele (M) / [intensity of the Unmethylated allele (U) +
intensity of the Methylated allele (M) + 100]
CpG: cytosine and guanine separated by a phosphate group
DNA: Deoxyribonucleic acid
IDAT: proprietary data format is used to store BeadArray data from the genomewide profiling platforms
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IDAT: proprietary data format is used to store BeadArray data from the genomewide profiling platforms
from Illumina Inc.
R: a programming language and software environment for statistical computing and graphics
VPA: vaplroic acid
Last update: 14 January 2016
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PROCEDURE DETAILS, 14 January 2016
DNA methylation analysis using HumanMethylation450 microarray
DB-ALM Protocol n° 170
The protocol was developed within the NOTOX EU integrated project (Seurat-1)
Contact Details
Bioinformatician Pavlo Lutsik
PhD student
FR8.3 Life Sciences, Genetics/Epigenetics
Saarland University
Campus, Bld. A2 4
Saarbrücken D-66123
email: p.lutsik@mx.uni-saarland.de
telephone: +49 681 302 2881
Dr. Sascha Tierling
Post-Doc, Biologist
FR8.3 Life Sciences, Genetics/Epigenetics
Saarland University
Campus, Bld. A2 4
Saarbrücken D-66123
email: s.tierling@mx.uni-saarland.de
telephone: Tel: +49 681 302 3295
Materials and Preparations
Cell or Test System
HepaRG cells, primary hepatocytes or any other cell line or tissue can be used
Equipment
Fixed Equipment
Illumina iScan or HiScan machines
NanoDrop 2000c (Thermo Scientific)
Consumables
GenElute™ Mammalian Genomic DNA Miniprep Kit (Sigma)
EZ DNA Methylation™ Kit (Zymo Res.)
Illumina HumanMethylation450 BeadChip Array
Media, Reagents, Sera, others
DMEM with particular supplements (can be obtained from eg. Biopredic Int.)
Preparations
Test Compounds
Valproic acid , acetaminophen
Positive Control(s)
Control oligos on the 450K BeadChip array
Negative Control(s)
Untreated samples
Method
Routine Culture Procedure
Cells were scraped from one well of a 6-well plate, centrifuged for 5 minutes at 900g and washed once
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with 1xPBS. Then cells were split equally in two aliquots and frozen at -80°C until DNA/RNA preparation.
Test Material Exposure Procedures
HepaRG cell line exposed to 0.05 and 0.15 mM valproic acid up to 21 days and 1 mM acetaminophen up
to 1 day. Primary hepatocytes were exposed to 1 mM acetaminophen for up to 21 days.
Cells were scraped from one well of a 6-well plate, centrifuged for 5 minutes at 900g and washed once
with 1xPBS. Then cells were split equally in two aliquots and frozen at -80°C until DNA/RNA preparation.
Endpoint Measurement
DNA is prepared from one HepaRG cell aliquot using the GenElute™ Mammalian Genomic DNA
Miniprep Kit (Sigma) according to the manufacturer´s protocol.
1.
DNA is eluted in 200 µl ddH2O, concentrated by speed vac to a final volume of 20 µl and measured by
NanoDrop 2000c (Thermo Scientific).
2.
DNA integrity is checked by loading 250 ng on a 1.2% agarose gel.3.
500 ng of genomic DNA were subjected to bisulfite treatment using the EZ DNA Methylation™ Kit
(Zymo Res.) according to the manufacturer´s protocol.
4.
Bisulfite-treated DNA is analysed on Infinium HumanMethylation450 BeadChip array in the iScan
machine (Illumina).
5.
Raw data were processed and evaluated using the RnBeads software (Assenov et al., 2014).6.
Acceptance Criteria
Quality checks include the check of bisulfite conversion and the evaluation of control regions on the
BeadChip.
Quality of the results is mostly dependent on input DNA quality and bisulfite treatment efficiency.
Data Analysis
Raw HumanMethylation450 data is obtained from the iScan control software (Illumina) as IDAT files.
The data is then loaded into R statistical environment and initially preprocessed using the RnBeads
package (Assenov et al., 2014).
The raw intensities are normalized using the manufacturer recommended scaling procedure,
implemented as method "illumina" in Bioconductor package methylumi (Davis et al., 2015).
The normalized data is further analyzed using the RnBeads default pipeline to generate an HTML
analysis report.
Each called CpG position is tested for association with the VPA treatment and cultivation variable
independently for each combination of the VPA concentration and cultivation time, comparing to the
corresponding control samples.
Prediction Model
Not Applicable
Annexes
Application note:
http://res.illumina.com/documents/products/appnotes/appnote_dna_methylation_analysis_infinium.pdf
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DB-ALM Protocol n° 171 : Analysis of histone modifications via chromatin
immunoprecipitation and sequencing (ChIP-seq)
Mechanistic Studies
A detailed protocol for ChIP-seq sample preparation when conducting epigenomic evaluations for all
scientists interested in genome-wide histone modification analysis. The protocol is applicable to any
histone modification of interest.
Résumé
ChIP-seq technique is the current state of the art regarding histone modification profiling on
genome-wide scale.
There is a wide range of commercially available antibodies validated for ChIP-seq allowing a deep
characterization of histone modification landscapes. The authors studied genome-wide histone
modifications of treated and control samples using chromatin immunoprecipitation followed by deep
sequencing (ChIP-seq). ChIP-seq data yield valuable information for the characterization of regulatory
genomic regions.
The ChIP-seq protocol described here (buffers and solutions) is based on:
Walter K., Lichtinger M., 2011 Chromatin-Immunopräzipitation (ChIP). In: Jansohn M, Rothhämel S
(Eds.), Gentechnische Methoden: eine Sammlung von Arbeitsanleitungen für das molekularbiologische
Labor., Spektrum Akademischer
Experimental Description
Endpoint and Endpoint Measurement:
Measurement is based on antibody-enriched sequencing depth, normalizing and comparing read
numbers. The comparison is made between treated and untreated cells, eg. HepaRG
Experimental System(s):
Chromatin Immuno-precipitates analysed with high-throughput sequencing on the HiSeq2500
machine (Illumina)
Discussion
ChIP-seq data yield valuable information for the characterization of regulatory genomic regions and it is
considered a golden standard for genome-wide histone modification profiling.
One known limitation of ChIP-seq is the bias introduced by sonication-assisted chromatin
fragmentation.
Status
Known Laboratory Use:
The method is widely accepted by the scientific community as golden standard for genome-wide histone
modification profiling.
Health and Safety Issues
General Precautions
During the fixation step 1% formaldehyde solution is used, which is a highly toxic substance and, in case
of improper handling, can be harmful. Therefore, all the operations involving formaldehyde should be
carried out with all necessary precautions by specially trained staff.
Abbreviations and Definitions
ChIP-seq: chromatin immunoprecipitation followed by deep sequencing
PIC: Protease Inhibitor Cocktail
Last update: 14.01.2016
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PROCEDURE DETAILS, 14 January 2016
Analysis of histone modifications via chromatin immunoprecipitation and sequencing (ChIP-seq)
DB-ALM Protocol n° 171
The protocol was developed within the NOTOX EU integrated project (Seurat-1)
Contact Details
Dr. Sascha Tierling
Post-Doc, Biologist
FR8.3 Life Sciences, Genetics/Epigenetics
Saarland University
Campus, Bld. A2 4
Saarbrücken D-66123
email: s.tierling@mx.uni-saarland.de
telephone: Tel: +49 681 302 3295
Biologist Kathrin Kattler
PhD student
FR8.3 Life Sciences, Genetics/Epigenetics
Saarland University
Campus, Bld. A2 4
Saarbrücken D-66123
email: kathrin.kattler@googlemail.com
telephone: +49 681 302 2443
Materials and Preparations
Cell or Test System
HepaRG cells, treated with Valproic Acid
Equipment
Fixed Equipment
Instrument Supplier
Bioruptor® NGS System Diagenode
1.5 ml TPX microtubes Diagenode
DynaMagTM Invitrogen
Agilent 2100 Bioanalyzer Agilent Technologies
cBot Illumina
HiSeqTM 2500 Illumina
DynaMagTM Invitrogen
Consumables
Product Supplier
1.5 ml TPX microtubes Diagenode
H3K4me3 polyclonal antibody Diagenode
H3K9ac polyclonal antibody Diagenode
Qubit® dsDNA HS Assay Kit Invitrogen
Bioanalyzer High Sensitivity DNA Kit Agilent Technologies
TruSeq ChIP Sample Preparation Kit Illumina
TruSeq v2 LT Sample Prep Kit PCR Box Illumina
TruSeq PE Cluster Kit v3-cBot-HS Illumina
TruSeq SBS Kit v3 - HS (200 Cycles) Illumina
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Media, Reagents, Sera, others
DMEM medium plus supplements (can be obtained from Biopredic Int.)
Preparations
Media and Endpoint Assay Solutions
ChIP A
10 mM HEPES-NaOH
10 mM EDTA
0.5 mM EGTA
0,25 % (v / v) Triton X-100
PIC
ChIP B
10 mM HEPES-NaOH
200 mM NaCl
1 mM EDTA
0.5 mM EGTA
0.01 % (v / v) Triton X-100
PIC
ChIP buffer
25 mM Tris-HCl
150 mM NaCl
2 mM EDTA
1 % (v / v) Triton X-100
0.25 % (w / v) SDS
PIC
ChIP dilution buffer
25 mM Tris-HCl
150 mM NaCl
1 mM EDTA
1 % (v / v) Triton X-100
0.75 % (v / v) Glycerol
PIC
ChIP washing buffer 1
20 mM Tris-HCl
150 mM NaCl
2 mM EDTA
1 % (v / v) Triton X-100
0.25 % (w / v) SDS
ChIP washing buffer 2
20 mM Tris-HCl
500 mM NaCl
2 mM EDTA
1 % (v / v) Triton X-100
0.25 % (w / v) SDS
ChIP washing buffer 3
10 mM Tris-HCl
250 mM LiCl
1 mM EDTA
0.5 % (v/v) NP-40
0.5 % (w/v) Sodiumdesoxycholate
TE / NaCl
10 mM Tris-HCl
50 mM NaCl
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50 mM NaCl
1 mM EDTA
ChIP elution buffer
(freshly prepared)
100 mM NaHCO3
1 % (w / v) SDS
NaPO4 buffer
(93 : 7; v / v)
1 M Na2HPO4
1 M NaH2PO4
PIC
Complete Protease Inhibitor Cocktail Tablets (Roche)
Test Compounds
Valproic acid
Positive Control(s)
none
Negative Control(s)
Untreated cells; non-antibody enriched ChIP fraction
Method
Routine Culture Procedure
Chromatin Preparation
Cells are detached by trypsination from each well of a 6-well plate. For each replicate, two wells were
pooled resulting in approximately 5 x 106 cells.
1.
After fixation with 1% formaldehyde for 10 minutes, cross-linking is stopped by adding glycine to a
final concentration of 125 mM and incubation for 5 minutes at room temperature. Samples are kept
on ice or at 4° C.
2.
Centrifugation steps throughout the chromatin preparation are performed at 800 x g for 5 minutes at
4° C. After washing twice with 125 mM glycine in PBS and once in 1 x PBS, cells are resuspended
consecutively in 5 ml ChIP buffer A, respectively ChIP buffer B, and rotated for 10 minutes.
3.
After centrifugation, pellets are resuspended in 500 μl ChIP buffer and kept on ice for 10 minutes.
Sonication of chromatin is performed in 166 μl volumes in 0.5 ml shearing tubes using the Bioruptor
NGS (Diagenode) at 4° C on high power setting with 30 (+ X) cycles consisting of 30 seconds
sonication and 30 seconds recovery time. 
Samples with appropriate size distribution were diluted with double volume ChIP dilution buffer. 20
μl of diluted samples were stored at – 20° C until later use as Input controls.
4.
Immunoprecipitation
Protein G beads (Invitrogen) are washed twice with 100 mM NaPO4 buffer and resuspended in 10 μl
100 mM NaPO4. 2 μl antibody (polyclonal antibodies against H3K4me3 and H3K9ac (Diagenode)) as
well as 5 μl BSA (10 mg / ml) are added.
1.
After rotation at 4° C for 2 hours, 300 μl sheared chromatin (equivalent to 1 million cells) are added.2.
Immunoprecipitation is conducted overnight. Afterwards supernatant is completely removed and
beads are consecutively washed with 1 ml of ChIP wash buffer 1, ChIP wash buffer 2 (twice), ChIP
wash buffer 3 and TE / NaCl buffer. All washing steps are performed under rotation at 4° C for 10
minutes.
3.
Samples are transferred into new tubes and incubated with 100 μl freshly prepared elution buffer for
15 minutes at room temperature in a shaking device.
4.
Eluates are collected in new tubes. Elution is repeated and both eluates are subsequently combined.
Besides, 20 μl of saved Input controls were mixed with 180 μl elution buffer and carried along.
5.
To each sample 4 μl 5 M NaCl, 2 μl 0.5 M EDTA and 2.5 μl Proteinase K (20 mg / ml) are added.
Reversion of cross-linking is carried out in a shaking device at 55° C over night.
6.
After adding 2 μl 1 M Tris-HCl, DNA is extracted with 200 μl PCI solution (25 / 24 / 1; v / v / v) under
rotation at room temperature for 10 minutes. Samples are centrifuged at 13000 rpm for 15 minutes
7.
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rotation at room temperature for 10 minutes. Samples are centrifuged at 13000 rpm for 15 minutes
and the aqueous phase was transferred into a new tube. Extraction is repeated likewise with 200 μl
CI solution (24 / 1; v / v).
DNA is precipitated with 20 μl 3 M NaOAc, 1 μl glycogen (20 mg / ml) and 500 μl ice-cold absolute
ethanol at – 20° C over night.
8.
Samples are centrifuged at 13000 rpm at 4° C for 40 minutes, pellets are washed with 700 μl ice-cold
70 % ethanol. After centrifugation for 20 minutes pellets are dried at room temperature.
9.
Input control samples are disssolved in 50 μl, 
Immunoprecipitated DNA in 20 μl ddH2O.
10.
DNA concentration is measured with the Qubit® dsDNA HS Assay Kit (Invitrogen) using 2 μl sample.11.
DNA sequencing
Up to 10 ng DNA are applied for library preparation using the Truseq ChIP Sample Preparation Kit
(Illumina).
End Repair, 3’-Adenylation, adapter ligation as well as enrichment PCR (using 8 cycles (replicate 1)
or 9 cycles (replicate 2)) are conducted strictly according to the manufacturer’s protocol.
1.
Size selection is achieved using Ampure XP beads (Beckman Coulter) after adapter ligation (replicate
1) or more effectively before end repair reaction (replicate 2). For selection of DNA fragments
between 100 bp and 500 bp, 0.5X beads are added to the sample.
2.
After 10 minutes, samples are magnetically separated and supernatant is transferred into a new tube.3.
1.3X beads are added to the supernatant. After 10 minutes incubation, the supernatant is discarded
and beads are washed twice with 80 % ethanol.
4.
From the dried beads DNA is eluted using 20 µl resuspension buffer (Illumina).5.
Libraries are sequenced 2 x 100 bp paired-end on the HiSeq2000 (Illumina).6.
Test Material Exposure Procedures
HepaRG cells were exposed to 0.05mM, 0.15 mM and 0.5 mM valproic acid over 14 and 21 days.
Acceptance Criteria
Fixed samples should not be stored more than 6 month as prolonged storage intensifies sonication
biases. Sonication parameters for each cell type should be determined in advance.
Quality checks by performing technical replicates; duplication rate assessment; sequencing of
non-antibody-bound fraction to determine background signals.
Data Analysis
Low quality ends (phred score=20) of FastQ format reads were trimmed in addition to adapter removal
using Trim Galore (version 0.3.3).
The trimmed reads were aligned to the human reference genome (hs37d5) using GEM mapper (version
1.376 beta).
bamToBed from samtools (version 1.1) was used to convert SAM to BAM format. MarkDuplicate (version
1.115) from picard Tools was used to mark the PCR duplications.
The coverage tracks (bigwig files) were generated by bamCoverage (version 1.5.8.1) from deepTools.
MACS (version 2.1.0.20140616) was used for peak calling.
MACS2 together with IDR pipeline were used to assess the reproducibility of the called peaks in case of
replicates (d0 and d21).
Bibliography
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Physiologically-Based Kinetic models 
A Physiologically Based Kinetic (PBK) model is a mathematical model for predicting 
the absorption, distribution, metabolism and excretion (ADME) of a compound in 
humans and other animal species. The model can be used to simulate relevant time 
profiles concentration of selected chemicals and its metabolites using a calibrated 
PBK model for rat and for human. The present PBK models will be implemented into 
the KNIME workflow, in order to create an automated tool for Risk Assessment. 
Further use of the workflow can be in cosmetic Risk Assessment as well for HTS, for 
in vitro testing design. The KNIME workflow is available via COSMOS space. A web 
version of the model was also implemented, allowing to execute the model via a web 
browser. It is available through the COSMOS KNIME WebPortal.. 
Method Summary no 161…………………………………………………………………81 
 
The Virtual Cell Based Assay 
The Virtual Cell Based Assay (VCBA) is a mathematical model for predicting the fate 
of a chemical within an in vitro system. The model can be used to simulate relevant 
intracellular concentrations of selected chemicals in cell lines, and it can be coupled 
with physiologically based kinetic (PBK) models to predict human in vivo toxic doses 
from concentrations that cause effects in vitro. The characterization of the 
concentration that produces an effect (whether this is a perturbation of a molecular 
pathway or an apical toxic endpoint) is necessary at two levels: first, in analysing the 
results of vitro experiments, since “nominal” concentrations do not represent the real 
concentration experienced by the cell; and, second, in extrapolating to humans, 
since the true concentration experienced by cells within the target organ is more 
representative for human toxicity assessment. In order to analyse the results of in 
vitro experiments, a VCBA was developed for liver cell lines (3T3cBalbc, HepG2 and 
HepaRG). The VCBA model has been further extended to include cell lines from 
different organs: lung A459 cells and from heart cardiomyocytes. The KNIME 
workflow is available via COSMOS space. A web version of the model was also 
implemented, allowing to execute the model via a web browser. It is available 
through the COSMOS KNIME WebPortal. 
Method Summary no 162……………...…………………………………………………103 
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The Human Bio-Accumulation Model 
The Human Bio-Accumulation Model is a mathematical model based on in vitro liver 
metabolism data, minimal renal excretion and a chronic exposure, to assess the 
bioaccumulative potential of a chemical. The approach has been analysed using 
literature data for some well-known bioaccumulative compounds, data from the 
EURL ECVAM database, and for a subset of the ToxCast phase I chemical library. 
The aim of the present method was to develop an open source approach for 
assessing the potential of chemicals (personal care products and cosmetics) to 
bioaccumulate in humans following realistic exposure scenarios. An important 
characteristic, addressed in the work of Tonnelier et al. (2012) is to assess 
chemicals for human bioaccumulative potential using a simple physiologically based 
toxicokinetic model, which ranks chemicals based on their human bio concentration 
factor (hBCF). The work on the model was carried out at the Joint Research Centre 
under the COSMOS project, SEURAT 1 Research Initiative. The KNIME workflow is 
available via COSMOS space. A web version of the model was also implemented, 
allowing to execute the model via a web browser. It is available through the 
COSMOS KNIME WebPortal. 
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PPARγ full agonists’ pharmacophore-based predictor 
The PPARγ full agonists’ pharmacophore-based predictor is an in silico model to 
predict the potential of chemicals to bind and activate PPARγ (PPARγ full agonism 
prediction). Taking into consideration that ligand-dependent activation of PPARγ can 
be a molecular initiating event (MIE) that triggers downstream events leading to liver 
steatosis, the model can be used for in silico prediction of potential prosteatotic 
compounds that are PPARγ full agonists. The implemented model is based on a 
dataset of 170 PPARγ ligands extracted from Protein Data Bank (PDB) 
(www.rcsb.org) and scientific literature. The model is based on a two-step procedure: 
docking of the chemical structures into the PPARγ binding site and filtering using a 
pharmacophore model of PPARγ full agonists. The work on the model was carried 
out under the COSMOS project, SEURAT 1 Research Initiative. 
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QSAR model for the prediction of LXR binding potential 
This quantitative structure-activity relationship ((Q)SAR) model is a classification 
model (based on PLS-DA) for the prediction of Liver X Receptor (LXR) binding 
potential. The binding and activation of LXR has been identified among the 
molecular initiating events leading to liver steatosis. Thus, this QSAR model may be 
used as part of integrated approaches to testing and assessment (IATA)/integrated 
testing strategies (ITS) to screen chemicals potentially sharing the same AOP (i.e. 
from LXR activation to liver steatosis). The model may also find application in the 
grouping of chemicals to support read-across justification, in terms of mechanistic 
plausibility (as molecular initiating event leading to long-term adverse effects in the 
liver), and weight of evidence evaluations. The KNIME workflow is available via 
COSMOS space. A web version of the model was also implemented, allowing to 
execute the model via a web browser. It is available through the COSMOS KNIME 
WebPortal. 
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PPARγ full agonists’ potency predictor 
PPARγ full agonists’ potency predictor is a three dimensional QSAR (Quantitative 
Structure-Activity Relationships) model for prediction of chemical compounds' 
potency (transactivation activity, pEC50) to induce PPARγ-mediated expression of 
target reporter gene. PPARγ activation by full agonists has been outlined as one of 
the possible molecular initiating events for mode of action leading to non-alcoholic 
fatty liver disease (NAFLD) (Al Sharif et al., 2014). The experimental data reported in 
the literature used for the selected endpoint has been obtained from Luciferase 
reporter gene assay. The last is relevant to the OECD conceptual framework, 
presenting the most promising assays to detect and characterise chemical effects on 
the PPAR signaling pathway and is among the in vitro assays that are going to be 
considered for incorporation into new or existing Test Guidelines for the detection of 
endocrine disrupting chemicals after refinement and validation (OECD, 
ENV/JM/MONO(2012)23). The 3D QSAR model is developed using a data set of 
122 full PPARγ agonists (83 – training set, 39 – test set), selected from a previously 
constructed and publically available PPARγ ligands’ dataset 
(http://biomed.bas.bg/qsarmm/) with structural and biological (binding affinity, IC50; 
transactivation activity, EC50; relative efficacy, %max) data for 439 agonists (full and 
partial). The model predicts transactivation activity using calculated electrostatic, 
acceptor and hydrophobic similarity indices as 3D descriptors, generated by CoMSIA 
(Comparative Molecular Similarity Indices Analysis) 3D QSAR approach. The work 
on the model was carried out under the COSMOS project, SEURAT 1 Research 
Initiative. 
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Parallel Artificial Membrane Permeability Assay (PAMPA) logPm predictor 
PAMPA logPm predictor is a mathematical model for prediction of chemical 
compounds' permeability in Parallel Artificial Membrane Permeability Assay 
(PAMPA), which is assumed to be a practical estimator of passive gastro-intestinal 
absorption (GIA) of low molecular weight compounds. The implemented model is 
developed using a data set of 276 compounds and predicts permeability coefficient 
Pm using in silico calculated distribution coefficient (logD) and the ratio of the 
Topological Polar Surface Area (TPSA) to Molecular Weight (MW) as descriptors. 
With a view to the free and open implementation of the models and lack of such tools 
for logD estimation, two implementations of the model were produced based on logD 
estimations readily obtainable through free online services. The KNIME workflow is 
available via COSMOS space. A web version of the model was also implemented, 
allowing to execute the model via a web browser. It is available through the 
COSMOS KNIME WebPortal. 
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In silico screening for potential nuclear receptor ligands and alerts towards 
hepatosteatosis 
Many pathways in toxicology can be traced back to nuclear receptors (NR) as initial 
target. One notable example is endocrine disruption, another the development of 
fatty liver (hepatosteatosis) associated with chronic exposure to the agonists of some 
nuclear receptors, e.g. Retinoic Acid Receptor, Retinoid X receptor, Liver X Receptor 
and Peroxisome Proliferator-Activated Receptor (Moya et al 2010). For the purpose 
of this model the structural and physico-chemical features of NR ligands have been 
investigated using data from ChEMBL and the Protein Data Bank (PDB). The 
information obtained was implemented into a KNIME workflow (see Steinmetz et al 
2015) and can be used for screening for potential NR ligands during drug 
development and risk assessment, which can support hazard identification, category 
formation for read-across and provide knowledge to anchor adverse outcome 
pathways (AOPs). The KNIME workflow is available via COSMOS space. A web 
version of the model was also implemented, allowing to execute the model via a web 
browser. It is available through the COSMOS KNIME WebPortal. 
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In silico profiler for covalent DNA binding 
One of the fundamental and initial steps for genotoxicity is the formation of a 
covalent bond between nucleophile and electrophile molecules of DNA and 
xenobiotic. DNA binding can thus be a molecular initiating event in an adverse 
outcome pathway (AOP) leading to both mutagenicity and carcinogenicity. The in 
silico profiler for covalent DNA binding was developed based on the review of current 
scientific knowledge relating to mutagenicity and genotoxic carcinogenicity structural 
alerts and mapping the existing structural alerts in terms of their relationships with 
mechanistic organic chemistry, i.e. identifying alerts from the published compilations 
related to covalent DNA binding. The mapping was performed to achieve maximum 
overlap and usability whilst restricting redundancy in the alerts, and to ensure that 
the alerts related to the molecular initiating event of covalent DNA binding. A total of 
111 structural alerts, supported by mechanistic information and meta data, have 
been created. The KNIME workflow is available via COSMOS space. A web version 
of the model was also implemented, allowing to execute the model via a web 
browser. It is available through the COSMOS KNIME WebPortal. 
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In silico profiler for hepatotoxicity 
The in silico profiler for hepatotoxicity consists of 16 structural alerts coded into 
SMARTS patterns. The alerts can be used in the screening of compounds to 
highlight potential hepatotoxicity. The profiler is envisaged to be used to develop 
chemical categories based upon similar mechanisms as part of the adverse outcome 
pathway paradigm. The profiler has also the potential to act as a knowledge 
generator serving as a starting platform from which to conduct additional 
toxicological studies. The KNIME workflow is available via COSMOS space. A web 
version of the model was also implemented, allowing to execute the model via a web 
browser. It is available through the COSMOS KNIME WebPortal. 
Method Summary no 179……………………………………………………………….177 
 
  
SEURAT-1 TOOLS & METHODS CATALOGUE PAGE 79
In silico profiler for mitochondrial toxicity  
The main goal of the in silico profiler is grouping chemicals into mechanism based 
categories centred on the knowledge of a number of key molecular initiating events 
(MIEs) for mitochondrial toxicity as part of the adverse outcome pathway (AOP) 
paradigm. The in silico profiler for mitochondrial toxicity consists of 21 structural 
alerts coded into SMARTS patterns. The KNIME workflow is available via COSMOS 
space. A web version of the model was also implemented, allowing to execute the 
model via a web browser. It is available through the COSMOS KNIME WebPortal. 
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In silico profiler for covalent protein binding  
For a number of toxicological endpoints, such as hepatotoxicity (liver fibrosis),skin 
sensitisation, respiratory sensitisation or aquatic toxicity, one of the fundamental 
steps is the formation of a covalent adduct between a reactive exogenous chemical 
(electrophile) and biological protein (nucleophile). Protein binding can thus be a 
molecular initiating event for a number of adverse outcome pathways. The in silico 
profiler for covalent protein binding was developed based on the review of current 
scientific knowledge on structural alerts relating to a number of toxicity endpoints. 
The KNIME workflow is available via COSMOS space. A web version of the model 
was also implemented, allowing to execute the model via a web browser. It is 
available through the COSMOS KNIME WebPortal. 
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In silico skin permeability estimation 
Dermal absorption is of great importance for safety evaluation of chemicals taken up 
via dermal route of exposure regarding the availability of the substance in the 
organism. The purpose of this in silico workflow is to estimate the skin permeability 
coefficient (kp) for an organic compound, based on calculated physico-chemical 
descriptors. The KNIME workflow is available via COSMOS space. A web version of 
the model was also implemented, allowing to execute the model via a web browser. 
It is available through the COSMOS KNIME WebPortal. 
Method Summary no 182………………………………………………………………211 
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DB-ALM Method summary n° 161 : Physiologically-Based Kinetic models
Systemic Toxicity, Biokinetics
A Physiologically Based Kinetic (PBK) model is a mathematical model for predicting the absorption,
distribution, metabolism and excretion (ADME) of a compound in humans and other animal species.
The model can be used to simulate relevant time profiles concentration of selected chemicals and its
metabolites using a calibrated PBK model for rat and for human. The models were programmed in R
(free software environment for statistical computing) for further incorporation into KNIME workflows.
1. General Information
Corresponding author(s):
Dr. Andrew Worth, European Commission - Joint Research Centre 
Date of data sheet creation: 15 January 2015
Last version number: 1
Last update: 15 January 2015
Section No.5 Contact Details provides a complete list of the authors and method developers.
The method summary presented here describes a mathematical model.
In the context of this document, the term "method" in the paragraph headings refers to the PBK model.
Proprietary and/or Confidentiality Issues:
None. Work carried out at the Joint Research Centre with partial support from the FP7 COSMOS project.
Status
Development completed
The PBK models have been built in R and have been translated in
KNIME (the Konstanz Information Miner) automated workflows,
as a part of the COSMOS (Integrated In Silico Models for the
Prediction of Human Repeated Dose Toxicity of Cosmetics to
Optimise Safety) project, within the SEURAT-1 Research Initiative
(Safety Evaluation Ultimately Replacing Animal Testing 1) cluster
(2011-2015). More information on the COSMOS project is available
on its dedicated website:
http://www.cosmostox.eu
The KNIME workflows and documentation are available via COSMOS Space:
http://cosmosspace.cosmostox.eu
A web version of the models was also implemented, allowing to execute the models via a web browser. It
is available through the COSMOS KNIME WebPortal:
http://knimewebportal.cosmostox.eu
A tutorial is available at: 
https://www.youtube.com/watch?v=Ihn4I_g981Q/
2. Method Definition
Purpose of the Method
TYPE OF TESTING : Part of an integrated testing strategy
LEVEL OF TOXICITY ASSESSMENT : Risk assessment
PURPOSE OF TESTING : Safety
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Context of use
The main goal of this method is to develop and optimise computer-assisted physiologically-based
toxicokinetic (PBK) and dynamic (PBD) models to predict the biological and toxicological effects of
chemicals in humans under single and repeated exposure conditions. Further use of the workflow can be
in cosmetic Risk Assessment as well for HTS in vitro experiments.
The modelling approach was illustrated through its application (to selected chemicals found in
consumer products and food, as well as some drugs. With a view to the implementation of the models
into open-source tools, the models were programmed in R for further incorporation into KNIME
workflows. See the R project for statistical computing for technical documentation:
 http://www.r-project.org/ 
KNIME is a user-friendly graphical workbench for the analysis process such as data access, data
transformation, initial investigation, visualization and reporting. It integrates various components for
machine learning and data mining through its modular data pipelining concept. Further use of the
workflow can be in cosmetic risk assessment as well for high throughput screening (HTS) to facilitate the 
in vitro test design.
 http://www.knime.org/ 
The purpose of the model is to simulate relevant time profiles concentration of selected chemicals and its
metabolites using a calibrated PBK model for rat and for human. The present PBK model is implemented
into the KNIME workflow, in order to create an automated tool for Risk Assessment. The PBK model (and
the this specific KNIME workflow) was adapted to estimate subject-specific concentration-time profiles
in human biological samples (serum and urine) with the ultimate goal to back-extrapolate to the time of
intake, assuming that the dose ingested is known.
Chemicals used
Coumarin, Estragole, Hydroquinone, Caffeine, Ethanol, Isopropanol, Styrene, Methyliodide, Nicotine
Target Users and Uses
For in vitro toxicologists:
External dose → concentration in blood or selected organ → → → In vitro testing strategy planning
For Risk Assessors:
External dose → concentration in blood or selected organ → → → Point of Departure (PoD) for extrapolation
(Risk Assessment).
Potential Applications
Predict from in vitro to in vivo
Extrapolate from low dose to high dose response
Extrapolate from route to route exposure
Buid for characterisation of cosmetic ingredients, however it can be applied for cosumer products
and food components and additives (e.g. coumarin, ethanol and estragole)
Scientific Principle of the Method
Toxicokinetic modelling is currently seen as the most adequate approach to simulate the fate of chemical
compounds in the human body (including the possible emergence of metabolites) and their absorption,
distribution, metabolism and excretion (ADME) (Adler et al., 2011). 
The present PBK model was developed at the JRC to analyse the effects of human exposure to selected
chemicals. Physiologically-based toxicokinetic (PBTK) and toxicodynamic (PBTD) models for the
healthy adult Caucasian population were constructed and parameterised for the nine case study
compounds, which include industrial chemicals and substances found in consumer products and food:
coumarin, estragole, hydroquinone, caffeine, ethanol, isopropanol, methyl iodide, styrene and nicotine
(Gajewska et al., 2014; 2015; unpublished data).
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Model components
The schematic representation of the human PBK model is given in Figure 1. A PBK model tries to mimic
the human body compartment including the blood circulation to and from the organs and the
movement of a chemical substance throughout the compartments and its metabolism as realistically as
needed for the purpose of the exercise and as realistically as possible based on constraints with respect
to previous knowledge on parameters (in order to prevent what is called an ‘overparameterisation').
Figue1: General Structure of the PBTK model
Model exposure routes
Exposure Routes used in the present PBK model are: Oral, Dermal and Inhalation (Figures 2, 3 and 4 
below). 
In the human PBTK model for oral absorption, the human GI tract is represented by 6
sub-compartments (Figure 2). In modelling absorption along the GI tract following gavage
administration dissolution from matrix, stomach emptying rate and a first order rate of absorption from
stomach, small and large intestine were taken into account.
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Figure 2: GI tract sub-compartments in human PBK model for oral exposure.
For PBK modelling of human dermal exposure, 4 compartments were used for dermal exposure (surface
compartment for the product formulation and 3 skin sub-compartments (stratum corneum, viable
epidermis and dermis perfused by blood). For dermal caffeine exposure, one extra skin
sub-compartment had to be added, i.e. hair follicles (see Figure 3).
Figure 3: Skin divided into sub-compartments in human PBK model for dermal exposure
The respiratory tract consists of 3 main compartments (24 Weibel generations): convection and diffusion
segments (with metabolism that may occur at any stage) (Figure 4). This dynamic lungs model is more
suitable for reactive substances, drugs and nanoparticles. For simple compounds this refinement is not
necessary but it allows for a better control of the inhalation/exhalation process. A sinusoidal breathing
pattern is incorporated in the model with time frame in seconds (higher computational burden than
other exposure types). The model, additionally, consists of blood/air partition coefficient, Ostwald
solubility in lungs and rate of dissolved gas removed from lungs due to blood perfusion on overall model
prediction performance.
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Figure 4: Inhalation in humn PBK model
Procedure Description
Biological Endpoint and Measurement:
Physiologically based (pharmaco)kinetic model (PBK)
Dose-response
Time-reponse
Bioavailability
Basic procedure:
The PBK model is a mathematical approach. Examples of the equations used in the individual model
components are described in the next section: 2.1 Model Description. The models for coumarin and
caffeine are already coded and implemented in KNIME and can be acessed via COSMOS space:
 http://cosmosspace.cosmostox.eu/app/home 
A presenation on the COSMOS Automated in silico tools for in vitro to in vivo extrapolation was
recorded for the American Society for Cellular and Computational Toxicology (ASCCT). Method
developer Dr. Alicia Paini explains the composition of the model and the use of the KNIME workflows:
https://youtu.be/vJc1UEbuWdE
2.1 Model Description
 Model Equations 
The mathematical equations were programmed in R language by combining functionalities of the
following R packages available from “The Comprehensive R Archive Network” website
(http://cran.r-project.org): deSolve, ReacTran, PK, FME, rgenoud and AICcmodavg. Ordinary differential
equations (ODEs) were solved by the method lsoda available in the deSolve package. The method of lines
was used to solve partial differential equations (PDEs). Further details are given below.
Model Equation Examples
PBK models were built for several compounds taking into account mode of action of the chemical. We
report as an example of mathematical equation describing the processes, the simplest first order rate of
absorption PBK 1 model. However, several PBK models were built describing the absorption, oral and
dermal with different sub compartment, for instance:
 PBK 3: GI tract: sub-compartments: stomach content and tissue, small and large intestine content
and absorbed quantity
1.
PBK 2: Skin: 2 compartments: one with Fickian diffusion and one with blood mix.2.
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For further information on these two models (PBK 3, GI tract; and PBK 2, Skin) please consult Gajewska
et al. (2014 and 2015).
PBK 1: 
GI tract: 1 compartment with first order rate of absorption
If (t>t lag)
dAabs,GI 
= - kaabs,GI •Aabs,GI - kelabs,GI •Aabs,GI ; else
dAabs,GI 
= 0 (A1.1)
dt dt 
Skin: 1 compartment with first order rate of absorption
If (t>tlag)
dAabs,skn 
= - kaabs,skn• Cabs,skn ; else
dAabs,skn 
= 0; Cabs,skn = 
Aabs,skn ; Vabs,skn=Area• L (A1.2)dt dt 
The rest of compartments/tissues are common for PBK 1, PBK2 and PBK 3:
Adipose tissue (adp), highly perfused tissues (hpt) and poorly perfused tissues (ppt):
dAon
= fon •  (Cart  — 
Con ) Aon (t =0)=0 Cart = 
Aart Con = 
Aon (A1.3)
dt PCon Vart Von
where: on = organ name (adp, hpt, ppt )
Kidney: 
dAkid
= fkid •  (Cart —
Ckid ) — CLR• Ckid (A1.4)
dt PCkid PCkid
Liver (without zonation): 
dAliv
= flowGItract+ Formliv + fliv  •  (Cart — 
Cliv ) — METliv Aliv (t=0)=0 Cliv = 
Aliv (A1.5)
dt PCliv Vliv
For a parent compound:
GI tract with 1 compartment:
flowGItract =
dAAbs,GI 
dt 
GI tract with sub-compartments:
flowGItract = fra •  fgit •  
Cstm + frb •  fgit * 
CSI + frc •  fgit •  
CLI
PCgit PCgit PCgit
FORMliv =0 (rate of formation of metabolites)
METliv includes all the metabolism equations
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Venous blood: 
dAven = fliv  •  
Cliv + fppt •  
Cppt + fhpt •  
Chpt + fadp  •  
Cadp 
+ fkid •  
Ckid + FSKIN - F_ crd •  Cven dt PCliv PCppt PChpt PCadp PCkid 
Aven (t=0)=0 Cven = 
Aven 
(A1.6)
Vven 
For dermal absorption only: 
Skin with 1 compartment:
FSKIN= 
dAAbs,skn 
dt 
Skin with 2 compartments:
FSKIN=Fskin •  
Cskn 
PCskn 
Skin with sub-compartments:
FSKIN= 
3 
•  fskin •  
Cskn + 
1 
•  fskin •  
Csknhf 
4 PCskn 4 PCsknhf 
Plasma quantification:
Cven,PL =
Aven /(0.55 • Vven ) 
RBP 
Arterial blood and lungs: 
dAlng 
= flng •  ( Cven — 
Clng ) Alng (t=0)=0 Clng = 
Alng (A1.7)
dt PClng Vlng 
dAart 
= f_crd • ( Clng — Cart ) Alng (t=0)=0 (A1.8)dt PClng 
Table 1: Equations used to calculate toxicokinetic parameters
Parameter Area under
curve (AUC)
Bioavailability Systemic
clearance
Volume of
distribution (VD)
Elimination
(half-life)
Equation
Where: 
C org =
organ/tissue
concentration
Where: 
ven=venous blood, 
t = oral, dermal,
inhalation;
IV= intravenous
Where: 
I = no of organs in
the model
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 Input data: Model Parameters 
For the human oral model, the most sensitive parameters (GIT dissolution rates, first order uptake rate
constants and metabolism parameters for liver) were optimized using measured human data. Liver
metabolism parameters were taken from the literature and were optimized with respect to in vivo blood
concentrations using human data for the main metabolites only. All physiological parameters for a
reference man, woman and rat that are independent of the chemical and constitute a constant part of
the model equations are given in Table 2 below. The values were taken from the study of Brown and
colleagues (Brown et al., 1997).
Table 2: Physiological system data for human (reference woman and man).
Quantity Reference woman
(standard deviation)
Reference man
(standard deviation)
Average body weight [kg] 65 (15) 78 (15)
Organ Organ weights fractions
(fractions of body weight)
Liver 0.026 (0.006) 0.026 (0.006)
Adipose tissue 0.327 (0.127) 0.213 (0.096)
Lungs 0.0105 (0.002) 0.012 (0.002)
Kidney 0.0044 (0.0004) 0.0044 (0.0004)
GI tract:
Stomach:
Small Intestine:
Large Intestine:
0.0265 (0.0095)
0.00337
0.0146
0.0085
0.025 (0.0095)
0.00318
0.0138
0.0080
Poorly perfused tissues
+Skin
0.473(0.07) 0.5855 (0.07)
Highly perfused tissues 0.0676 (0.0025) 0.0621 (0.0025)
Blood
Venous blood
Arterial blood
0.065 (0.0035)
0.04875
0.01625
0.072 (0.0035)
0.054
0.018
L [cm] 0.204 (0.1) 0.2906 (0.1)
L ve [cm] 0.0032 (0.001) 0.0047 (0.001)
L sc [cm] 0.0018 (0.0002) 0.0017 (0.0002)
Regional blood flow rates
(fraction of cardiac output [L/h])
Cardiac output [L/h] 15 . BW 0.74 
Liver 0.25 (0.05) 0.24 (0.05)
Adipose tissue 0.055 (0.005) 0.04 (0.005)
Lungs 0.025 (0.0009) 0.025 (0.0009)
Kidney 0.19 (0.02) 0.2 (0.02)
Poorly perfused tissues 0.135 (0.03) 0.16 (0.03)
GI tract
Fractions of GI tract flow rate
that go to Stomach tissue, small Intestine wall and large intestine
0.14 (0.01)
0.2, 0.6, 0.2
0.13 (0.01)
0.2, 0.6, 0.2
Skin 0.05 (0.01) 0.05 (0.01)
Highly perfused tissues 0.155 (0.015) 0.155 (0.015)
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The physicochemical properties for each individual chemical, with parameters to represent the
Absorption, Dstribution, Metablism and Excretion (ADME) , including partition coefficients and
absorption rates, are reported in Gajewska et al. (2014 and 2015).
Model Settings:
Species : Human
Dosage: Variable to be set from user (in mg or mg/kg)
Exposure route: Oral, Dermal, inhalation
Exposure Time: Variable to be set from user
Exposure Type: Single or repeat
Chemical Application type: Variable to be set from user (example, liquid, solid, gel tablet, pill, vehicle
for dermal application)
Additional information
A total of 9 PBK models have been developed to date in COSMOS project. The list of available models
with respective dosage settings can be found in the summary table below. The models for coumarin and
caffeine are implemented in KNIME and can be acessed via COSMOS space.
Table 3: Summary of available models with respective dosage settings.
Compound
name 
PBTK: oral PBTK: dermal PBTK: inhalation PBTK-PBTD Reference 
Coumarin single single - single- Gajewska et al., 2014
Estragole single - - single- Unpublished
Hydroquinone single single - - Gajewska et al., 2014
Caffeine single
repeated
single - single
repeated
Gajewska et al.,
2014 and 2015
Ethanol single single single - Unpublished
Isopropanol single single single - Unpublished
Styrene - - single - Unpublished
Methyl iodide - single - Unpublished
Nicotine single
repeated
single
repeated
single
repeated
single
repeated
Gajewska et al.,
2014 bis
3. Method Performance
Robustness of the Method
General performance measures:
The PBTK model underwent an extensive evaluation, described in the next section: 3.1 Evaluation of
model performance. 
3.1 Evaluation of Model Performance
Sensitivity analysis
Sensitivity analysis and parameter identifiability were performed to identify the most important and
sensitive parameters with respect to the blood/plasma AUC for the case study chemicals according to
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Soetaert and Petzoldt (Soetaert and Petzoldt,2010; Soetaert, 2010) prior to their optimization In local
sensitivity analysis (Eq. (1)), all parameters were evaluated individually in a very small region close to
their nominal value. A parameter value divided by the average of simulated outputs was used as a scaling
factor (SF).
Eq. (1)
Eq. (2)
Eq. (3)
where:
y is vector of function outputs for a specific variable;
x is vector of state variables;
is vector of parameters (0 parameter estimate);
u is vector of inputs;
N is number of time points;
ˆS is the columns of the sensitivity matrix that correspond to the parameters included in
the set;
EV is estimation of the eigenvalues
The following kinetic and compound-specific parameters were analyzed: GItract absorption rates (Diss
(or Dt), kastm, kaSI, kaLI, kelLI, kmax, kmin), liver metabolic rates (vmax, Km, Kmet), skin absorption
parameters (Dsc, Dve, Dhf, kaform, kahf, PCsc, PCscve, PChf), blood-to-plasma ratio and tissue-to-blood
partition coefficients: PCl iv,PCadp, PCppt, PChpt, PCkid, PClng, PCgit, PCskn.
The higher the absolute sensitivity value, the more important is the parameter. These sensitivity
functions are collapsed into summary values (L1 and L2 are used as selection criteria) (Eq. (2)). Based on
the sensitivity functions of blood AUC to selected parameters, the identifiability of a set of parameters to
be fine-tuned by calibration is then calculated. As a rule of thumb, a collinearity value less than about 20
means “identifiable” (in general, when the collinearity index exceeds 20, the linear dependence is
assumed to be critical (Eq. (3)) (Brun et al., 2001; Omlin et al.,2001).
The collinearity is a measure of approximate linear dependence between sets of parameters. The higher
its value, the more the parameters are related. In this context, “related” means that several parameter
combinations may produce similar values of the output variables.
Monte Carlo simulations were used to quantify the impact of variability and uncertainty in parameter
distributions separately by drawing parameter values according to a predefined distribution (normally
distributed random samples), running the model with each of these parameter combinations, and
calculating the values of the selected output variables at each output interval.
Optimization was carried out by applying the Levenberg–Marquardt algorithm to nonlinear data fitting
(Moré, 1978).
Evaluation of the goodness-of-fit of the PBK models
To compare the performance of the PBK models, the coefficient of deter-mination (R2), mean squared
error (MSE) and Akaike’s Information Criterion (AIC)(Kletting and Glatting, 2009) were used. For model
discrimination, AIC penalizes models with a large number of parameters when having the same
agreement interms of mean squared error. The model with the lowest algebraic AIC therefore indicates
the best agreement with experimental data while minimizing the risk of over fitting. In addition, a
corrected AIC (AICc) was applied to adjust for a small number of data points (Kletting and Glatting,
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2009).
Calibration and Validation
The summary of all the literature experimental data (in vitro, in vivo) used for calibrating and validating
the PBK-D models for human are presented in Tables 4-6 for all the 9 case study compounds.
Table 4: Summary of experimental data sources for toxicokinetic modelling.
Compound in vitro data in vivo data 
Coumarin Skin permeation:
(Ritschel et al., 1977)
Liver metabolism:
(Born et al., 2000;
Rietjens et al., 2008;
Vassallo et al., 2004)
Oral data:
Single: (Ritschel et al., 1979, 1977)
Dermal data:
Single: (Ford et al., 2001)
Estragole Metabolic rates in liver
microsomes:
(Punt et al., 2009)
Oral data:
(Zeller et al., 2009)
Hydroquinone Liver metabolism:
Isolated hepatocytes
(Poet et al., 2004)
Oral data:
(Corley et al., 2000)
Dermal data:
(Wester et al., 1998)
Caffeine Skin permeation:
Cosmetics Europe
JRC (Mennecozzi et al.,
2011)
and
(Doucet et al., 1998;
Treffel et al., 1993)
(Wilkinson et al., 2006)
Liver metabolism:
(Ha et al., 1996)
Oral data:
Single: gelatin capsule (Lelo et al., 1986)
Single: commercial dietary supplement (Csajka et al.,
2005)
Single: gelatin capsule (Newton et al., 1981)
Single: beverage (Robertson et al., 1981)
Single and repeated: gelatin capsule (Acheson et al., 1980)
Repeated: coffee (Denaro et al., 1991)
Dermal data :
Single: Caffeine in 30%ethanol/70% propylene glycol
(Otberg et al., 2008)
Ethanol - Oral data:
(Jones et al., 1988; Wilkinson et al., 1977a, 1977b)
(Lostia et al., 2013) + King’s College
Dermal data:
(Kramer et al., 2007)
Inhalation:
(Nadeau et al., 2003)
Isopropanol - Inhalation data:
(Kumagai et al., 1999)
(Clewell Iii et al., 2001)
Oral data:
(Clewell Iii et al., 2001; Lacouture et al., 1989; Monaghan
et al., 1995)
Dermal data:
(Turner et al., 2004)
Methyl Iodide - Inhalation data:
(Morgan et al., 1967; Morgan and Morgan, 1967)
i.v. data
(Robertz-Vaupel et al., 1991)
Styrene - Inhalation data:
(Johanson et al., 2000; Ramsey and Young, 1978; Wigaeus
et al., 1984)
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Nicotine - IV infusion:
Repeated (Porchet et al., 1988)
Oral data:
Nicotine capsules: single (Green et al., 1999)
Nicotine with the straw: single and repeated (D’Orlando
and Fox, 2004)
Dermal data:
Nicotine patch: single and repeated (Bannon et al., 1989)
Nicotine patch: single and repeated (Gupta et al., 1993)
Via straw:
Inhalation: repeated (Teeguarden et al., 2013)
Table 5: Summary of experimental data sources for toxicodynamic modelling
Compound References 
Nicotine Blood pressure
Heart rate
(Fattinger et al., 1997; Mündel and Jones, 2006; Porchet
et al., 1988; Sofuoglu et al., 2012)
Caffeine (Damirchi et al., 2009; Daniels et al., 1998; Denaro et al.,
1991; Karatzis et al., 2005; Mousavi et al., 2011; Ping et
al., 2010; Shi, 1993; Sung et al., 1990)
Table 6: Uncertainty in model evaluation
Assumption Uncertainty Potential
consequence for
internal dose metrics 
Potential risk assessment
consequences 
First order oral
absorption
First order oral absorption has
been stated to be applicable to
many pharmaceuticals.
However, for
non-pharmaceuticals, this is
uncertain. Also, the value for
the first order absorption rate
constant used may change for
significantly different exposure
conditions.
Predicted AUC as well
as Cmax values may
deviate significantly
from the real AUC and 
Cmax (rat, human).
Significant over- or
underestimation of actual risk.
No human first
pass metabolism
in skin
First pass metabolism reduces
the internal exposure to the
parent chemical.
Internal exposure to
the parent chemical is
overestimated (either
as AUC or as Cmax).
No consequence in
comparison to default
approach (just using total
external dose).
Larger risks predicted
compared to when first pass
metabolism in skin would
have been taken into account.
No genetic
polymorphism in
the human
population
The values used for Vmax and
Km may are not valid for whole
human population (it is known
that there is genetic
polymorphism)
Predicted AUC and 
Vmax are not valid for
whole human
population.
Risks maybe over- or under
predicted for part of the
human population.
4. Discussion
The PBK models were developed to predict the internal dose metrics (AUC and Cmax) for selected
chemicals. The human models were set up to mimic typical/realistic single or repeated oral exposure
(gavage as was actually used in the volunteer study for coumarin and gavage as a surrogate for the
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gelatine capsule containing caffeine that was administered) and dermal human exposure scenarios. The
use of GI and dermal sub-compartments in the PBK model gives a better simulation of absorption for the
cosmetic ingredients than a simple model structure. However, the parameters estimated for pure
substances may not apply to mixtures. For the substances studied, QSPR predictions provide a reliable
alternative to in vivo dermal penetration experiments, which can be used as reliable input parameters to
the dermal PBK model. Interspecies extrapolation by PBK modelling gives different results compared
with a simple scaling to the human equivalent dose, which takes into account body weight and surface
area only. When the same absolute dose is applied orally and dermally, different concentration–time
profiles in blood and liver are obtained.
 Ethical issues and considerations for 3R’s impact 
This study illustrates a strategy for the oral-to-dermal extrapolation of toxicity data based on PBK
modelling using cosmetic ingredients. This modelling framework could be used to guide the generation
of additional experimental data to refine the PBK models and extend their applicability, with the ultimate
aim of applying the models in chemical risk assessment without the use of any animal studies
 Known strengths and/or limitations of the method 
PBK modeling requires different type of data, ranging from the physiological, biochemical, and
physicochemical processes that occur in biological systems. Furthermore different age groups or certain
physiological and pathological conditions can influence a chemical reaction within the body and thus
should be included in the model prediction. These type of data are not always available from one source,
which may lead to some confusion and to a problem in establishing a reliable source of accurate and
consistent information. the JRC PBK models are also built and calibrated against the available in vivo
data found in the literature and for certain type of exposure scenarios, giving higher uncertainty
concerning the applicability of the model for the overall population and for different exposure scenarios.
As reported in Khalil and Laer (2011) PBK models reflect the current scientific knowledge, and while
some processes are known to be well characterized, others are partly or poorly characterized, as
information gaps may exist. Information gaps or poor characterization of some physiological processes.
Therefore, it is important to emphasize that the validity and quality of the simulations depends on the
corresponding model and its incorporated data as well as its purpose, and uncertainty concerning the
data used to build the model should be properly reflected.
 Potential for future development 
- To include Monte Carlo Simulation to take into account variability within the population. To be able to
use the model and scale it up to all population.
- Develop more refined models to overcome uncertainties.
 Additional Considerations 
- The KNIME WEB version (KNIME WebPortal) will make the PBK model an easy to use tool. 
http://cosmosspace.cosmostox.eu/app/home 
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6. Abbreviations & Definitions
A amount
ADME Absorption, Distribution, Metabolism, and Excretion
adp adipose tissue
AIC Akaike’s Information Criterion
AICc corrected AIC
Aon amount of a chemical in organ/tissue [mg]
Area application Area on skin [cm2]
art arterial blood
AUC Area under Cruve, reflects that total amount of chemical to which an organ is
exposed to.
BW body weight
C concentration
CLR renal clearance rate [L/h]
Cmax maximum concentration of a chemical in an organ
Con or Corg concentration of a chemical in organ/tissue [mg/L]
COSMOS EU integrated project: COSMOS develops an integrated suite of computational
tools to predict the effects of long-term exposure to chemicals in humans based
on in silico calculations and estimation techniques. Website:
http://www.cosmos-tox.eu/
Dhf diffusion coefficient in coefficient in hair follicles [cm2/h]
Diss dissolution from a coated matrix [L/h]
Dsc diffusion coefficient in stratum corneum [cm2/h]
Dt drinking rate [L/h]
Dve diffusion coefficient in viable epidermis [cm2/h]
f_crd cardiac output [L/h]
GI Gastrointestinal
GIT Gastrointestinal tract
hpt highly perfused tissues
HTS High Througput Screening
iv intravenous
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kaform intake rate of chemical from formulation by stratum corneum [mL/h]
kahf intake rate of a chemical from formulation by hair follicles [mL/h]
kaLI absorption rate from large intestine lumen [1/h]
kaSI absorption rate from small intestine lumen [1/h]
kastm absorption rate into stomach tissue [1/h]
kelLI elimination rate in large intestine lumen [1/h]
kid kidney
Km chemical concentration at which the reaction rate is half of the maximal [mg/L]
Kmet first order rate of formation of metabolites [L/h]
kmin, kmax kinetic constants of stomach emptying rate of a chemical to small intestine
[1/h]
KNIME Konstanz Information Miner, is an open source data analytics, reporting and
integration platform, which integrates various components for machine
learning and data mining through its modular data pipelining concept.
Website: www.knime.org
liv liver
lng lungs
L Skin thickness [cm]
Lsc thickness of stratum corneum [cm]
Lve thickness of viable epidermis [cm]
METliv metabolism eqations
MSE mean squared error
ODE Ordinary Differential Equation
on or org organ name
PBD Physiologically Based Dynamic (model)
PBK Physiologically Based Kinetic (model)
PBTK Physiologically-Based Toxicokinetic (model)
PC partition coefficient
PCadp Tissue to blood partition coefficient - Adipose tissue
PCgit Tissue to blood partition coefficient - GI tract
PChf partition coefficient hair follicle /solvent
PChpt Tissue to blood partition coefficient - highly perfused tissues
PCkid Tissue to blood partition coefficient - Kindney
PCliv Tissue to blood partition coefficient - Liver
PClng Tissue to blood partition coefficient - Lungs
PCorg or PCon tissue-to- blood partition coefficients
PCppt Tissue to blood partition coefficients - Poorly perfused tissues
PCsc partition coefficient stratum corneum/ solvent
PCscve partition coefficient stratum corneum/ viable epidermis
PCskn Tissue to blood partition coefficient - skin
PDE Partial Differential Equation
Poct Octanol/water partition coefficient
PoD Point of Departure
ppt poorly perfused tissues
QSPR quantitative structure-property relationship
R R is a programming language and software environment for statistical
computing and visualisaton. Website: http://www.r-project.org/
R2 coefficient of determination
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RPB Plasma to blood concentration ratio
SEURAT 1 EU integrated projects cluster. SEURAT-1 Research Initiative develops a
long-term research strategy leading to pathway-based human safety
assessments in the field of repeated dose systemic toxicity testing of chemicals.
Website: http://www.seurat-1.eu/
SF scaling factor
skn skin
tlag the time lag of absorption in the skin
V volume
ven venous blood
Vmax the maximum rate metabolic rate at maximum (saturating) concentration of a
chemical [mg/h]
Von volume of organ/tissue
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DB-ALM Method summary n° 162 : The Virtual Cell Based Assay
Systemic Toxicity
The Virtual Cell Based Assay (VCBA) is a mathematical model for predicting the fate of a chemical within
an in vitro system. The model can be used to simulate intracellular concentrations of selected chemicals
in cell lines, and it can be coupled with physiologically based kinetic (PBK) models to predict human i n
vivo toxic doses from concentrations that cause effects in vitro. 
1. General Information
Corresponding author(s):
Dr. Andrew Worth, European Commission - Joint Research Centre 
Dr. Jose Vicente Sala Benito, European Commission - Joint Research Centre 
Date of data sheet creation: 10 February 2015
Last version number: 1
Last update: 10 February 2015
Section 5. Contact Persons provides a complete list of the authors and method developers.
The method summary presented here describes a mathematical model.
In the context of this document, the term "method" in the paragraph headings refers to the VCBA model.
Proprietary and/or Confidentiality Issues:
None - publicly available.
The model has been developed by the Joint Research Centre (JRC), with partial support from the FP7
COSMOS project.
Status
Development
Development of Version 1.0 completed. The model is currently
under revision. The VCBA models for simulation of single and
repeat exposure are built in R and have been translated in KNIME
(the Konstanz Information Miner) automated workflows, as a part
of the COSMOS project (Integrated In Silico Models for the
Prediction of Human Repeated Dose Toxicity of Cosmetics to
Optimise Safety), within the SEURAT-1 Research Initiative (Safety
Evaluation Ultimately Replacing Animal Testing 1) cluster
(2011-2015). More information on the COSMOS project is available
on its dedicated website:
http://www.cosmostox.eu
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2. Method Definition
Purpose of the Method
TYPE OF TESTING : Part of an integrated testing strategy
LEVEL OF TOXICITY ASSESSMENT : Risk assessment
PURPOSE OF TESTING : Safety
Context of use
The Virtual Cell Based Assay (VCBA) is a mathematical model for predicting the fate of a chemical within
an in vitro system. The model is designed to simulate intracellular concentrations of selected chemicals
in cell lines, and can be coupled with physiologically based kinetic (PBK) models to predict human in
vivo toxic doses from concentrations that cause effects in vitro (in vitro to in vivo extrapolation), thereby
supporting chemical risk assessments.
The characterization of the concentration that produces an effect (whether this is a perturbation of a
molecular pathway or an apical toxic endpoint) is necessary at two levels: first, in analysing the results of
vitro experiments, since “nominal” concentrations do not represent the real concentration experienced
by the cell; and, second, in extrapolating to humans, since the true concentration experienced by cells
within the target organ is more representative for human toxicity assessment. In order to analyse the
results of in vitro experiments, a VCBA was developed for liver cell lines (3T3cBalbc, HepG2 and HepaRG)
and it has been extended to include cell lines from different organs: lung A459 cells and from heart
cardiomyocytes ( Paini A., et al., and Sala Benito et al., both in preparation).
VCBA simulates processes in an in vitro system, especially the fate of a chemical within the well, taking
into account partitioning with protein, lipids, and plastic binding (Zaldívar et al., 2010 and 2011). The
VCBA consists also of a cell partitioning and cell growth model (G1, S, G2, M phases). An additional
feature takes into account the cell toxicity. The latter part of the model was based on two parameters: the
no-effect concentration (NEC) and the killing rate (kt), which are linked to experimental cell viability. The
main simulated property is the intracellular concentration of a specific chemical within the cell, and its
corresponding effect on cell viability (Zaldívar et al., 2010 and 2011). A mitochondrial compartment has
been added to the VCBA. This model was introduced in order to be sure that the model predictions were
within the order of magnitude of the in vitro results obtained.
Target Users and Uses
For in vitro toxicologists:
External dose → concentration in blood or selected organ → → → In vitro testing strategy planning
For Risk Assessors:
External dose → concentration in blood or selected organ → → → Point of Departure (PoD) for extrapolation
(Risk Assessment).
Potential Applications
In particular, it is suggested that the use of VCBA model coupled to Physiologically Based Kinetic (PBK)
models [DB-ALM Method Summary No. 161] to translate the in vitro to the in vivo kinetics of chemicals
can be further used to extended to simulate the dynamics of chemical-induced effects on different type of
cells, and can be used for the quantitative in vitro to in vivo extrapolation (QIVIVE).
Scientific Principle of the Method
Model components
The VCBA model has been developed by the JRC, based on the initial and original formulation of Zaldívar
et al. (2010, 2011). The original model has been refined, extended, and recoded for implementation in
the KNIME platform.
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It consists of ordinary differential equations whose solution allows the calculation over time of the
dissolved concentration of a chemical in cell culture as well as the internal concentration in the cells
(Figure 1). The VCBA model currently comprises four or five linked models (1-5, below) which take into
account the experimental set up conditions (6 below):
[1] The in vitro fate and transport model that calculates the time-dependent chemical concentration in
the medium as well as in the headspace. This takes into consideration a series of processes including
evaporation, partitioning of chemicals from the dissolved phase to serum proteins and lipids, adsorption
onto the plastic, and also degradation and metabolism.
[2] The cell partitioning model that was built on the assumption that once the chemical is taken up by
the cell, a partitioning occurs between three compartments: one aqueous fraction and two non-aqueous
fractions corresponding to structural components (proteins) and energy resources (lipids).
[3] The cell growth and division model that is based on a four stage based approach, with each stage
corresponding to one of the four cell cycle phases: G1, S, G2 and M.
[4] Toxicity and effects model. The direct effects of a chemical concentration, C, on cell dynamics
(survival/mortality) are expressed by using the killing rate, kt, and the no effect concentration, NEC.
[5] Mitochondrial compartment. The in vitro effects were monitored in terms of the mitochondrial
membrane potential (mmp) and were translated into a mathematical model by the addition of a new
mitochondrial compartment within the cell.
[6] Experimental set up: takes into account the surface, area, size and shape of the well or well-plate, as
well as incubation conditions (usually 37°C).
Figure 1. Schematic representation of the VCBA model.
Procedure Description
Biological Endpoint and Measurement:
CELL VIABILITY expressed as %
CELL GROWTH AND FATE
CELLULAR FUNTIONAL PARAMETERS: INTRACELULAR CONCENTRATION
Basic procedure:
The VCBA model is a mathematical approach. The model is coded and -implemented in the open-source
KNIME platform, avaialble via COSMOS space:
 http://cosmosspace.cosmostox.eu/app/home 
The KNIME workflow is designed to be user friendly, and is divided into three zones: input, core and
output (Sala Benito et al., in preparation). In the input zone, the user selects the test compound, the cell
type, and the experimental conditions; in the core zone the application of the mathematical model is
hidden; and the results are displayed in the output zone in graphical or tabular format.
page 3 / 15
© EURL ECVAM DB-ALM: Method Summary
SEURAT-1 TOOLS & METHODS CATALOGUE PAGE 105
The workflow gives us possible use of the VCBA model in an automated way and user-friendly way. This
workflow and the VCBA model can be used not only to design in vitro experiments but also for risk
assessment purposes.
Examples of the equations used in the individual model components are described in the next section: 
2.1 Model description .
A presenation on the COSMOS Automated in silico tools for in vitro to in vivo extrapolation was recorded
for the American Society for Cellular and Computational Toxicology (ASCCT). Method developer Dr.
Alicia Paini explains the composition of the model and the use of the KNIME workflows:
 https://youtu.be/vJc1UEbuWdE 
2.1 Model Description
 Model Equations [Zaldivar et al., 2010, 2011] 
The in vitro fate and transport model consists of a dynamic mass balance that includes a time-variable
chemical transport and fate model for calculating the chemical concentration in the medium as well as
in the headspace. The gas phase has been included to consider, in a second step, the possible losses and
cross contamination between the 96 wells in the TC plates, since the TC are not hermetic even though
the system was designed to minimize this aspect. To quantify this phenomenon, there are not enough
experimental data at the moment.
Assuming a well-mixed medium and headspace and that the sorption processes are fast compared with
the other processes then the mass balance equations for both compartments can be written as:
- Total concentration in the medium:
VM •  
dCT 
= AS •FAW -k•VM •Cdis (1)dt 
where V M refers to the volume of the medium (m3) and T refers to the total concentration (mg•m-3); the
first term of the rhs represents the transfer of chemical across the air-water interface whereas the second
term represent transformation/losses from the medium, e.g. degradation, decomposition, etc.
- Total concentration in the air:
A similar equation can be written for the headspace:
VH •
dCAir 
= AS •FAW - Al •Fl (2)
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To model the partitioning of an organic chemical in the medium (Kramer, 2010), we can consider that the
compounds are either purely dissolved (Cdiss), bound to the serum in the culture medium (CS), bound to
the cells (Cb) and bound to the (plastic/glass) surface of the culture vessel (Cp). Therefore, the total
concentration of an organic contaminant in the medium, CT , can be described by following equation:
CT = Cdis +Cs +Cb +CP •
SM (3)
VM 
where SM refers to the surface of the well in contact with the medium.
In the cell partitioning model we extrapolate the equation concerning the cell model. The total number
of moles of a compound ( ntot ) in the cell is their sum in the different compartments (Zaldivar et al.,
2010, 2011):
ntot =naq +np +nL =(Vaq •Caq +VP •CP +VL •CL ) (4)
where the V i 's refer to the compartment volumes (l) and the Ci 's refer to the compartments
concentration (mol• l-1). Also the total number of moles of a chemical can be expressed as:
ntot =W•Cb /MW (5)
where W is the organism weight (g), MW is the molecular weight of the chemical (g•mol -1) and Cb is the
chemical concentration in the cell (g•gw•w -1).
The chemical is assumed to be in equilibrium between the different compartments with fixed values
partition coefficients: KP =CP /Caq and KL=C /Caq .
The time evolution of this substance in the cell can be calculated by a simple mass balance, assuming
that the uptake and depuration rates r ad and rda (l•cm-2 •s-1) are proportional to the surface area of the
cell (passive diffusion) and the transfer occurs through the aqueous compartment only as:
dntot
= V 2/3 (rda •ACdiss - rad •ACaq ) (6)dt 
where Cdiss and Caq refer to the chemical concentration (mol•l-1) outside of the cell and in the aqueous
compartment of the cell (mol•l-1), respectively. Appling the chain rule of derivation to equation 4 we have:
dntot
= 
1 
•(W• dCb +Cb •  
dW 
) (7)
dt MW dt dt 
and rearranging terms we obtain:
dCb 
= 
MW•V2/3 
• ( rda •Cdiss - rad •Caq ) -
Cb 
•  
dW 
(8)
dt W W dt 
the last term represents the dilution due to growth of the cell that in the case of HepaRG and
cardiomyocytes can be neglected.
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Since the concentration in the aqueous fraction Caq is not a value that is measured, then we have to
convert in terms of Cb using the partitioning approach. The wet weight, W can also be expressed as a
function of the volumes of the different compartments:
W=  •V=  
 
•  ( Vaq +Vp +VL ) (9)
On the other hand:
VP =WP / P (10)
VL =WL / L (11)
Vaq =Waq / aq (12)
where WP, WL and Waq are the masses of proteins, lipids and aqueous compartments in the cells and P , 
L and aq their densities.
To find the correlation between Caq and Cb we have to combine ntot in equations 4-5, the partition
coefficients and equations 7-9, then we have:
(13)
where f i 's refer to the mass fraction of each compartment (aqueous, lipid, proteins) in the cell. Replacing
this equation into equation 6 and rearranging we obtain:
 
(14)
The model takes into account a cell growth and division which is a four steps mechanism: G1, S, G2, M.
In the stage-based type of modelling the matrix A , called Leslie matrix, which describes the
transformation of a cell population from time t to time t+1,
nt+1 =A•nt (15)
has the following structure:
A= 
P1 0 0 F 
G1 P2 0 0 
0 G2 P3 0 
0 0 G3 P4 
(16)
where nt is a vector describing the cell population at each stage at time t, Pi is the probability of surviving
and staying in stage i, Gi is the probability of surviving and growing into the next stage and F is the
fecundity rate per unit time (h), i=1,2,3,4. Both Pi and Gi are functions of the survival probability pi and
grow probability  :
Pi = pi •(1-  ) (17)
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Gi =pi •  i (18)
where
pi =exp(-zi ) (18)
and
i = 
(1-pi )• pi d i -1 (19)
1- pi d i -1
where zi is the hourly instantaneously mortality rate and d i is the duration (h) within the i-th stage. To
study the direct effects of a chemical concentration, C , on survival [Toxicity and effects model] may be
expressed using the following equation:
pi =exp(-zi ) (20)
by the addition of a term which can be written as:
zi = 
zi + kt(Cb-NEC)...Cb>NEC 
(21)
zi
where Cb is the internal concentration of the toxicant in the cell, kt is the killing rate and NEC is the no
effect concentration term.
The next differential equation describes the evolution in time of the cell connected to the toxicodynamic
effect described by the two parameters kt and NEC :
dn 
= -kt•(Cb - NEC) •n (22)dt 
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The Mitochondrial model 
The refined cell model is described by four compartments: lipid, proteic, aqueous and mitochondrial
(Figure 2). The interchange of the chemical through the cell membrane occurs by a diffusion mechanism
and then the chemical is distributed into the 3 compartments of the cell (aqueous, lipidic and proteic by
partitioning) and depending on the chemical size by passive (<1500Da) or mediated (>5000Da) diffusion
into mitochondrial (Alberts et al., 2002).
Figure 2: A new four-compartment cell model, including a single mitochondrial compartment. 
With regard to mitochondrial model compartment, the chemical enters through a diffusive mechanism
from the aqueous department to mitochondria:
dCmito
= Kmit • (Caq -Cmit ) (23)dt 
Where Caq is the concentration in the aqueous phase, Cmit is the concentration inside of the
mitochondria and kmit is a diffusive parameter depending on the chemical and cell line applied.
Finally, solving together the differential equations the model can simulate the predictions of the viability,
intracellular concentration, and concentration inside of mitochondria and mitochondria membrane
potential can be obtained.
Experimental set up:
The total volume of the well is given by assuming a truncated cone equation:
V W =1/3 (r 2 +r•R+R2)•h [m3] (25)
The headspace volume [m3] is given by subtracting from equation 25 the Volume of the medium.
The surface of the well in contact with the medium, S =p •(r+r)g+S ,
where r is the radius of the occupied volume and g is the slant height.
Area of the cell-based assay medium, As =π • r2m .
Model Input Parameters
[1] A fate model: chemical properties
For the fate model the following parameters are needed. They can be calculated with sevral in silico
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tools, EPI suite, QSARToolBox etc.
1. Henry constant; 2. LogKow; 3. Air and water degradation; 4. Molar volume; 5. Atomic diffusion.
[2] A cell model: mass fraction of compartments [protein, lipids, water], partition coefficients within the
cell, uptake rate. (Example with HepaRG)
A virtual cell (VC) model for the HepaRG liver cell line was established based on the VCBA model
described in Zaldivar et al., (2011 and 2012). Briefly, the model takes into account the fate of a compound
within a cell. The cell is divided in 3 compartments (aqueous, lipids, and proteins) a cell growth model
was derived, however it was set to initial G1 phase, since the HepaRG cell line does not proliferate.
Finally the model also features a toxicodynamic effect model that takes into account mortality, by means
of cell viability. The mortality parameters of the cells due to chemical effect are described by the NEC and
kt.
Table 1. Examples of Parameters for the HepaRG virtual cell model (Zaldívar et al., 2010, 2011)
Parameter type Abbreviation used
in the model 
Value Units 
Mass fraction of compartment f x (aq- 
aqueous , l-lipids, p-proteins)
faq ,
fL ,
fP 
0.72
0.012
0.268
% weight
Uptake rate rda 35.208 L m-2 h-1 
Elimination rate rad 35.208 L m-2 h-1 
Wet weight W 1.79•10-9 gr
Volume of the cell V 1.67•10-15 m3 
Cell cycle* duration G1 849 h
Mortality M 1.19•10-6 h-1 
*HepaRG cell do not proliferate the models keeps only one cell cycle step G1.
[3] A cell growth model: information on cell cycle dynamics. See Table 1. Cell cycle duration G1, S, G2, M.
[4] A toxic effect model [5] mitochondrial model: NEC and killing rate kt
In order to optimize the model experimental curves, concentration response curve are needed. These i n
vitro curves should be measured at 24 hrs for cytotoxicity and mmp effects.
Figure 3. Example of concentration response curve, measured output cell viability.
[6] Experimental set up 
List of parameters to describe the experimental set up:
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Incubator temperature
The parameters used to describe the configuration of the well test plate, are (examples for 96 Well plate):
Top internal radius: 3.425.10-3 m.
Bottom internal diameter: 3.175.10-3 m.
Depth: 10.76 .10-3 m.
Bottom area 3.16 .10-5 m2 
Volume of medium. 100uL ( VM = 10-7 m3 ),
Headspace volume (m3 ): VH = 2.683.10-7 m3 .
Amount of protein in medium: Assuming a 5% (v/v) serum in the medium, then [S]0 = 2.34 10-2 mol
protein m -3 .
Model Settings:
The model was built taking into consideration both single and repeat exposure.
1) VCBA Model mode:
This mode is chosen to run the Cell Based Assay Model, based on a concentration-response curve. The
concentrations are written in one column of an XLS file (node XLS Reader: Simulation Data). The final
result is a graphical representation made up of four graphics; with the evolution in time of the chemical
concentrations in the medium, headspace, and inside the cell, and the number of cells.
2) Parameter Optimization mode:
This mode is selected to optimise values of the toxicodynamic parameters, the No Effect Concentration
(NEC) and the killing rate (kt). The initial values of the NEC and kt , along with experimentally derived cell
viability values, are entered in the Optimization Parameters tab.
3) Check Optimization mode:
From the new values of NEC and kt obtained by running the Parameter Optimization mode and the
experimental values in the XLS file, a figure can be drawn which is used to check how good the model fits
the experiments.
4) Repeat dose mode:
This mode simulates the effects of different doses and regular intervals of exposure. The results are
depicted as a graph, representing a time-response curve of the cell viability (using different doses).
3. Method Performance
Robustness of the Method
General performance measures:
The VCBA model has undergone an extensive evaluation, described in the next section: 3.1 Evaluation of
Model Performance.
3.1 Evaluation of Model Performance
Optimization Analysis
We briefly explain how to optimize the values of the Toxicity effect model: the No Effect Concentration
(NEC) and the killing rate (kt). The initial values of the NEC and kt, along with experimentally derived cell
viability values, are entered in the Optimization Parameters tab.
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Table 2. Input experimental values introduced into workflow: concentration (of the test compound),
viability (response), and standard deviation.
Input experimental values are written into three columns of the XLS file introduced into workflow by the
XLS Reader node: concentration (of the test compound), viability (response), and standard deviation (or
error), Table 2. The results of the parameter optimization are new values of NEC and kt that minimize
the differences between the experimental viability and the viability from the model (error). The input
parameters can be manually (recommended) or automatically selected by the user from the XLS Reader
node. In the automatic mode the selection is the entire data sheet. If the selection is done manually, the
user must select the rows and columns of the excel sheet which are of interest to him.
Evaluation of the goodness-of-fit of the VCBA model
From the new values of NEC and kt obtained by running the Parameter Optimization mode and the
experimental values in the XLS file, a figure can be drawn which is used to check how good the model fits
the experiments (goodness of fit). The core model calculates the simulated viability for each of the
chemical concentrations using the NEC and kt values calculated in the Parameter Optimization Mode.
This functionality was separated from the Parameter Optimization in order to operate and test the values
of NEC and kt from other sources without running each time the time-consuming Parameter
Optimization Mode.
Test Compounds
Chemicals used
Table 3 reports the list of chemicals present in the VCBA model and corresponding cell line tested.
Table 3. List of chemicals tested for each type of cell type 
Name of Compound Single Exposure Repeat Exposure 
Cardiomyocyte HepG2 HepaRG A549 HepaRG 
acetaminophen X X X X
acetylsalicylic acid X
acrylamide X
amiodarone X X X X
caffeine X X X X
carbamazepine X
colchicine X
coumarin X
cycloheximide X X
diazepam X
diquat dibromide X
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estragole X X
ethanol X
isopropanol X
Limonene X
nicotine X X
pentachlorophenol X
rifampin X
sodium lauryl sulphate X X
tert-butylhydroperoxide X
tetracycline hydrochloride X
thioridazine hydrochloride X
valproic acid X X
verapamil hydrochloride X X
4. Discussion
Known strengths and/or limitations of the method
The VCBA model requires different types of data, ranging from the biochemical, and physicochemical
processes that occur in biological systems. Furthermore cell population or certain physiological and
pathological conditions (example contamination) can influence a chemical reaction within the well and
thus should be explored how to include these effects into the model prediction. These types of data are
not always available from one source, which may lead to difficulties in establishing a reliable source of
accurate and consistent information. Information gaps or poorly characterized processes can lead to
unreliable simulations. Therefore, it is important to emphasize that the reliability of the simulations
depends on the corresponding model and the uncertainty related to the incorporated data.
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6. Abbreviations & Definitions
As medium-headspace exchange surface area, m2,
Al headspace losses surface area, m2,
alfa a parameter linked to the in silico simulation of the mmp values.
C Concentration, mg/m3,
[C] concentration of cell lipid in medium, kg m-3,
Caq the concentration in the aqueous phase,
Cb convention in the cell, g.gw.w-1,
Cmit the concentration inside of the mitochondria,
COSMOS EU integrated project: COSMOS develops an integrated suite of computational tools
to predict the effects of long-term exposure to chemicals in humans based on in
silico calculations and estimation techniques. Website: http://www.cosmos-tox.eu/ 
D diffusion coefficient, m2 s-1,
d i duration (in hours), within the i-th stage,
F mass flow, mg m-2 s-1,
F the Faraday constant
f i refer to the mass fraction of each compartment (aqueous, lipid, proteins) in the cell,
H Henry law constant, Pa m3 mol-1,
KC cells-medium partitioning coefficient, m3 kg-1 lipid,
KGL gas-liquid distribution coefficient,
kmit diffusive parameter in mitochondria depending on the chemical and cell line
applied,
KNIME Konstanz Information Miner, is an open source data analytics, reporting and
integration platform, which integrates various components for machine learning
and data mining through its modular data pipelining concept. 
Website: www.knime.org 
Kow octanol-water partition coefficient
KP plastic-medium partitioning coefficient, m,
KS partitioning coefficient between serum and medium, m3 mol-1,
kAW two film mass transfer coefficient, m s-1,
kG air film mass transfer coefficient, m s-1,
kL liquid film mass transfer coefficient, m s-1,
kt killing rate,
k reaction rate constant, s-1,
mmp mitochondrial membrane potential
MW molecular weight, g/mol
n number of moles of a compound
NEC no effect concentration
P pressure, Pa,
QIVIVE Quantitative In vitro to in vivo extrapolation
R universal gas constant
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R A programming language and software environment for statistical computing and
visualisaton. Website: http://www.r-project.org/ 
Sc Schmidt number,
[S] concentration of proteins in medium, mol m-3,
SEURAT EU integrated projects cluster. SEURAT-1 Research Initiative develops a long-term
research strategy leading to pathway-based human safety assessments in the field of
repeated dose systemic toxicity testing of chemicals. Website: 
http://www.seurat-1.eu/ 
SM plastic- medium exchange surface area, m2
t time, s,
T temperature, K
V volume, m 3 or in liter L,
W organism wet weight, g,
zi mortality rate, h.
Superscripts used in the formula's 
diss dissolved
p plastic
S serum
T total
Subscripts used in the formula's 
AW air-water
degr degradation
l loses
M medium
H headspace
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DB-ALM Method summary n° 163 : The Human Bio-Accumulation Model
Systemic Toxicity, Bioavailaibility
The Human Bio-Accumulation Model is a mathematical model for screening of chemicals for human
bioaccumulative potential using a simple physiologically based toxicokinetic model, which ranks
chemicals based on their human bioconcentration factor (hBCF).
1. General Information
Corresponding author(s):
Dr. Andrew Worth, European Commission - Joint Research Centre 
Date of data sheet creation: 10 February 2015
Last version number: 1
Last update: 10 February 2015
Section No.5 Contact Persons provides a complete list of the authors and method developers.
The method summary presented here describes a mathematical model.
In the context of this document, the term "method" in the paragraph headings refers to the hBCF PBK
model.
Proprietary and/or Confidentiality Issues:
None. Work carried out at the Joint Research Centre with partial support from the FP7 COSMOS project.
Status
Development completed
The hBCF - PBK model for simulation of single and repeat
exposure is built in R and translated in KNIME (the Konstanz
Information Miner) automated workflows, as a part of the
COSMOS project (Integrated In Silico Models for the Prediction of
Human Repeated Dose Toxicity of Cosmetics to Optimise Safety),
within the SEURAT-1 Research Initiative (Safety Evaluation
Ultimately Replacing Animal Testing 1). 
More information on the COSMOS project is available on its
dedicated website:
http://www.cosmostox.eu
The KNIME workflows and documentation are available via COSMOS Space:
http://cosmosspace.cosmostox.eu
A web version of the models was also implemented, allowing to execute the models via a web browser. It
is available through the COSMOS KNIME WebPortal:
http://knimewebportal.cosmostox.eu
2. Method Definition
Purpose of the Method
TYPE OF TESTING : Screening, Part of an integrated testing strategy
LEVEL OF TOXICITY ASSESSMENT : Risk assessment
PURPOSE OF TESTING : Safety
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Context of use
Toxicologists evaluating personal care products and cosmetics have the possibilities to find within the
product several harmful ingredients such as pesticides, carcinogens, reproductive toxicants, endocrine
disruptors, plasticizers, degreasers and surfactants. To prevent cases in which the presence of a
contaminant can result in unacceptable consequences for human health, it is generally agreed that risk
analysis has to be carried out on the specific chemical. However, this is not always feasible due to the
large number of existing chemicals and, for many of them; there is a lack of detailed information on their
behavior in the environment and to human exposure. Generally screening approaches are necessary to
prioritize and to select chemicals of concern for a more detailed risk characterization and analysis (Muir
and Howard 2006; Daginnus et al., 2011).
Substances identified during a screening phase as PBT or vPvB - (very) persistent, (very) bioaccumulative
are of the highest concern and subjected to a detailed risk assessment (ECHA, 2014).
The risk assessment paradigm is based on two aspects: first, the hazard of a given chemical, which ideally
can be related to its physico-chemical properties, and second its exposure levels to ecosystems and to
humans. A comparison of exposure levels and safe chemical doses/concentrations is then carried out
and the risk is evaluated. Hazards of a substance are evaluated according to its persistence in the
environment, long-range transport potential (LRTP), bioaccumulation characteristics and toxicity
(Klasmeier et al. 2006). An important characteristic which was addressed in the work of Tonnelier et al.,
(2012) was to assess the screening of chemicals for human bioaccumulative potential using a simple
physiologically based toxicokinetic model, which ranks chemicals based on their human bio
concentration factor (hBCF).
A generic physiologically based kinetic (PBK) model, based on in vitro human liver metabolism data,
minimal renal excretion and a constant exposure, was developed to predict the bioaccumulation
potential of a chemical. The aim of the presented method is to provide an open source approach for
assessing the potential of chemicals to bioaccumulate in humans following realistic exposure scenarios.
Target Users and Uses
The model can be used by Risk Assessor, when performing risk assessment, to rank potency of chemicals
based on their BCF, and thus give priority for testing (refinement of in vitro strategy testing), especially if
found in traces as contaminants in cosmetics products.
Scientific Principle of the Method
Model components
The hBCF - PBK model has been developed by the JRC, based on the initial and original formulation of
Tonnelier et al. (2012). The original model has been refined, extended, and recoded for implementation
in the KNIME platform.
As a starting point a generic PBK model was used that, based on in vitro liver metabolism data, minimal
renal excretion and a chronic exposure, is able to assess the bioaccumulative potential of a chemical. The
approach has been analysed using literature data for some well-known bioaccumulative compounds,
data from the ECVAM (European Centre for the Validation of Alternative Methods) database, and for a
subset of the ToxCast phase I chemical library.
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Figure 1. Left: Schematic representation of a minimal PBK model used to simulate perfusion-limited
uptake of compound under a chronic exposure; Right: time profile of the increase in blood
concentration of the chemical with repeat exposures. The dotted line is the trajectory of the averaged
PBK model (from Tonnelier et al., 2012). 
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Procedure Description
Biological Endpoint and Measurement:
Bioavailability
Systemic availability
Bioaccumulation - the continuous increase in the concentration of a chemical in an organism,
compared to the chemical’s concentration in the environmental media to which the organism is
exposed, i.e., air, water, soil, food, etc.
Endpoint Value:
Human Bioconcentration Factor (hBCF)
Basic procedure:
The hBCF PBK model is a mathematical approach. The model is coded in R and implemented in the
open-source KNIME platform. The workflow is available through the COSMOS space:
 http://cosmosspace.cosmostox.eu/app/space/ 
The equations used in the individual model components are described in the next section: 2.1 Model
description.
A presenation on the COSMOS Automated in silico tools for in vitro to in vivo extrapolation was
recorded for the American Society for Cellular and Computational Toxicology (ASCCT). Method
developer Dr. Alicia Paini explains the composition of the model and the use of the KNIME workflows:
https://youtu.be/vJc1UEbuWdE
2.1 Model Description
Model Equations
Based on Tonnelier et al. (2012) the simplified PBK model was re-written in R. The three compartment
physiologically based model equivalent to the minimal Simcyp model (Simcyp Limited, Sheffield, UK)
was implemented. The absorption of the substance is assumed to occur at different times ( ti ) at a small
dose (noted D) , and the elimination occurs through renal filtration and liver metabolism (Tonnelier et
al., 2012). The toxicokinetics of each substance is described by a system of differential equations of the
following form, and taking into account the uptake that appears in the portal vein compartment using a
supplementary compartment, leading to the following coupled system of differential equations:
VPV •  
dCpv 
= QPV • (CSYS -CPV)+ fa•FG •ka•Dexp(-ka(t-ti ))H(t-ti ) [1A]dt 
VPV •  
dCpv 
= QPV •(CSYS -CPV ) + ka •A(t) [1B]dt 
VPV •  
dCPV 
= QPV • (CSYS -CPV ) +D/T [1C]dt 
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Vliv •  
dCliv 
= QPV • (CPV -Cliv ) + QHA •( CSYS - Cliv ) -CLH •Cliv [2]dt 
VSS •  
dCSY 
= QPV • (Cliv -CSYS ) + QHA •( Cliv -CSYS ) -CLR • CSYS dt 
where
CPV ,Cliv and CSYS are the concentrations of the compound in the portal vein, liver and systemic
circulation, respectively;
 VPV and Vliv are the volumes of portal vein blood and liver, respectively,
 QPV and QHA are the blood flows in the portal vein and hepatic artery;
 fa is the fraction of the compound absorbed into the enterocytes;
 FG is the intestinal availability of the substrate;
 ka is the first-order absorption rate constant;
 H is the Heaviside step function;
 CLH is the hepatic clearance and
 CLR is the renal clearance.
Model developers considered here a complete absorption, fa =1 , and a full intestinal availability FG =1.
The rate of renal excretion is estimated by multiplying the percent of unbound chemical by the normal
adult glomerular filtration rate ( Q f =6.7l/h) (Rotroff et al., 2010). The hepatic clearance CLH is based on
the whole-blood toxicant concentration and is derived from the experimentally measured intrinsic
metabolic clearance (CLuin t), based on unbound drug concentration.
The route of exposure does not appear explicitly in the averaged model and the amount of compound, D 
, could be seen as the result of the sum of different uptake routes (oral and dermal for instance). After a
transient, the averaged model stabilizes on a steady state ( C*PV, C*Siv, C*SYS ) from which the human
bioconcentration factor is calculated as:
hBCF =
C*SYS VPV /t [3]D/T 
The concentration in the systemic compartment is used to measure the extent to which a compound
accumulates in the body and is compared with a theoretical concentration of compound in the portal
vein, assuming a complete absorption of the dose D . The term D/VPV reflects the concentration of the
compound in the portal vein where the volume of portal vein is used as a reference. This choice stems
from the occurrence of the dose D in the kinetics equation of the portal vein where the dose D occurs
through the rate flow D/T . The quantity t in Equation [3] is a time set to one hour. Therefore, the factor
VPV /t is a normalizing factor that provides a dimensionless bioaccumulation factor.
The steady-state is reached when the time-variations of the concentrations vanish and it is
straightforward to calculate C*SYS from [2] by equating to zero all the rate of change in the different
compartments (left-hand side of system [2]). From [3], the approximated value of hBCF is found: 
hBCF =
VPV 
[4]
CLH +fuQf ( 1+ 
CLH )
QPV+QHA 
where CLR = fuQf is used. Neither the dose D nor the duration T occur in the analytical expression and
therefore the proposed metric for bioaccumulation assessment (Expression [4]) is, on average,
independent of the exposure scenario used to compute it.
Input data: Model Parameters
Chemical Parameters: MW, LogKow, pKa.
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Additionally the following parameters are needed:
The blood ratio (which value is set for all chemical to 0.55),
Clint - the clearance values for liver (µM/min/ 106 cells) and kidney (L/h),
Fu - unbound fraction of chemical in plasma,
Fumic - the free fraction of compound in the microsomal preparation.
C*SYS steady-state concentration
Tsys time in h,
PBK model Parameters: QPV = portal vein flow, 63 L/h.
QHA = hepatic arterial flow, 18 L/h.
QF = Standard glomerular filtration rate, 6.7 L/h.
VPV = Volume portal vein, 3.2 L.
Vliv = Volume Liver, 1.75 L.
Vsys = Volume systemic circulation, 1 L.
FG =intestinal availability (absorption rate), 1.
fa= absorption rate, 1.
Liver weight= liver weight, 1500 g
D= dose, 0.01 mg.
T= dose interval, 0.1 h.
Init= initial time point (simulation), 0 h.
End= end time point (simulation), 5 h.
3. Method Performance
Robustness of the Method
General performance measures:
The hBCF PBTK model underwent an extensive evaluation, described in the next section: 3.1 Evaluation
of Model Performance.
PBK Model Validation
The PBK model described in Tonnelier et al. (2012) was validated as follows: the PBK model simulations
for twelve chemicals were compared with published pharmacokinetic/toxicokinetic data and published
PBK model predictions.
The results agree with those obtained by Rotroff et al. (2010) concerning 2,4-dichlorophenoxyacetic acid,
oxytetracycline dehydrate, triclosan, bisphenol A and parathion.
Simulated results, at 40 h, agree with experimental data on plasma elimination half-lifes of warfarin for
the two enantiomers: R-warfarin 46 ± 7 h and S-warfarin 36 ± 13 h, respectively.
The prediction of the maximum plasma concentration for chlorpyrifos and propranolol hydrochloride
was similar to human kinetic studies and published PBPK model results. In the last case, also the data on
the time at which Cmax was reached are gathered and compared with the simulation, i.e., 2 h in the two
experiments (10 and 20 mg day−1 oral dose) and 2.1 h in the simulations.
Apart from the well-known persistent compounds such as PCBs, DDT and PFOS were uncertainty on the
estimations (Simcyp could only run for 200 days, and the values were extrapolated), and the
experimental variability (e.g. for PCB-153, published values between 5 and 27.5 years were found) tends
to be higher, the main discrepancy is obtained for thioridazine where the predicted elimination half-life
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value is much higher than the experimental one: an elimination half-life that oscillates around 26 h has
been reported while the model predicted 87 days.
This points out a limitation of the approach due to the fact that the model only considers liver
metabolism and minimal renal excretion, whereas the main excretion route of thioridazine seems to be
through the faeces.
A similar limitation holds for oxytetracycline where the observed overprediction of the concentration
possibly lies in the fact that a 100% oral absorption has been considered, whereas a low oral
bioavailability has been reported for this compound (Nielsen and Gyrd-Hansen 1996). However, as
stated before, the main interest of model developers was a fast screening procedure to estimate human
bioaccumulation potential for risk assessment and, as a conservative approach, false-positive predictions
were not main concern.
Test Compounds
In Tonnelier et al. (2012), the chemicals selected were: 55 organic chemicals, mostly drugs and
pesticides, which is a subset selected from the list of an international ICCVAM validation (2009), and a
subset of 35 substances (Rotroff et al. 2010), mostly pesticides, of the ToxCast Phase I chemical library
(http://www.epa.gov/nccttoxcast/chemicals.html). For the ECVAM database chemicals, liver
metabolism and unbounded fraction data were taken from Pelkonen et al. (2009) and Rousu et al. (2010),
whereas a similar data for the chemicals in ToxCast phase I have been published in Rotroff et al. (2010).
The list of selected chemicals as well as their physico-chemical parameters can be found as the
Supplementary Material in Tonnelier et al. (2012).
4. Discussion
Known strengths and/or limitations of the method
Due to the high number of substances produced by the chemical industry, there exists the need to
prioritise them to focus the risk analysis effort. Therefore, the aim of a chemical prioritization exercise is
to screen a considerable number of substances to select the ones for which a detailed risk assessment
would be necessary according with the type of selection criteria defined beforehand.
Bioaccumulative potential (B) is an important element in all exercises of chemical prioritization. The
approach followed (if no experimental data are available) is based on the calculation of the lipophility of
the substance, sometimes based on correlations between a certain human Bioconcentration Factor
(hBCF) and the octanol-water partition coefficient (Kow). Even though this approach takes into account
the fact that hydrophobic compounds tend to bioaccumulate in lipids, it does not consider the processes
that will tend to decrease the concentration of the compound in a certain organisms, such as excretion,
depuration and/or metabolization processes.
A direct and straightforward estimation of the hBCF based solely on a limited number of compound
parameters would be of advantage in prioritization of chemicals and may provide an efficient
pre-screening criterion for a rapid assessment, this approach can be applied in the assessment of
cosmetics ingredients.Tonnelier et al., (2012) developed a simplified mapping based on  in vitro human
liver metabolism data, minimal renal excretion and a constant exposure. Two parameters to assess the
bioaccumulation potential of compounds: clearance and protein-binding affinity were measured in vitro
to be used as model input. The proposed measure of hBCF is derived from the steady state reached by the
PBK model after successive exposures.
This model was designed to incorporate not only the chemical properties of the compounds, but also the
processes that tend to decrease the concentration of the compound, such as metabolism. Following this
work the generic PBK model was implemented and re-written in R, in the open source KNIME interface
using MySQL database. The outputs are:
a graphical figure expressed as concentration versus time;1.
the systemic concentration (Csys) at steady state of the selected compound; and2.
the human bioconcentration factor (hBCF).3.
The ability to describe the bioaccumulative potential of a compound through the metabolism combined
with the renal excretion shows that the clearance is the main determinant factor for human
bioaccumulation.
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The vast majority of the approaches to predict the bioaccumulation potential consider only the
partitioning of the chemical and not the biotransformation potential of the organism. The results
obtained in this study suggest that it is possible to have a pre-assessment of the human potential
bioaccumulation by performing two in vitro tests: one to calculate the chemical binding to plasma
proteins and the other to estimate the liver clearance by in vitro measuring the metabolite formation
and/or the substrate depletion of the compound using human hepatocytes.
Both types of tests are suited to high-throughput analysis and therefore can be used for screening
purposes for the prioritisation of new compounds. However, there are several aspects that should be
considered carefully in this approach. First, it is assumed that the in vitro measurements adequately
describe the in vivo activity. Second, the experimental conditions in the in vitro tests should have been
properly selected, e.g., compounds concentration low enough to avoid saturation when measuring
substrate depletion. Third, concerning the in vitro clearance, it is assumed that there is no further
biotransformation in the gastrointestinal tract and, in addition, metabolism occurs only in the liver.
Normally, all these assumptions are conservative, and therefore, it is more probably to obtain false
positives than false negatives as it can be observed in the compounds that deviate in the comparison
between experimental data and predictions.
Potential for future development
Risk assessors could use this simple PBK model to rank chemicals based on their potency, and thus give
priority for testing (refinement of in vitro strategy testing), especially if found in traces as contaminants in
cosmetics products. Furthermore, there is the need to develop sensitive throughput analytical techniques
that can allow a better understanding of the kinetics aspects in  in vitro experiments. This would also
help in determining a general procedure for performing in vitro–in vivo extrapolation (IVIVE) and being
able to move from concentration to dose response without the use of animal experiments (Adler et al.
2011). This IVIVE approach could be applied to cosmetics ingredients and would be based on their
potential to bio-accumulate in human.
The relevant dose would be calculated back by reverse dosimetry, using PBK modelling. This would be a
good approach to be implemented in the cosmetics world; however, there is a lack of experimental data.
These data could be easily produced using HTS techniques in a fast and reliable way.
Model developers recommended this approach, by first screening literature for available data for
cosmetics ingredients and/or to generate new experimental data for the specific cosmetics ingredients,
especially protein binding affinity and the hepatic clearance. It is therefore essential that in vitro
metabolic clearance tests with metabolic competent cell lines be performed for suspected B compounds.
Conclusions and recommendations
Dermal exposure is an essential exposure pathway and should be included in the present PBK
model. This refinement of the model is at the moment being carried out at JRC, once the model is
validated it could be used for prediction and potency ranking using the hBCF.
To include Monte Carlo Simulation to take into account variability within the human population. To
be able to use the model and scale it up to all human population.
Develop more refined QSAR models to overcome uncertainties.
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6. Abbreviations & Definitions
CPV the concentrations of the compound in the portal vein,
Cliv the concentrations of the compound in the liver
CSYS the concentrations of the compound in the systemic circulation
CLH is the hepatic clearance and
CLR is the renal clearance.
CLuint experimentally measured intrinsic metabolic clearance
COSMOS EU integrated project:. COSMOS deveops an integrated suite of computational
tools to predict the effects of long-term exposure to chemicals in humans based
on in silico calculations and estimation techniques. Website:
http://www.cosmos-tox.eu/
D amount of compound,
ECVAM European Centre for the Validation of Alternative Methods. As of 2011, ECVAM
has been established as the European Union Reference Laboratory for
Alternatives to Animal Testing (EURL ECVAM).
fa the fraction of the compound absorbed into the enterocytes;
FG the intestinal availability of the substrate;
H the Heaviside step function;
hBCF human Bio-Concentration Factor
ICCVAM Interagency Coordinating Committee on the Validation of Alternative Methods, a
permanent committee of the NIEHS under the National Toxicology Program
Interagency Center for the Evaluation of Alternative Toxicological Methods
(NICEATM). ICCVAM is composed of representatives from 15 U.S. Federal
regulatory and research agencies that require, use, generate or disseminate
toxicological and safety testing information.
ka the first-order absorption rate constant;
KNIME Konstanz Information Miner, is an open source data analytics, reporting and
integration platform, which integrates various components for machine learning
and data mining through its modular data pipelining concept. Website: 
www.knime.org
PBK Physiologically Based Kinetic models
QPV and QHA are the blood flows in the portal vein and hepatic artery;
QSAR Quantitative Structure Activity Models
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R A programming language and software environment for statistical computing
and visualisaton. Website: http://www.r-project.org/
SEURAT 1 EU integrated projects cluster. SEURAT-1 Research Initiative develops a
long-term research strategy leading to pathway-based human safety
assessments in the field of repeated dose systemic toxicity testing of chemicals.
Website: http://www.seurat-1.eu/
VPV and Vliv are the volumes of portal vein blood and liver, respectively,
VSS is the volume of distribution of substrate;
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DB-ALM Method summary n° 168 : PPAR full agonists’ pharmacophore-based predictor
Systemic Toxicity
The PPAR full agonists’ pharmacophore-based predictor is an in silico model to predict the potential of
chemicals to bind and activate PPARγ (PPARγ full agonism prediction). The model is based on a two-step
procedure: docking of the chemical structures into the PPARγ binding site and filtering using a
pharmacophore model of PPARγ full agonists.
1. General Information
Corresponding author(s):
Dr Ivanka Tsakovska, Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of
Sciences (BAS) Bulgaria
Date of data sheet creation: 16 November 2015
Last version number: 1
Last update: 16 November 2015
Section No.5 Contact Details provides a complete list of the authors and method developers.
The method summary presented here describes a mathematical model.
In the context of this document, the term "method" in the paragraph headings refers to the model.
Proprietary and/or Confidentiality Issues:
Public
Status
Development
Development completed. The PPARγ full agonists’
pharmacophore-based predictor was developed as a part of the
COSMOS (Integrated In Silico Models for the Prediction of Human
Repeated Dose Toxicity of Cosmetics to Optimise Safety), within
the SEURAT-1 (Safety Evaluation Ultimately Replacing Animal
Testing) Research Initiative. More information on the project is
available on its dedicated website: 
http://www.cosmostox.eu 
2. Method Definition
Purpose of the Method
TYPE OF TESTING : Screening
LEVEL OF TOXICITY ASSESSMENT : Toxic potential
Context of use
PPARγ is one of the important nuclear hormone receptors that contribute to excessive accumulation of
triglycerides in hepatocytes. A prosteatotic AOP, integrating the ligand-induced activation of the PPARγ
as a molecular initiating event (MIE) has been proposed (Al Sharif et al., 2014). The PPARγ full agonists’
pharmacophore-based predictor is intended for prediction of this particular MIE. Thus it could be used
for the in silico screening of full agonists of hepatic PPARγ that can function as steatosis inducers.
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Scientific Principle of the Method
Taking into consideration that ligand-dependent activation of PPARγ can be a molecular initiating event
(MIE) that triggers downstream events leading to liver steatosis, the molecular docking model can be
used for in silico prediction of potential prosteatotic compounds that are PPARγ full agonists. The i n
silico model was developed using data for PPARγ full agonists extracted from Protein Data Bank (PDB) (3D
receptor-ligand complexes, www.rcsb.org) and from scientific literature. It includes development of a
pharmacophore model of PPARγ full agonists and implementation of virtual screening (VS) protocol to
dock the chemical structures into the PPARγ binding site and to filter the developed pharmacophore.
Model Description
Structural and experimental data for 439 PPARγ ligands were collected from PDB and the scientific
literature (publicly available at http://biomed.bas.bg/qsarmm/). A subset of 170 PPARγ full agonists was
extracted from the initial dataset. The selected ligands constituted a structurally diverse dataset of PPARγ
full agonists with relative efficacy ≥ 70% and/or PDB ligands with structural features fitting the developed
PPARγ full agonists’ pharmacophore.
The pharmacophore model was built based on the three most active agonists extracted from PPARγ PDB
complexes (Tsakovska et al., 2014). It outlines seven important pharmacophore features that were
observed in the most active agonists: four polar atoms and functional groups capable of performing
hydrogen bonding and ionic interactions and three hydrophobic and aromatic structural elements. The
seven-feature pharmacophore model was evaluated further among 21 full agonists from PDB, selected
based on reliable data about their full agonistic activity. The analysis was performed by superposition of
the agonist structures on the pharmacophore model and estimation of the correspondence between
pharmacophore points and their respective substructures. Most of the compounds comprise 4–5
pharmacophore features. Thus for the purposes of the subsequent VS protocol the five-points
pharmacophore model was used.
The VS protocol developed consists of three steps:
protein preparationi.
docking of the ligands into the PPARγ binding siteii.
filtering of the generated poses based on the five-points pharmacophore model of PPARγ full agonists.iii.
The last step means the final poses that did not satisfy the pharmacophore were eliminated.
The pharmacophore was developed using the “Pharmacophore Query Editor” tool in molecular
modelling (MM) platform MOE v. 2014.0901 (CCG Inc.). The application refers to the generation of a
pharmacophore hypothesis for the binding interactions in a particular active site. In MOE, the
computerised representation of a hypothesised pharmacophore is called a pharmacophore query. A
MOE pharmacophore query is a set of query features that are typically created from ligand annotation
points.
The receptor’s ligand binding domain used in the docking protocol (X-ray structure of PPARγ with
rosiglitazone, PDB ID 1FM6) was initially prepared using the Protonate3D application in MOE. This
application assigns the hydrogens following the optimal free energy proton geometry and ionisation
states of titratable protein groups using the Generalized Born electrostatics model. The physiologically
relevant parameters were set during the minimisation: temperature 310°K; pH = 7.4; ion concentration:
0.152 mol/L. The ligands were docked into the binding site of the prepared protein structure. The
London dG scoring function without subsequent refinement was applied to score the poses of the
docked ligands (MOE). The highly scored poses of each ligand with a negative value of the scoring
function only were kept. The pharmacophore model was used as a placement method in the docking
procedure. 
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Procedure Description
Biological Endpoint and Measurement:
Receptor binding: Peroxisome proliferator-activated receptor gamma 1 (PPARγ 1)
Receptor binding: Peroxisome proliferator-activated receptor gamma 2 (PPARγ 2)
Experimental System:
 In silico mathematical model to predict the potential of chemicals to bind and activate PPARγ1 and
PPARγ2, jointly referred to as PPARγ
3. Method Performance
Test Compounds
Curated data from PDB and scientific literature consisted of 170 PPARγ full agonists and 87 partial
agonists that have been extracted from the initial dataset collected (structural and biological data for 439
PPARγ ligands, publicly available at http://biomed.bas.bg/qsarmm/). The threshold proposed by Henke
et al. (1998) was adopted who considered full agonists those compounds that elicited in average at least
70% activation of PPARγ as compared to rosiglitazone.
Predictive capacity:
The model was evaluated on different datasets:
Application of the model on the set of 170 PPARγ full agonists. In total 144 out of the 170 ligands were
correctly predicted as full agonists (model sensitivity of 85%).
Application of the model on a subset of 87 PPARγ partial agonists. In total 38 did not pass the filter
and were correctly classified as not being full agonists (model specificity in relation to the partial
agonists of 44%).
Application of the model on a subset of 2527 decoys randomly extracted from the full set of 25867
PPARγ decoys (each 10 th structure was selected after removal of duplicates) in DUD-E database
(Directory of Useful Decoys - Enhanced, http://dude.docking.org); of which 1949 were correctly
classified as not being full agonists (model specificity in relation to decoys of 77%).
Applicability:
The model is based on publicly available structural and biological data for PPARγ full agonists. Therefore
it is applicable to structures possessing the typical pharmacophoric features of PPARγ full agonists.
4. Discussion
Known experimental strengths and/or limitations of the method
The model is based on reliable 3D structural data and is applicable to broad range of chemical structures
possessing the typical pharmacophoric features of PPARγ full agonists.
The model is of broader toxicological significance since the MIE has been implicated in a range of
adverse effects, including developmental and reproductive toxicity.
More conservative approach is applied meaning implementation of the less restrictive five-points
pharmacophore model. This gives higher probability to predict false positives (partial agonists predicted
as full) than false negatives.
In general scoring is the critical step in the docking simulations. There is no universal scoring function
that is suitable for all types of binding pockets and ligands. Thus the prediction ability of the developed
model is restricted by inherent limitation of the scoring function used in the docking procedure.
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The application of the model requires availability of specialised molecular modelling software.
Technical requirements
Computer system capable of running MOE molecular modelling software.
Potential for future development
Further refinement of the model to differentiate better between full and partial agonists; elaboration of
free docking software.
Comparisons to other methods
The present model is built on extended data set of full agonists covering most of the publicly available
data in PDB and scientific literature. Thus it is applicable to compounds with much broader structural
range.
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6. Abbreviations & Definitions
AOP: Adverse Outcome Pathway
COSMOS: EU Integrated Project. COSMOS developed an integrated suite of computational
tools to predict the effects of long-term exposure to chemicals in humans based
on in silico methods. Website: http://www.cosmostox.eu
Decoy: Compounds that are selected to resemble the receptor binders’ physicochemical
properties but at the same time are topologically dissimilar to them in order to
minimise the likelihood of the actual binding
Docking: Modelling technique that positions the ligand in different orientations and
conformations within the binding site to calculate optimal binding geometries
and energies
DUD-E database: Directory of Useful Decoys - Enhanced
MIE: Molecular Initiating Event
MM: Molecular Modelling
PDB: Protein Data Bank http://www.rcsb.org/pdb/home/home.do
Pharmacophore: An ensemble of steric and electronic features that is necessary to ensure the
optimal interactions with a specific biological target and to trigger (or block) its
biological response
PPARγ: Peroxisome Proliferator-Activated Receptor γ
SEURAT-1: Safety Evaluation Ultimately Replacing Animal Testing 1
VS: Virtual Screening
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DB-ALM Method summary n° 169 : QSAR model for the prediction of LXR binding potential.
Systemic Toxicity
This quantitative structure-activity relationship ((Q)SAR) model is a classification model (based on
PLS-DA) for the prediction of Liver X Receptor (LXR) binding potential. The binding and activation of
LXR has been identified among the molecular initiating events leading to liver steatosis. 
1. General Information
Corresponding author(s):
Dr Simona Kovarich, S-IN Soluzioni Informatiche S.r.l. Italy
Date of data sheet creation: 03 November 2015
Last version number: 1
Last update: 03 November 2015
Section No.5 Contact Details provides a complete list of the authors and method developers.
The method summary presented here describes a mathematical model.
In the context of this document, the term "method" in the paragraph headings refers to the model.
Proprietary and/or Confidentiality Issues:
Public
Status
Development
Development completed. Developed in the FP7 COSMOS Project,
which was part of the Research Initiative SEURAT-1: Towards the
Replacement of In Vivo Repeated Dose Systemic Toxicity Testing
(2011-2015). More information on the COSMOS project is available
on its dedicated website:
http://www.cosmostox.eu
The model is implemented as a KNIME workflow, available on the COSMOS project COSMOS Space
website:
http://cosmosspace.cosmostox.eu
A web version of the model was also implemented, allowing to execute the model via a web browser. It is
available through the COSMOS KNIME WebPortal: 
http://knimewebportal.cosmostox.eu 
A tutorial is available at:
https://www.youtube.com/watch?v=EkB1i9a4TWI
2. Method Definition
Purpose of the Method
TYPE OF TESTING : Part of an integrated testing strategy
LEVEL OF TOXICITY ASSESSMENT : Toxic potential
PURPOSE OF TESTING : Screen or priority setting
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Context of use
The binding and activation to LXR has been identified among the molecular initiating events leading to
liver steatosis (Landesmann et al., 2012). Thus, a QSAR model for the prediction of potential LXR binding
may be used as part of integrated approaches to testing and assessment (IATA)/integrated testing
strategies (ITS) to screen chemicals potentially sharing the same Adverse Outcome Pathway (AOP) (i.e.
from LXR activation to liver steatosis). The model may also find application in the grouping of chemicals
to support read-across justification, in terms of mechanistic plausibility (as molecular initiating event
leading to long-term adverse effects in the liver), and weight of evidence evaluations.
The QSAR model has been developed according to the OECD principles for QSAR validation for
regulatory purposes (OECD, 2006; OECD, 2007). The QMRF (QSAR Model Reporting Format) is made
available in COSMOS Space (http://cosmosspace.cosmostox.eu) and will be submitted for publication in
the JRC (Q)SAR Model Database.
Scientific Principle of the Method
The binding and activation to LXR has been identified among the molecular initiating events involved in
the adverse outcome pathway leading to liver steatosis.
A (quantitative) structure-activity relationship ((Q)SAR) model is a mathematical model relating one or
more quantitative parameters derived from a chemical structure to a quantitative measure (continuous or
categorical) of a property or activity. This QSAR model predicts potential LXR binding by classifying
chemicals as potential binders (“active”) or not-binders (“inactive”). The QSAR is based on a set of few
molecular descriptors encoding for basic electronic properties, hydrophobicity, molecular shape and
complexity. These features are known to be important for binding to the hydrophobic ligand binding
pocket of LXR receptor.
Model Description
The prediction model provides a classification of potential binders and not-binders to LXR.
The dataset used for model development consisted of 97 chemicals selected from a wider dataset of 356
known LXR binders (biological data and structure collected from the literature and available database).
The dataset included 50 ligands characterised by an IC50<20 nM, which were assigned to the ACTIVE
class, and 47 ligands with an IC50>1000 nM, which were assigned to the INACTIVE class. A detailed
description of dataset assembling and class assignment is provided in the model QMRF.
After a preliminary explorative analysis of the dataset (e.g., response distribution, physico-chemical and
2D structural space PCA analysis), several PLS-DA (Partial Least Square – Discriminant Analysis)
classification models were developed using the commercial in-house software SIMCA (SIMCA ver.
13.0.3.0, 2012) based on different combination of MOSES molecular descriptors (MOSES.Descriptors,
2011 -  www.molecular-networks.com), e.g. physico-chemical and 1D-2D-3D descriptors. The
classification performance was evaluated using Cooper statistics (Cooper et al., 1979) and the following
equations:
Sensitivity: Sn = TP / (TP+FN)
Specificity: Sp = TN / (TN+FP)
Overall Accuracy: OA = (TP+TN) / (TP+FN+FP+TN)
where: TP (true positive) and TN (true negative) are the number of compounds correctly classified as
active and inactive, respectively; FN (false negative) is the number of active compounds classified as
inactive, and FP (false positive) is the number of inactive compounds classified as active. As a
precautionary principle, the misclassification of active compounds as inactive (false negative) should be
considered a much greater error than the misclassification of inactive compounds as active (false
positive). For this reason the number of FN was minimized for the selection of the best models.
Models were internally validated by means of 7-fold full cross-validation, and externally validated by
means of an a priori 30% splitting of the dataset into training (78 compounds) and test set (19
compounds). One PLS-DA classification model was finally selected based on classification accuracy
(optimizing sensitivity), external predictivity, model interpretability and reproducibility. The model was
based on three latent variables (A) derived from seven MOSES 2D descriptors (selected based on the
parameter Variable Influence on Projection, that maximizes Q2CV), which encode basic electronic
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parameter Variable Influence on Projection, that maximizes Q2CV), which encode basic electronic
properties, hydrophobicity, molecular shape and complexity: HDon_O (Number of oxygen atom-based
hydrogen bonding donors), Polariz (polarizability), NRotBond (Number of rotatable bonds), NAtoms
(Number of atoms), NStereo (Number of tetrahedral stereo centers), Complexity (Molecular complexity),
Rgyr (radius of gyration).
To allow for model applicability and reproducibility, the QSAR PLS-DA model was implemented into
KNIME (Berthold et al., 2007) and a workflow was developed for model development, validation
(cross-validation (CV) and external), prediction generation (also for new chemicals) and applicability
domain definition. In particular, two approaches were used to define the applicability domain of the
model: i) Leverage approach, ii) Similarity approach (based on Euclidean distances). Applicability
domain thresholds (ADT) were calculated for each approach employing two Enalos KNIME nodes
(http://www.novamechanics.com/knime.php), namely Enalos Domain-Leverage (Melagraki et al., 2009;
Afantitis et al., 2008) and Enalos Domain-Similarity (Melagraki et al., 2010; Afantitis et al., 2011).
ADT for Leverage = 0.231
ADT for Similarity = 16.55
Compounds with leverage/similarity values greater than the specified thresholds are considered outside
the applicability domain of the model and their predictions could be not reliable since model
extrapolations.
To make the model freely available, two related PLS-DA models based on freely available molecular
descriptors, namely PaDEL (Yap, 2011) and RDKit descriptors, were developed and implemented as
KNIME workflows (Berthold et al., 2007). Six PaDEL descriptors and five RDKit descriptors, highly
correlated to the seven MOSES modelling descriptors and encoding for similar structural information
(e.g., hydrophobicity, molecular shape and complexity), were selected as modelling variables. The
PLS-DA classification models implemented in KNIME showed similar classification performance as
compared to the original QSAR model developed in SIMCA. In particular, the QSAR classification model
based on PaDEL descriptors include the following six modelling descriptors: AMR (molar refractivity),
nHeavyAtoms (number of heavy atoms, i.e. not hydrogen), nBonds (number of bonds, excluding bonds
with hydrogen), FMF (complexity of a molecule), RotBFrac (fraction of rotatable bonds, excluding
terminal bonds), XlogP (octanol-water partition coefficient by Wang et al. (1997)).
The model algorithm (PLS-DA) was coded in R (model stored as an R object and can be read by the R
Model Reader Node), the applicability domain was calculated using Enalos Domain nodes.
Furthermore a web version was implemented, allowing to execute the model via a web browser: it is
available through the COSMOS KNIME WebPortal (http://knimewebportal.cosmostox.eu).
Procedure Description
Biological Endpoint and Measurement:
Receptor binding: Liver X receptor (LXR)
Endpoint Value:
IC50: LXRβ binding affinity values, converted into a binary variable: “active” (IC50 < 20 nM) and
“inactives” (IC50 > 1000 nM)
Experimental System:
A mathematical QSAR model that predicts potential LXR binding by classifying chemicals as potential
binders (“active”) or not-binders (“inactive”).
Quality/Acceptance Criteria
The QSAR model was developed according to the OECD principles for QSAR validation for regulatory
purposes (OECD, 2006; OECD, 2007):
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Defined endpoint: Liver X Receptor (LXR) binding potential1.
Defined algorithm: Partial Least Squares Discriminant Analysis (PLS-DA); six PaDEL descriptors
(AMR, nHeavyAtom, nBonds, FMF, RotBTFrac, XLogP).
2.
Defined applicability domain: leverage approach and similarity approach (based on Euclidean
distances)
3.
Internal and external validation: Cooper statistics provided for training and test sets.4.
Mechanistic interpretation: a posteriori mechanistic interpretation of the modelling descriptors.5.
3. Method Performance
Robustness of the Method
General performance measures:
Cooper statistics measuring goodness-of-fit:
Sensitivity = 0.85; Specificity = 0.84; Overall Accuracy = 0.85
FN = 6; TP = 34; TN = 32; FP = 6
FN: False Negative, i.e. active compound predicted as inactive; FP: False Positive, i.e. inactive compound
predicted as active; TN: True Negative, i.e. inactive compound predicted as inactive; TP: True Positive,
i.e. active compound predicted as active.
Test Compounds
The test set includes 19 compounds. Test set compounds were selected by a priori 30% random splitting
of the whole dataset (N = 97) into a training set of 78 compounds and a test set of 19 compounds. The test
set was not used for model development.
The test set is well represented by the training set. Training and test set are balanced in term of chemical
structure and response.
Predictive capacity:
Cooper statistics measuring predictive performances:
Sensitivity = 0.70; Specificity = 0.89; Overall Accuracy = 0.79
FN = 3; TP = 7; TN = 8; FP = 1
FN: False Negative, i.e. active compound predicted as inactive; FP: False Positive, i.e. inactive compound
predicted as active; TN: True Negative, i.e. inactive compound predicted as inactive; TP: True Positive,
i.e. active compound predicted as active.
Applicability:
Applicability domain of the QSAR model is defined by two methodologies: the leverage approach and the
similarity approach (based on Euclidean distances). The employed methodologies assess the "structural"
distance of the target compound from the model training set.
Enalos Domain-Leverage (Melagraki et al., 2009; Afantitis et al., 2008) and Enalos Domain-Similarity
(Melagraki et al., 2010; Afantitis et al., 2011) KNIME nodes are included in the workflow for the
applicability domain analysis. Applicability domain thresholds (ADT) are defined for each approach
(ADT for Leverage = 0.231; ADT for Similarity = 16.55). Compounds with leverage/similarity values
greater than the specified thresholds are considered outside the applicability domain of the model and
their predictions could be not reliable. 
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4. Discussion
Known experimental strengths and/or limitations of the method
Freely available.
Easy-to-use (user friendly interface - COSMOS KNIME WebPortal).
No time-consuming (few minutes needed to run the workflow).
Extendible (the QSAR model can be adapted, expanded and/or modified through the KNIME
Analytics platform).
Reproducible.
The QSAR model can be applied in batch.
The model only requires information on 2D chemical structure of the target compound (e.g., MOL,
SMILES) to provide predictions.
The modelling descriptors do not take into account 3D ligand-receptor interactions.
Not suitable for inorganic compounds, polymers, mixtures or UVCB substances as well as for
compounds falling outside the model applicability domain.
Prediction of LXR binding potency, but not LXR activation.
Technical requirements
The WebPortal version of the QSAR model can be run in a web browser without installation of the
KNIME software
The Desktop version requires installation of the KNIME Analytics Platform as well as additional
nodes:
PaDEL Nodes
KNIME nodes for PaDEL can be downloaded from
http://padel.nus.edu.sg/software/padeldescriptor/
R packages
To run the model a few additional packages have to be installed in R. If using a local R
software: installation of caret, pls, e1071 packages with dependenciesWithout having R
installed: go to you KNIME folder on local desktop, then follow into the folder
plugins\org.knime.ext.r.bin.win32.x86_2.15.2\R-Inst\bin
Select the folder i386 or x64 - depending on the KNIME version - then double click on
Rgui. When R starts, select Packages->Install packages from the top menu bar. Choose
any of the mirror servers and accept clicking ok. From the long list of available
packages choose: caret, pls and e1071.
Enalos nodes
Domain-Leverage and Domain-Similarity Enalos nodes available at: 
http://www.novamechanics.com/knime.php
Modifications of the method
A related QSAR model was developed using RDKit descriptors (instead of PaDEL descriptors). The
RDKit-based QSAR model is implemented as a KNIME workflow and is available to be executed both in
the COSMOS KNIME WebPortal and in the KNIME Analytics platform. Information on this model is
available in the COSMOS Space (http://cosmosspace.cosmostox.eu).
Potential for future development
The workflow can be extended using additional or different modelling descriptors as well as different
methodologies for applicability domain and reliability analysis.
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Comparisons to other methods
Several in silico methodologies (e.g., structural alerts, 3D-QSAR, molecular modelling) are currently
available to predict LXR binding, each characterised by strengths and limitations. Some models are
published in the literature (e.g., Spreafico et al., 2010; Zhao et al., 2011; Salum et al., 2012, etc.) and/or
have been implemented into software solutions (e.g., Virtual ToxLabTM, Endocrine Disruptome (Kolšek et
al., 2014), COSMOS-KNIME workflow for Nuclear Receptor Ligand Screening). In addition, within the
COSMOS Project, a profiler based on a combination of different molecular modelling methodologies
(namely, ensemble docking, e-Pharmacophore and fingerprints-based similarity) was developed and
used in the context of SEURAT-1 Level 2 and Level 3 case studies (Fioravanzo et al., 2015). The
complementary use of different in silico approaches would enhance the accuracy of predictions.
Additional Considerations
Additional details on the QSAR model and KNIME workflow as well as the user guides to run the
workflow in KNIME Analytics platforms and in the KNIME Web Portal are available in COSMOS Space
(http://cosmosspace.cosmostox.eu).
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6. Abbreviations & Definitions
ADT: Applicability Domain Threshold
AOP: Adverse Outcome Pathway
KNIME: Konstanz Information Miner, an open source data analytics, reporting and integration platform
IATA: Integrated Approaches to Testing and Assessment
ITS: Integrated Testing Strategy
LXR: Liver X Receptor
PLS-DA: Partial Least Squares - Discriminant Analysis
QMRF: QSAR Model Reporting Format
QSAR: Quantitative Structure-Activity Relationship
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DB-ALM Method summary n° 175 : PPAR full agonists’ potency predictor
Systemic Toxicity
PPAR full agonists’ potency predictor is a three dimensional QSAR (Quantitative Structure-Activity
Relationships) model for prediction of chemical compounds' potency (transactivation activity, pEC50) to
induce PPARγ-mediated expression of target reporter gene. The model predicts transactivation activity
using calculated electrostatic, acceptor and hydrophobic similarity indices as 3D descriptors, generated
by CoMSIA (Comparative Molecular Similarity Indices Analysis) 3D QSAR approach.
1. General Information
Corresponding author(s):
Dr Ivanka Tsakovska, Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of
Sciences (BAS) Bulgaria
Date of data sheet creation: 16 November 2015
Last version number: 1
Last update: 16 November 2015
Section No.5 Contact Details provides a complete list of the authors and method developers.
The method summary presented here describes a mathematical model.
In the context of this document, the term "method" in the paragraph headings refers to the model.
Proprietary and/or Confidentiality Issues:
Public
Status
Development
Development completed. PPARγ full agonists’ potency predictor
was developed as a part of COSMOS project (Integrated In Silico
Models for the Prediction of Human Repeated Dose Toxicity of
Cosmetics to Optimise Safety), within the SEURAT-1 Research
Initiative (Safety Evaluation Ultimately Replacing Animal Testing
1). More information on the project is available on its dedicated
website: http://www.cosmostox.eu .
2. Method Definition
Purpose of the Method
TYPE OF TESTING : Screening, Part of an integrated testing strategy
LEVEL OF TOXICITY ASSESSMENT : Toxic potential
Context of use
Toxicity-induced liver injury involves a spectrum of pathological conditions, including NAFLD (hepatic
steatosis / steatohepatitis), which may progress toward cirrhosis and hepatocellular carcinoma.
Chemical hazard identification and characterisation at early stages, such as expression of NAFLD
biomarkers, are central in a risk assessment strategy focused on repeated dose hepatotoxicity. The
developed 3D QSAR model is based on an Adverse Outcome Pathway (AOP) (Al Sharif et al., 2014), which
integrated experimental evidence for an array of PPARγ target proteins. Since their overexpression
synergistically drives disease development and progression, the in silico prediction of PPARγ ligands’
transactivation activity is suggested as mechanistically justified rational for the screening and
prioritisation for further testing of potentially prosteatotic chemicals.
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Scientific Principle of the Method
PPARγ activation by full agonists has been outlined as one of the possible molecular initiating events for
mode of action leading to non-alcoholic fatty liver disease (NAFLD) (Al Sharif et al., 2014). Agonist
binding involves non-covalent protein-ligand interactions leading to PPARγ activation and triggering
target protein expression. The development of a 3D QSAR model based on this biological response
involved:
selection of full PPARγ agonists that are expected to share common mode of action and receptor
binding mode
i.
 generation and alignment of potentially bioactive conformersii.
calculation of 3D properties, relevant to receptor bindingiii.
establishment of predictive quantitative structure-activity relationship using CoMSIA 3D QSAR
approach
iv.
The experimental data reported in the literature used for the selected endpoint has been obtained from
Luciferase reporter gene assay. The last is relevant to the OECD conceptual framework, presenting the
most promising assays to detect and characterise chemical effects on the PPAR signaling pathway and is
among the in vitro assays that are going to be considered for incorporation into new or existing Test
Guidelines for the detection of endocrine disrupting chemicals after refinement and validation (OECD,
ENV/JM/MONO(2012)23).
Model Description
An initial dataset (http://biomed.bas.bg/qsarmm/) with structural and biological (binding affinity, IC 50 ;
transactivation activity, EC 50 ; relative efficacy, %max) data for 439 PPARγ agonists (full and partial) was
subjected to refinement by: (i) data gaps removal; (ii) selection of full agonists (relative efficacy ≥ 70%)
avoiding duplicates and data uncertainties; (iii) stereochemistry consideration – with a preference for S
stereoisomers when the potency of racemic mixtures was reported. For the selected 170 full agonists the
negative logarithm of the EC 50 data was used as dependent variable in the model development.
The 170 structures of the selected compounds were generated based on structurally similar scaffolds of
Protein Data Bank (PDB) ligands and were aligned by pharmacophore-based docking procedure
(Tsakovska et al., 2014) in the ligand-binding domain of PPARγ using the molecular modelling (MM)
platform MOE v. 2014.0901 (CCG Inc.). The conformers were selected based on docking scores and visual
inspection versus template structure (ligand UNT from PDB ID 3IA6; pEC 50 = 7.886, 103% relative
efficacy). For these compounds CoMSIA steric, electrostatic, donor, acceptor and hydrophobic fields
were calculated in MM software suite SYBYL-X v. 2.1 (Certara USA, Inc.). Applicability domain outliers
and response outliers were excluded. The final modelling set consisted of 122 compounds (83 – training,
39 – test set). Multiple 3D QSAR models were obtained. Their internal and external predictivity were
assessed through leave-one-out (LOO) cross-validation and potency prediction of a test set, respectively.
CoMSIA electrostatic, acceptor and hydrophobic fields were used to correlate 3D structure variability
with differences in transactivation activity trough Partial Least Squares (PLS) statistical analysis. The
developed 3D QSAR model is able to predict the potency of full PPARγ agonists.
Procedure Description
Biological Endpoint and Measurement:
This method is an in silico model, which provides information on the following, biologically relevant,
endpoint:
Ligand-induced transactivation of peroxisome proliferator-activated receptor gamma (PPARγ)
Endpoint Value:
EC50
Experimental System:
 In silico mathematical model to predict the potential of chemicals to bind and activate PPARγ1 and
PPARγ2, jointly referred to as PPARγ
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3. Method Performance
Robustness of the Method
General performance measures:
The robustness of the model was evaluated by LOO cross-validation basing on the cross-validated
coefficient qcv2, the optimal number of principle components Nopt, and the cross-validated standard
error of prediction (SEPCV).
LOO qCV2 = 0.610
Nopt = 7
SEPCV = 0.505
Test Compounds
The modelling subset of 122 full PPARγ agonists utilised in this study comprised different homologous
series retrieved from 15 literature sources: eight series of chemicals contain a PPARγ ligand with a crystal
structure deposited in the PDB, one contains a PPARα ligand, and six do not contain resolved PDB
structures (the literature sources and training/test set assignment for the compounds used in 3D QSAR
modelling are available in the dataset description at http://biomed.bas.bg/qsarmm/). The training set
includes 83 compounds with slight prevalence of human over animal in vitro data, wide range of pEC50
data and consisting of structures from all collected series of compounds. The test set consists of 39 full
PPARγ agonists, within the applicability domain of the model.
Predictive capacity:
The predictive power of the obtained model was evaluated by external validation. The predictive
correlation coefficient rpred2 was calculated with training (ntraining set) to test set (ntest set)ratio approx. 2:1.
Statistical parameters:
ntraining set = 83
ntest set = 39
rpred2 = 0.552
Applicability:
The model is applicable to full PPARγ agonists. The applicability domain outliers were identified on the
basis of the calculated CoMSIA fields using the "extent of extrapolation" approach (Tropsha et al., 2003;
Netzeva et al., 2005) as implemented in Enalos domain leverage node (Melagraki et al., 2009) in the
KNIME Analytics Platform (Berthold et al., 2007).
4. Discussion
Ethical issues and considerations for 3R’s impact 
The combination of in vitro experimental data and in silico modelling follows the main principles of the
3Rs. Compared to previously published 3D QSAR pEC50-based models, this one is significantly enriched
with data from chemicals’ testing on human cell lines (human to animal cell line ratio is 0.649/1.147 for
the training/test sets) thus underlining the effort towards humane and reliable safety evaluation.
Known experimental strengths and/or limitations of the method
The model has straightforward mechanistic interpretation. It predicts ligand-induced in vitro
transactivation (EC50) since it is capable to reflect the agonistic activity of the compounds. The EC50
covers the complex cascade of receptor binding and activation followed by the downstream molecular
events triggering gene expression, therefore it is an appropriate in vitro experimental model of the
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quantitative relationship between the MIE (PPARγ activation) and the earliest downstream key event –
increased synthesis of target proteins. Although complex in its nature and thus challenging to be
modelled, EC 50 may reflect, in a more complete manner, the mechanism behind the particular
pathology.
The quality of the model may be limited by intra- and inter-laboratory variations in the experimental
settings for measuring the test compounds’ transactivation activity and in the selection of a reference
compound for calculating their relative efficacy.
The application of the model requires availability of molecular modelling specialised software.
Technical requirements
Computer system capable of running the MM platforms MOE v. 2014.0901 (CCG Inc.) and SYBYL-X v. 2.1
(Certara USA, Inc.).
Potential for future development
Additional external validation could be performed based on a test set consisting of experimentally
observed prosteatotic chemicals.
Comparisons to other methods
The 3D QSAR model of PPARγ agonism relies on the bioactive conformers, providing more
comprehensive mechanistical understanding and interpretation of the molecular events.
Using potency instead of binding affinity data reflects, in a more complete manner, the mechanism
behind the considered pathology.
The developed 3D QSAR model, involving electrostatic, acceptor and hydrophobic CoMSIA fields is as a
good improvement over the previous ones published in the scientific literature, based on:
the largest and structurally diverse training set (83 full agonists)i.
reasonable training to test set ratio (83/39, 2:1)ii.
reasonable pEC50 range (3.7/2.6 log units for the training/test sets)iii.
reporting the full range of statistical parameters necessary to apply the model for predictive purposesiv.
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6. Abbreviations & Definitions
AOP: Adverse outcome pathway
CoMSIA: Comparative molecular similarity indices analysis
COSMOS: EU Integrated Project. COSMOS developed an integrated suite of computational tools to
predict the effects of long-term exposure to chemicals in humans based on in silico methods. Website:
http://www.cosmostox.eu/
LOO: Leave-one-out
MM: Molecular modelling
NAFLD: Non-alcoholic fatty liver disease
Nopt: Optimal number of PLS components
OECD: Organization for Economic Cooperation and Development
pEC50: Negative logarithm of the half maximal effective concentration
PLS: Partial least squares
PPARγ: Peroxisome proliferator-activated receptor γ
qcv2: Squared cross-validated correlation coefficient
rpred2: Squared predictive correlation coefficient
SEPcv: Cross-validated standard error of estimation
SEURAT 1: Safety Evaluation Ultimately Replacing Animal Testing 1
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DB-ALM Method summary n° 176 : Parallel Artificial Membrane Permeability Assay (PAMPA)
logPm predictor
Systemic Toxicity
PAMPA logPm predictor is a mathematical model for prediction of chemical compounds' permeability
in Parallel Artificial Membrane Permeability Assay (PAMPA), which is assumed to be a practical estimator
of passive gastro-intestinal absorption (GIA) of low molecular weight compounds. The model predicts
permeability coefficient Pm using in silico calculated distribution coefficient (logD) and the ratio of the
Topological Polar Surface Area (TPSA) to Molecular Weight (MW) as descriptors. 
1. General Information
Corresponding author(s):
Petko Alov, Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences
(BAS) Bulgaria
Date of data sheet creation: 11 November 2015
Last version number: 1
Last update: 11 November 2015
Section No.5 Contact Details provides a complete list of the authors and method developers.
The method summary presented here describes a mathematical model.
In the context of this document, the term "method" in the paragraph headings refers to the model.
Proprietary and/or Confidentiality Issues:
Public
Status
Development
Development completed. The model was developed in the FP7
COSMOS Project, which was part of the Research Initiative -
SEURAT-1 - Towards the Replacement of In Vivo Repeated Dose
Systemic Toxicity Testing (2011-2015). More information on the
COSMOS project is available on its dedicated website:
http://www.cosmostox.eu
The model is implemented as a KNIME workflow, available on the COSMOS project COSMOS Space
website:
http://cosmosspace.cosmostox.eu
A web version of the model was also implemented, allowing to execute the model via a web browser. It is
available through the COSMOS KNIME WebPortal: 
http://knimewebportal.cosmostox.eu 
A tutorial is available at:
https://www.youtube.com/watch?v=WJLAz9GnvcM/
2. Method Definition
Purpose of the Method
TYPE OF TESTING : Screening
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Context of use
The estimation of bioavailability after oral and dermal administration is of key importance for example
in prediction of the chronic toxicity of cosmetic-related ingredients: whilst cosmetics are usually applied
dermally, the majority of available repeated dose toxicity data are obtained from oral administration.
The method predicts a parameter useful in further predictions or exposure assessment. PAMPA logPm
predictor is a mathematical QSAR model for prediction of chemical compounds' permeability in Parallel
Artificial Membrane Permeability Assay (PAMPA), expressed as logPm, which is assumed to be a practical
estimator of passive gastro-intestinal absorption (GIA) of low molecular weight compounds.
Scientific Principle of the Method
The implemented QSAR mode was developed using a data set of 276 compounds from the Database of
Double-Sink PAMPA logP0, logPm at pH6.5 and logPm at pH7.4 (Avdeef A., 2012). It predicts permeability
coefficient Pm using in silico calculated distribution coefficient (logD) and the ratio of the Topological
Polar Surface Area (TPSA) to Molecular Weight (MW) as descriptors.
Data from Avdeef (2012) consisted of 290 entries for PAMPA logPm, obtained by PAMPA-DS
(double-sink) method. The data collection was subjected to removal of entries studied with variations of
the method, chemical structure retrieval (by means of NCI/CADD Chemical Identifier Resolver and
NCBI PubChem project), mixtures removal and desalting (CDK toolbox as implemented in KNIME
Analytics Platform). CAS numbers were retrieved for the majority of the compounds. The final number of
compounds used for modelling was 276.
The model is devised as an improvement of the model reported by Nakao and co-workers (2009). The
Nakao et al. (2009) model used logP, │pKa − pH│, and Topological Polar Surface Area (TPSA) as
descriptors, the present one uses the logD and TPSA/MW ratio. The rationale for changing the
descriptors was that (a) log D ≈ logP − │pKa − pH│, and (b) molecular weight (MW) is used as an estimator
of the total surface to account for the ratio of polar to total surface area.
With a view to the free and open implementation of the models and lack of such tools for logD
estimation, two implementations of the model were produced based on logD estimations readily
obtainable through free online services ChemSpider.com (calculated by ACD/Labs tools) and
Chemicalize.org (calculated by ChemAxon tools).
Model Description
The KNIME analytics Platform was used for the model implementation.
Two implementations of the model were produced based on logD estimations readily obtainable through
free online services:
ChemSpider.com (calculated by ACD/Labs tools) 
Chemicalize.org (calculated by ChemAxon tools)
The model development included removal of the applicability domain and response outliers (Gramatica,
2007), and final expressions are:
ACD/Labs-calculated-logD implementation:
logPm = ‒2.945(±0.228) +0.600(±0.046)logDpH7.4 ‒7.655(±0.811)TPSA/MW
n=246, r2adj=0.734, SEE=1.108, F=338.861
ChemAxon-calculated-logD implementation:
logPm = ‒2.280(±0.240) +0.494(±0.050)logDpH7.4 ‒10.063(±0.844)TPSA/MW
n=247, r2adj=0.711, SEE=1.164, F=303.713
Procedure Description
Biological Endpoint and Measurement:
Artificial Membrane Permeability Assay (PAMPA) is assumed to be a practical estimator of passive
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gastro-intestinal absorption (GIA) of low molecular weight compounds
Endpoint Value:
LogPm - membrane permeability coefficient
Experimental System:
A mathematical QSAR model for prediction of chemical compounds' permeability in Parallel Artificial
Membrane Permeability Assay (PAMPA)
3. Method Performance
Test Compounds
Curated data from Avdeef (2012) consisted of 276 compounds: commercial drugs, pesticides, several
derivatives of commercial drugs, and several other chemical compounds.
Predictive capacity:
Predictive capacity of the model was assessed by leave-one-out (LOO) cross-validation and by external
validation by means of splitting of the dataset into training (~80%) and test (~20%) groups.
ACD/Labs-calculated-logD implementation:
LOO q2=0.729, external validation q2=0.696 (training set 196 / test set 50)
ChemAxon-calculated-logD implementation:
LOO q2=0.705, external validation q2=0.722 (training set 197 / test set 50)
Applicability:
Applicability domain of the model was assessed by the extent of extrapolation approach (based on the
calculation of the leverage hi for each chemical compound) as implemented in the KNIME community
node developed by NovaMechanics.
4. Discussion
Known experimental strengths and/or limitations of the method
Simplicity, straightforward mechanistic interpretation, implementation in versatile open-source KNIME
Analytics Platform.
Technical requirements
Computer system capable of running KNIME Analytics Platform. 
The COSMOS KNIME WebPortal version can be executed through a web brower
(http://knimewebportal.cosmostox.eu).
Modifications of the method
Two modifications are described in the previous sections.
Potential for future development
Other in silico estimations of logD could be studied as potential descriptor in the model.
Comparisons to other methods
The present model is built on an extended data set of 276 compounds (compared to max. 97 compounds
in available literature, Fujikawa et al., 2007). The endpoint Pm was obtained by the most versatile
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in available literature, Fujikawa et al., 2007). The endpoint Pm was obtained by the most versatile
variation of the PAMPA method – double-sink PAMPA. The model is applicable to compounds with
much broader range of hydrophobicity as compared to similar models (Fujikawa et al., 2007; Nakano et
al., 2012).
5. Contact Details
Petko Alov
Department of QSAR & Molecular Modelling
Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences (BAS)
Corresponding author, Method developer / user
105 G. Bontchev Str
Sofia 1113
Bulgaria
email: petko.alov@biophys.bas.bg
telephone: +359 2 9793647
Dr Ivanka Tsakovska
Department of QSAR & Molecular Modelling
Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences (BAS)
Method developer / user
105 G. Bontchev Str
Sofia 1113
Bulgaria
email: ITsakovska@biomed.bas.bg
telephone: +359 2 9793605
Dr Ilza Pajeva
Department of QSAR & Molecular Modelling
Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences (BAS)
Method developer / user
105 G. Bontchev Str
Sofia 1113
Bulgaria
email: pajeva@biomed.bas.bg
telephone: +359 2 9793605
Ver n° Date Name Type of change
1 11 November 2015 Petko Alov Data sheet created
6. Abbreviations & Definitions
logD: 1-octanol / water distribution coefficient at a particular pH
logP: 1-octanol / water partition coefficient
logPm: membrane permeability coefficient
LOO: leave-one-out cross-validation
MW: molecular weight
PAMPA: parallel artificial membrane permeability assay
pKa: acid dissociation constant
SEE: standard error of estimation
TPSA: topological polar surface area
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DB-ALM Method summary n° 177 : In silico screening for potential nuclear receptor ligands
and alerts towards hepatosteatosis
Systemic Toxicity
A workflow based on the computational structural alerts to screen for nuclear receptor agonists,
containing 214 structural features, recorded computationally as SMARTS strings. They can be used for
grouping and screening during drug development and risk assessment and provide knowledge to anchor
adverse outcome pathways (AOPs).
1. General Information
Corresponding author(s):
Prof. Mark Cronin, Liverpool John Moores University 
Date of data sheet creation: 12 November 2015
Last version number: 1
Last update: 12 November 2015
Proprietary and/or Confidentiality Issues:
None. The model is publicly available. 
Status
Development
Development completed. Work carried out at Liverpool John
Moores University with support from the FP7 COSMOS Project
(Integrated In Silico Models for the Prediction of Human Repeated
Dose Toxicity of Cosmetics to Optimise Safety), within the
SEURAT-1 (Safety Evaluation Ultimately Replacing Animal Testing
1) cluster (2011-2015). More information on the COSMOS project is
available on its dedicated website:
http://www.cosmostox.eu
The in silico workflow contains a number of structural alerts coded into SMARTS patterns and translated
into KNIME (http://www.knime.org/) automated workflows as part of the COSMOS project. The KNIME
workflow is available via COSMOS Space:
http://cosmosspace.cosmostox.eu
A web version of the model was also implemented, allowing to execute the model via a web browser. It is
available through the COSMOS KNIME WebPortal:
http://knimewebportal.cosmostox.eu 
A tutorial is available at:
https://www.youtube.com/watch?v=ggkU6lZfDfY
2. Method Definition
Purpose of the Method
TYPE OF TESTING : Screening, Part of an integrated testing strategy
LEVEL OF TOXICITY ASSESSMENT : Toxic potential
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Context of use
Many pathways in toxicology can be traced back to nuclear receptors (NR) as initial target. One notable
example is endocrine disruption, another the development of fatty liver (hepatosteatosis) associated with
chronic exposure to the agonists of some nuclear receptors, e.g. Retinoic Acid Receptor, Retinoid X
receptor, Liver X Receptor and Peroxisome Proliferator-Activated Receptor (Moya et al 2010).
For the purpose of this model the structural and physico-chemical features of NR ligands have been
investigated using data from ChEMBL and the Protein Data Bank (PDB). The information obtained was
implemented into a KNIME workflow (see Steinmetz et al 2015) and can be used for screening for
potential NR ligands during drug development and risk assessment, which can support hazard
identification, category formation for read-across and provide knowledge to anchor adverse outcome
pathways (AOPs).
Scientific Principle of the Method
Nuclear receptor activation by xenobiotics has been linked to the onset of many different toxicities such
as endocrine disruption and hepatosteatosis. Therefore it is an important parameter in considering the
effects of chronic chemical exposure.
A workflow to screen for potential NR ligands and alerts towards hepatosteatosis has been developed by
the authors. Chemical descriptors required for receptor activation were implemented along with key
structural features which have been coded into SMARTS (SMiles ARbitrary Target Specification) strings
and translated into a KNIME workflow. SMARTS pattern allows for a definition of a sub-structure within
a molecule, which is then used to check whether a chemical structure contains any of the pre-defined
fragments.
The NRs associated with the onset of hepatosteatosis were identified, according to Moya et al (2010).
They are listed in Table 1. In the developed screening workflow that identifies potential agonists of all NR
of interest, those linked to hepatosteatosis are flagged with a special alert in the workflow output.
In total the following NR are included in the workflow: Aryl Hydrocarbon Receptor (AHR), Androgen
Receptor (AR), Estrogen Receptor (ER), Farnesoid X Receptor (FXR), Glucocorticoid Receptor (GR), Liver
X Receptor (LXR), Peroxisome Proliferator-Activated Receptor (PPAR), Progesterone Receptor (PR),
Pregnane X Receptor (PXR), Retinoic Acid Receptor (RAR)/ Retinoid X receptor (RXR), Thyroid Receptor
(THR), Vitamin D Receptor (VDR).
Table 1. Nuclear receptors associated with hepaosteatosis and abbreviations as defined by Mellor et al.
(2015).
Nuclear receptor name Abbreviation
Aryl Hydrocarbon Receptor AHR
Constitutive Androstane Receptor CAR
Estrogen Receptor ER
Farnesoid X Receptor FXR
Glucocorticoid Receptor GR
Liver X Receptor LXR
Peroxisome Proliferator-Activated Receptor PPAR
Pregnane X Receptor PXR
Retinoic Acid Receptor RAR
Retinoid X receptor RXR
Model Description
A computational structural alerts based workflow to screen for potential nuclear receptor agonists and
alerts towards hepatosteatosis was developed using data obtained from the ChEMBL database of active
molecules and the protein data bank (PDB) (Mellor et al., 2016). The information was used to identify
common structural and chemical features and the chemical space of known NR agonists and the
essential ligand-binding interactions that they form in order to bind to the nuclear receptor and cause
page 2 / 8
© EURL ECVAM DB-ALM: Method Summary
SEURAT-1 TOOLS & METHODS CATALOGUE PAGE 158
activation.
The identified rules were implemented in a KNIME workflow. The workflow uses a combination of
molecular fragments and other relevant chemical features. In total 214 structural features were recorded
computationally as SMARTS strings.
Source Data
Data was obtained from the ChEMBL database and the protein data bank (PDB).
Extracting data from ChEMBL
The ChEMBL (ChEMBL, 2015) database is a database of bioactive molecules comprising over 1.5 million
compounds and over 9,000 biological targets. Data from compounds with Ki, Kd, AC50 and EC50 values
towards the NRs of interest were downloaded, combined and sorted by their pChEMBL values. The
pChEMBL value is an approach to standardise different types of activity values (Bento et al., 2013). Every
compound with a value not less than five was regarded as active compound. Common substructures
were compared to ligand-protein-interaction information derived from PDB (PDB, 2015).
Analysis of agonistic ligands using the PDB
The PDB was searched for human NR structures. The human structures were then investigated regarding
their ligand-protein-interaction within PyMOL 1.3 (PyMOL, 2014) and studying the linked publications.
Important structural features for ligand-protein-interactions, e.g. functional groups forming hydrogen
bonds, were coded into SMARTS strings, listed in detail in the workflow description in COSMOS Space
(http://cosmosspace.cosmostox.eu) and in Mellor et al (2016).
Physico-chemical space
The physico-chemical space was investigated using the CDK node for molecular properties within
KNIME 2.9.4 (incl. community contributions). Different types of descriptors (vertex adjacency
information magnitude (VAIM) for structural complexity, number of rotational bonds (RB) for flexibility,
molecular weight (MW) for molecular size and Log K OW (XLogP) for lipophilicity), were calculated.
 Chemical features identified
After studying the data obtained from ChEMBL and PDB, the common structural features of the NR
agonists were identified along with the essential functional groups needed for ligand binding to each NR,
e.g. hydroxyl groups needed to form hydrogen bonds with key amino acid residues on the NR.
Building rules for the screening workflow
Rules based on physico-chemical properties and structural features were established. The structural
features and essential functional groups were coded into SMARTS strings. The rules and SMARTS strings
applied for each NR are listed in detail in the workflow description in COSMOS Space
(http://cosmosspace.cosmostox.eu).
KNIME implementation
A KNIME workflow executing the rules was built based on KNIME community contribution nodes. It is
checking the physico-chemical space (CDK node for calculating molecular properties) and for important
structural features (Indigo substructure matcher). Data processing is executed with standard KNIME
nodes.
The NR ligands which are associated with hepatosteatosis get an extra alert in addition to the NR
prediction. It shall be pointed out that many NR ligands are regarded as promiscuous, i.e. bind more than
one receptor. Thus multiple predictions are likely, and hence shown by employing the grouping node. As
the workflow is thought to be an initial screening tool for large datasets, only ligands with at least one NR
prediction are shown in the results. In case no prediction/alert is triggered, a message saying “no
potential NR ligands found” will pop-up, so that the user knows that the workflow was executed properly.
The methods used to create the workflow are described in Steinmetz et al (2015) and Mellor et al (2016).
An overview of the KNIME workflow is shown in Figure 1, details on substructure checking within the
workflow in Figure 2.
The model was implemented as KNIME workflow web version, an easy-to-use user-interface allowing to
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The model was implemented as KNIME workflow web version, an easy-to-use user-interface allowing to
execute the model via a web browser. It is available through the COSMOS KNIME WebPortal:
http://knimewebportal.cosmostox.eu
Figure 1: Workflow overview
The KNIME workflow is composed of twelve sub-workflows, one for each NR. In each workflow the
information on relevant substructures (SMARTS strings of scaffolds and functional groups) and
physico-chemical features, e.g. ranges for molecular weight, log P, vertex adjacency information
magnitude, topical polar surface area, number hydrogen bond donors and rotational bonds, is checked
and if applicable the compound is flagged as a potential ligand.
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Figure 2: Substructure checking within the workflow.
Procedure Description
Biological Endpoint and Measurement:
This method is an in silico model, which provides information on the following, biologically relevant,
endpoints:
Receptor binding: Aryl hydrocarbon receptor (AHR)
Receptor binding: Estrogen receptor (ER)
Receptor binding: Farnesoid X receptor (FXR)
Receptor binding: Glucocorticoid receptor (GR)
Receptor binding: Liver X receptor (LXR)
Receptor binding: Peroxisome proliferator-activated receptor (PPAR)
Receptor binding: Pregnane X receptor (PXR)
Receptor binding: Progesterone Receptor (PR)
Receptor binding: Retinoic acid receptor (RAR)/Retinoid X receptor (RXR)
Receptor binding: Thyroid Receptor (THR)
Receptor binding: Vitamin D Receptor (VDR)
Endpoint Value:
Qualitative: Structural alert
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Experimental System:
A computational model that predicts potential nuclear receptor binding and flags potential ligands,
with additional alerts for NRs associated with the onset of hepatosteatosis.
3. Method Performance
Robustness of the Method
General performance measures:
All chemicals which have been identified as NR binders within ChEMBL were also successfully predicted
by the model as ligands to their associated NRs, showing that the workflow was accurate at identifying
structural alerts (Mellor et al., 2016).
4. Discussion
The ability to predict organ-level toxicity is becoming increasingly important to the long term goal of
replacing animal use in determining a Lowest Observed (Adverse) Effect Level (LO(A)EL). The toxicity
induced by nuclear receptor activation has been linked to many toxicities such as endocrine disruption
and hepatic steatosis. Therefore, the links between the chemical structure of NR ligands and the
biological responses of the NR they bind to have been elucidated, this has provided knowledge of the
toxicological pathways linked to these NR, specifically to the adverse outcome of hepatic steatosis.
The workflow developed can be used to group chemicals, e.g. considering chemicals potentially linked to
hepatic steatosis, for read-across and for hazard identification as part of a risk assessment process.
Nota bene: There are also other nodes to calculate descriptors and to alter and filter (sub)structures
within KNIME (for example RDKit nodes).
5. Contact Details
Prof. Mark Cronin
Professor of Predictive Toxicology
School of Pharmacy and Biomolecular Sciences
Liverpool John Moores University
Corresponding author
Byrom Street
Liverpool L3 3AF
email: m.t.cronin@ljmu.ac.uk
telephone: + 44 151 231 2402
fax: + 44 151 231 2170
last contact update: 11 May 2016
Dr Fabian Steinmetz
School of Pharmacy and Biomolecular Sciences
Liverpool John Moores University
Method developer / user
Byrom Street
Liverpool L3 3AF
Dr Claire Mellor
School of Pharmacy and Biomolecular Sciences
Liverpool John Moores University
Method developer / user
Byrom Street
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Liverpool L3 3AF
Ver n° Date Name Type of change
1 12 November 2015 Prof. Mark Cronin Data sheet created
6. Abbreviations & Definitions
AHR: Aryl Hydrocarbon Receptor
AOP: Adverse Outcome Pathway
AR: Androgen Receptor
ER: Estrogen Receptor
FXR: Farnesoid X Receptor
GR: Glucocorticoid Receptor
LO(A)EL: Lowest Observed (Adverse) Effect Level
LXR: Liver X Receptor
MW: Molecular weight
PPAR: Peroxisome Proliferator-Activated Receptor
PR: Progesterone Receptor
PXR: Pregnane X Receptor
RAR: Retinoic Acid Receptor
RB: Rotational bonds
RXR: Retinoid X receptor
NR: Nuclear Receptor
SA: Structural Alerts
KNIME: KoNstanz Information MinEr
PDB: Protein Data Bank
THR: Thyroid receptor
VAIM: Vertex adjacency information magnitude
VDR: Vitamin D Receptor
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DB-ALM Method summary n° 178 : In silico profiler for covalent DNA binding
Genotoxicity/Mutagenicity
The in silico profiler for covalent DNA binding compiles mechanistic organic chemistry fragments (in the
form of structural alerts) for the binding of organic compounds to DNA. This profiler is envisaged to be
used to develop chemical categories based upon similar mechanisms as part of the adverse outcome
pathway paradigm. Additionally, the profiler could be utilised in screening large data sets in order to
identify chemicals with the potential to bind to DNA.
1. General Information
Corresponding author(s):
Dr Steve Enoch, Liverpool John Moores University 
Date of data sheet creation: 12 November 2015
Last version number: 1
Last update: 12 November 2015
Proprietary and/or Confidentiality Issues:
None. The model is publicly available.
Status
Development
Development completed. Work carried out at Liverpool John
Moores University with support from the European Chemicals
Agency (EChA) Service Contract No. ECHA/2008/20/ECA.203 and
the FP7 COSMOS Project (Integrated In Silico Models for the
Prediction of Human Repeated Dose Toxicity of Cosmetics to
Optimise Safety), within the SEURAT 1 (Safety Evaluation
Ultimately Replacing Animal Testing 1) cluster (2011-2015). More
information on the COSMOS project is available on its dedicated
website:
http://www.cosmostox.eu
Most of the structural alerts and associated mechanistic chemistry have been incorporated into the
Organisation for Economic Co-operation and Development (OECD) (Q)SAR Application Toolbox, a
software tool designed to fill data gaps in a regulatory environment without the need for further animal
testing: http://www.qsartoolbox.org 
The in silico profiler for covalent DNA binding has a number of structural alerts coded into SMARTS
patterns and translated into KNIME (http://www.knime.org/) automated workflows as part of the
COSMOS project. The KNIME workflow is available via COSMOS Space: 
http://cosmosspace.cosmostox.eu 
A web version of the model was also implemented, allowing to execute the model via a web browser. It is
available through the COSMOS KNIME WebPortal: 
http://knimewebportal.cosmostox.eu 
2. Method Definition
Purpose of the Method
TYPE OF TESTING : Screening, Part of an integrated testing strategy
LEVEL OF TOXICITY ASSESSMENT : Toxic potential
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Context of use
The main goal of the in silico profiler is grouping chemicals into mechanism based categories centred on
the knowledge of a number of key molecular initiating events (MIEs) for mutagenicity and genotoxic
carcinogenicity as part of the adverse outcome pathway (AOP) paradigm (e.g. AOP 15 "Alkylation of DNA
in male pre-meiotic germ cells leading to heritable mutations"; Yauk et al, 2016). Such categories allow
for read-across and data gap-filling to be applied. The premise behind these structurally developed
categories is that similar chemicals should have similar biological activities and therefore should have
the same MIE.
Furthermore, the categories produced using in silico profilers can be supported by, and - screening large
data sets in order to identify chemicals with the potential to bind to DNA - used to prioritise additional
testing using in vitro and/or in chemico methods, within an integrated testing strategy (ITS) or an
integrated approach to testing and assessment (IATA).
Such strategies can be used in hazard identification and risk assessment for regulatory purposes under
REACH (EU, 2006) or the Cosmetics Directive (EU, 2009). To facilitate the use in this context the covalent
DNA binding profiler was incorporated into in silico software tools such as the OECD QSAR Toolbox.
Scientific Principle of the Method
For both mutagenicity and carcinogenicity one of the fundamental steps is the formation of a covalent
bond between nucleophile and electrophile (i.e. the biological nucleophilic DNA molecule and an
exogenous chemical). DNA binding can thus be a molecular initiating event in an adverse outcome
pathway leading to genotoxicity (e.g. AOP 15: Alkylation of DNA in male pre-meiotic germ cells leading to
heritable mutations; Yauk et al, 2016).
Within the AOP paradigm, in silico methods contribute to identifying the key features of a chemical
(structural alerts) that induce a MIE. A collection of structural alerts that induce the same MIE are
considered to be an in silico profiler.
There are two types of profilers: mechanism-based profilers, as described here, and chemistry-based
profilers. The first type is comprised of structural alerts relating to a MIE that are supported by
experimental data illustrating how the alerts initiate the MIE, as for example also the in silico profilers for
covalent protein binding (DB-ALM Method Summary No. 181) or mitochondrial toxicity (DB-ALM
Method Summary No. 180). In comparison, the chemistry-based profiler, as for example the in silico
profilers for potential nuclear receptor ligands and alerts towards hepatosteatosis (DB-ALM Method
Summary No. 177) or hepatotoxicity (DB-ALM Method Summary No. 179), consists of structural alerts
that have been associated with inducing toxicity; thus, in contrast to mechanism-based profilers, a
chemistry-based profiler does not contain mechanistic information relating to how the observed toxicity
is initiated.
Due to these intrinsic differences, the two types of profilers should be used for different purposes;
mechanistic profilers should be used for category formation and read-across, whilst chemistry-based
profilers should be used to screen an inventory to prioritise chemicals to undergo further (non-animal)
testing. A category developed utilising a mechanism-based profiler enables missing toxicological data for
a chemical to be filled using available information from analogues within the same category via
read-across predictions (Enoch et al., 2011).
Model Description
The in silico profiler for covalent DNA binding was developed based on the review of current scientific
knowledge relating to mutagenicity and genotoxic carcinogenicity structural alerts and mapping the
existing structural alerts in terms of their relationships with mechanistic organic chemistry, i.e.
identifying alerts from the published compilations related to covalent DNA binding. The mapping was
performed to achieve maximum overlap and usability whilst restricting redundancy in the alerts, and to
ensure that the alerts related to the molecular initiating event of covalent DNA binding.
The existing literature compilations of structural alerts for DNA binding (Mekenyan et al 2004; Mekenyan
et al 2007; Serafimova et al 2007; Benigni et al 2008; Kazius et al 2005 and Kalgutkar et al 2005) have been
used in the analysis to add the mechanistic organic chemistry associated with each of the structural
alerts. The alerts cross six broad organic chemistry mechanisms (domains): acylation (AC), Michael
addition (MA), Schiff base formation (SB), unimolecular aliphatic nucleophilic substitution (S N1),
bimolecular aliphatic nucleophilic substitution (SN2) and radical mechanism (RD).
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The mechanistic information is intended to outline how the alert can act as a direct electrophile or how
it can be converted into an electrophile. Therefore, the important consideration within the mechanistic
chemistry framework is the inclusion of potential metabolic activation.
A total of 111 structural alerts, supported by mechanistic information and meta data, have been created.
The identified mechanistic structural alerts were further defined as SMARTS (SMiles ARbitrary Target
Specification, based on SMILES Simplified Molecular Input Line Entry System) patterns. SMARTS
pattern allows for a definition of a sub-structure within a molecule, which is then used to check whether
a chemical structure contains any of the pre-defined fragments.
The in silico profiler was implemented as KNIME workflow, and additionally as web version, allowing to
execute the model via a web browser. It is available through the COSMOS KNIME WebPortal:
http://knimewebportal.cosmostox.eu 
Table 1. Summary of the 111 structural alerts defined for covalent DNA binding.
AC - Acylation, MA - Michael addition, SB - Schiff base formation, SN1 - nucleophilic
substitution 1, SN2 - nucleophilic substitution 2, RD - Radical mechanistic domain
The full description of the DNA binding profiler is available in Enoch et al. (2010 and 2012).
Structural alerts SMARTS Mechanism 
Acyl-halide AC [CH,$(C(=O)[#6])](=O)[F,Cl,Br,I] Direct addition of
an acyl halide
Alkyl-carbamyl halides
AC
[NH2,$([NH](C=O)[#6]),$(N(C=O)([#6])[#6])]C(=O)[F,Cl,Br,I] Direct addition of
an acyl halide
Isocyanates AC [NH,$(N(=C=O)[#6])]=C=O Isocyanates and
isothiocyanates
Isothiocyanates AC [NH,$(N(=C=[SX1])[#6])]=C=[SX1] Isocyanates and
isothiocyanates
Thiazolidinediones AC C1C(=O)[NH]C(=O)S1 P450 mediated
activation to
isocyanates or
isothiocyanates
Formamides AC [NH2,$([NH]([CH]=O)[#6]),$(N([CH]=O)([#6])[#6])][CH](=O) P450 mediated
activation to
isocyanates or
isothiocyanates
Sulfonylureas AC [#6]S(=O)(=O)[NH]C(=O)[NH2,$([NH](C=O)[#6]),$(N(C=O)
([#6])[#6])]
P450 mediated
activation to
isocyanates or
isothiocyanates
Thioureas AC c[NH]C(=O)[NH]c P450 mediated
activation to
isocyanates or
isothiocyanates
Benzylamines AC c1ccccc1[CX4][NH2] P450 mediated
activation to
isocyanates or
isothiocyanates
1,1-Dihaloalkanes AC [CX4][CH]([F,Cl,Br,I])[F,Cl,Br,I] P450 mediated
activation to
isocyanates or
isothiocyanates
α,β-Unsaturated
aldehydes MA
[$([CH2]),$([CH]C)]=[CH,$(C[CX4])][CH]=O Polarised alkenes
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α,β-Unsaturated ketones
MA
[$([$([CH2]),$([CH]C)]=[CH,$(C[CX4])]C(=O)[#6]);!$([CH]
1=CC(=O)C=CC1(=O));!$([CH]1=CC(=O)C(=O)C=C1)]
Polarised alkenes
α,β-Unsaturated esters
MA
[$([CH2]),$([CH]C)]=[CH,$(C[CX4])]C(=O)O[#6] Polarised alkenes
α,β-Unsaturated amides
MA
[$([CH2]),$([CH]C)]=[CH,$(C[CX4])]C(=O)[NH2,$([NH]
(C=O)[#6]),$(N(C=O)([#6])[#6])]
Polarised alkenes
Azocarbonamides MA [NH2,$([NH](C=O)[#6]),$(N(C=O)([#6])[#6])]C(=O)N=NC
(=O)[NH2,$([NH](C=O)[#6]),$(N(C=O)([#6])[#6])]
Polarised azo
compounds
Quinones MA [$(C1(=O)[#6]=,:[#6]C(=O)[CH]=C1),$(C1(=O)C(=O)
[#6]=,:[#6][CH]=C1)]
Quinone and
quinone type
chemicals
Quinone methides MA [$(C1=CC(=O)[#6]=,:[#6]C1(=[CH][CX4])),$(C1(=[CH]
[CX4])C(=O)[#6]=,:[#6]C=C1)]
Quinone and
quinone type
chemicals
Quinone imines MA [$(C1(=O)[#6]=,:[#6][$(C=[NH]),$(C=N[CX4])][CH]=C1)
,$(C1(=O)[$(C=[NH]),$(C=N[CX4])][#6]=,:[#6][CH]=C1)
,$(C1(=O)[$(C=[NH]),$(C=N[CX4])]C=[CH][#6]=,:[#6]1)]
Quinone and
quinone type
chemicals
Quinone diimines MA [$([CH]1=C[$(C=[NH]),$(C=N[CX4])][#6]=,:[#6][$(C=[NH])
,$(C=N[CX4])]1),$([CH]1=C[$(C=[NH]),$(C=N[CX4])]
[$(C=[NH]),$(C=N[CX4])][#6]=,:[#6]1)]
Quinone and
quinone type
chemicals
Hydroquinones MA [$(c1([OH,$(O[CH3])])c[cH]c([OH,$(O[CH3])])cc1),
$(c1([OH,$(O[CH3])])c([OH,$(O[CH3])])cc[cH]c1)]
P450 mediated
activation to
quinones and
quinone type
chemicals
Alkyl phenols MA [$(c1([OH])ccc([CH3,$([CH2][CX4])])cc1),$(c1([OH])
c([CH3,$([CH2][CX4])])cccc1)]
P450 mediated
activation to
quinones and
quinone type
chemicals
Methylenedioxyphenyl
MA
[cH]1ccc(OCO2)c2c1 P450 mediated
activation to
quinones and
quinone type
chemicals
Arenes MA [cH,$(c(c)(c)[CX4])]1[cH][cH][cH,$(c(c)(c)[CX4])
][cH][cH,$(c(c)(c)[CX4])]1
P450 mediated
activation to
quinones and
quinone type
chemicals
PAHs MA [cH]1c[cH]c2cc3ccccc3cc2[cH]1 P450 mediated
activation to
quinones and
quinone type
chemicals
5-Alkoxyindoles MA [cH]1cc([OH,$(O[CH3])])cc2ccnc12 P450 mediated
activation to
quinones and
quinone type
chemicals
3-Methylindoles MA [CH3]c1c[nH]c2ccccc12 P450 mediated
activation to
quinones and
quinone type
chemicals
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Furans MA [cH]1[cH,$(c(c)(o)C)]o[cH,$(c(c)(o)C)][cH,$(c(c)(c)C)]1
Thiophenes MA [cH]1[cH,$(c(c)(o)C)]s[cH,$(c(c)(o)C)][cH,$(c(c)(c)C)]1 P450 mediated
activation of
heterocyclic ring
systems
Hydrazine SN1 [NH][NH2] Carbenium ion
formation
Aliphatic N nitro SN1 [CH3,$([CH2]([NX3])[#6]),$([CH]([NX3])([#6])[#6])]
[NH,$(N([CX4])([NX3])[#6])][N+](=O)[O-]
Carbenium ion
formation
Triazines SN1 [NH2,$([NH](N=N)[#6]),$(N(N=N)([#6])[#6])]N=N[CX4] Carbenium ion
formation
Diazoalkanes SN1 [$([C-][N+]#N),$(C=N=N)] Carbenium ion
formation
PAHs SN1 [cH]1[cH][cH]c2c(ccc3ccccc23)[cH]1 Carbenium ion
formation
Nitroso SN1 [CH3,$([CH2]([NX3])[#6]),$([CH]([NX3])([#6])[#6])]
[NH,$(N([CX4])([NX3])[#6])][NX2]=O
Carbenium ion
formation
Allyl benzenes SN1 C=C[CH2]c1ccccc1 Carbenium ion
formation
Pyrroloizidine alkaloids
SN1
[$([CX4]C(=O)OCc1ccn2CCC(OC([CX4])=O)c12),$([CX4]
C(=O)OCC1=CCN2CCC(OC([CX4])=O)C12),$([CX4]C
(=O)OC\C1=C\CN([CH3])CCC(OC([CX4])=O)C1=O)]
Carbenium ion
formation
a Halo ethers SN1 [#6][O,S][CH2,$([CH]([O,S])([F,Cl,Br,I])[CX4]),$(C([O,S]) 
([F,Cl,Br,I])([CX4])[CX4])][F,Cl,Br,I]
Carbenium ion
formation
Primary aromatic
amines SN1
[$([c][NH2]);r6;!$([c]([a]C)([a]C)[NH2]);!$([c]([c]C(=O) 
[OH])[NH2]);!$([c]([c]S(=O)(=O)[OH])[NH2]);!$([c] 
([a][c]S(=O)(=O)[OH])[NH2]);!$([c]([a][a][c]S(=O)(=O)[OH]) 
[NH2])]
Nitrenium ion
formation
Secondary aromatic
amines SN1
[$([c][NH][#6]);r6;!$([c]([a]C)([a]C)[NH][#6]);!$([c]([c]C(=O) 
[OH])[NH][#6]);!$([c]([c]S(=O)(=O)[OH])[NH][#6]);!$([c] 
([a][c]S(=O)(=O)[OH])[NH][#6]);!$([c]([a][a][c]S(=O) 
(=O)[OH])[NH][#6])]
Nitrenium ion
formation
Tertiary aromatic
amines SN1
[$([c]N([CH3])[CH3]);r6;!$([c]([a]C)([a]C)N([CH3]) 
[CH3]);!$([c]([c]C(=O)[OH])N([CH3])[CH3]);!$([c]([c]S(=O) 
(=O)[OH])N([CH3])[CH3]);!$([c]([a][c]S(=O) 
(=O)[OH])N([CH3])[CH3]);!$([c]([a][a][c]S(=O) 
(=O)[OH])N([CH3])[CH3])]
Nitrenium ion
formation
Aromatic nitros SN1 [$([c][N+](=O)[O-]);r6;!$([c]([a]C)([a]C)[N+](=O)[O-]);!$([c] 
([c]C(=O)[OH])[N+](=O)[O-]);!$([c]([c]S(=O)(=O)[OH]) 
[N+](=O)[O-]);!$([c]([a][c]S(=O)(=O)[OH])[N+](=O) 
[O-]);!$([c]([a][a][c]S(=O)(=O)[OH])[N+](=O)[O-])]
Nitrenium ion
formation
Aromatic nitrosos SN1 [$([c][NX2]=O);r6;!$([c]([a]C)([a]C)[NX2]=O);!$([c]([c]C(=O) 
[OH])[NX2]=O);!$([c]([c]S(=O)(=O)[OH])[NX2]=O);!$([c] 
([a][c]S(=O)(=O)[OH])[NX2]=O);!$([c]([a][a][c]S(=O) 
(=O)[OH])[NX2]=O)]
Nitrenium ion
formation
Aromatic N
hydroxylamines SN1
[$(c[NH][OH]);r6] Nitrenium ion
formation
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Aromatic azos SN1 [$([c]N=[NH,$(N(=N)[#6])]);r6;!$([c]([a]C)([a]C)N= 
[NH,$(N(=N)[#6])]);!$([c]([c]C(=O)[OH])N=[NH,$(N(=N) 
[#6])]);!$([c]([c]S(=O)(=O)[OH])N=[NH,$(N(=N)[#6])]);!$([c] 
([a][c]S(=O)(=O)[OH])N=[NH,$(N(=N)[#6])]);!$([c]([a][a] 
[c]S(=O)(=O)[OH])N=[NH,$(N(=N)[#6])])]
Nitrenium ion
formation
Aromatic phenylureas
SN1
[$([c][NH]C(=O)[NH2,$([NH](C=O)[#6]),$(N(C=O)([#6]) 
[#6])]);r6;!$([c]([a]C)([a]C)[NH]C(=O)[NH2,$([NH] 
(C=O)[#6]),$(N(C=O)([#6])[#6])]);!$([c]([c]C(=O) 
[OH])[NH]C(=O)[NH2,$([NH](C=O)[#6]),$(N(C=O)([#6]) 
[#6])]);!$([c]([c]S(=O)(=O)[OH])[NH]C(=O)[NH2,$([NH] 
(C=O)[#6]),$(N(C=O)([#6])[#6])]);!$([c]([a][c]S(=O) 
(=O)[OH])[NH]C(=O)[NH2,$([NH](C=O)[#6]),$(N(C=O) 
([#6])[#6])]);!$([c]([a][a][c]S(=O)(=O)[OH])[NH]C(=O) 
[NH2,$([NH](C=O)[#6]),$(N(C=O)([#6])[#6])])]
Nitrenium ion
formation
Aromatic ester
hydroxylamines SN1
[$([c][NH]OC(=O)[#6]);r6;!$([c]([a]C)([a]C)[NH]OC(=O) 
[#6]);!$([c]([c]C(=O)[OH])[NH]OC(=O)[#6]);!$([c]([c]S(=O) 
(=O)[OH])[NH]OC(=O)[#6]);!$([c]([a][c]S(=O)(=O)[OH]) 
[NH]OC(=O)[#6]);!$([c]([a][a][c]S(=O)(=O)[OH]) 
[NH]OC(=O)[#6])]
Nitrenium ion
formation
Primary heterocyclic
amines S N1
[$(c[NH2]);r5] Nitrenium ion
formation
Secondary heterocyclic
amines SN1
[$(c[NH][#6]);r5] Nitrenium ion
formation
Tertiary heterocyclic
amines SN1
[$(cN([CH3])[CH3]);r5] Nitrenium ion
formation
Heterocyclic nitro SN1 [$(c[N+](=O)[O-]);r5] Nitrenium ion
formation
Heterocyclic nitroso
SN1
[$(c[NX2]=O);r5] Nitrenium ion
formation
Heterocyclic
N-hydroxylamines SN1
[$(c[NH][OH]);r5] Nitrenium ion
formation
Heterocyclic azos SN1 [$(cN=[NH,$(N(=N)[#6])]);r5] Nitrenium ion
formation
Heterocyclic
phenylureas SN1
[$(c[NH]C(=O)[NH2,$([NH](C=O)[#6]),$(N(C=O)([#6])[#6])]);r5] Nitrenium ion
formation
Heterocyclic ester
hydroxylamine SN1
[$(c[NH]OC(=O)[#6]);r5] Nitrenium ion
formation
Nitroso SN1 N(c)(c)[NX2]=O Nitrosation
Aliphatic tertiary
amines SN1
[NX3](C)(C)C Iminium ion
formation
Thiophenes SN2 [cH,$(c(c)(c)C)]1[cH,$(c(c)(c)C)]s[cH][cH]1 P450 mediated
epoxidation
Coumarins SN2 [cH]1[cH]c(=O)oc2ccccc12 P450 mediated
epoxidation
Mustards SN2 [NX3,SX2][CH2,$([CH]([NX3,SX2])([CX4])[CX4])] 
[CH2,$([CH]([CX4])([Cl,Br,I])[CX4])][Cl,Br,I]
Episulfonium ion
formation
1,2-Dihaloalkanes SN2 [Cl,Br,I][CH2,$([CH]([Cl,Br,I])([CX4])[CX4])][CH2,$([CH] 
([Cl,Br,I])([CX4])[CX4])][Cl,Br,I]
Episulfonium ion
formation
Alkyl nitrate SN2 [CH3,$([CH2](O)[#6]),$([CH](O)([#6])[#6])]O[NX2]=O SN2 at an sp3
carbon atom
Alkyl carbamates SN2 [CH3,$([CH2]([NX3])[CX4]),$([CH]([NX3])([CX4])[CX4])] 
[NX3]([CH3])C(=[O,SX2])[O,SX2][CX4]
SN2 at an sp3
carbon atom
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Aliphatic halide SN2 [CH3,$([CH2]([F,Cl,Br,I])[#6]),$([CH]([F,Br,Cl,I])([#6]) 
[#6]);!$([CH2,CH]C=O);!$([CH2,CH] 
[CX4][NX3,SX2]);!$([CH2,CH][CX4][F,Cl,Br,I])][F,Cl,Br,I]
SN2 at an sp3
carbon atom
Sulfonates SN2 [#6]S(=O)(=O)O[CH3,$([CH2](O)[#6]),$([CH](O)([#6]) 
[#6])]
SN2 at an sp3
carbon atom
Sulfates SN2 [#6]OS(=O)(=O)O[CH3,$([CH2](O)[#6]),$([CH](O)([#6]) 
[#6])]
SN2 at an sp3
carbon atom
Phopshates SN2 [#6][O,SX2]P(=[O,SX1])([O,SX2][#6])[O,SX2][CH3,$([CH2] 
(O)[#6]),$([CH](O)([#6])[#6])]
SN2 at an sp3
carbon atom
Phosphonates SN2 [#6][O,SX2]P(=[O,SX1])([#6])[O,SX2][CH3,$([CH2] 
(O)[#6]),$([CH](O)([#6])[#6])]
SN2 at an sp3
carbon atom
Phosphonic esters SN2 [#6][PX4](=O)O[CH3,$([CH2](O)[#6]),$([CH](O)([#6])[#6])] SN2 at an sp3
carbon atom
Lactones SN2 C1CC(=O)O1 Ring opening SN2
Sultones SN2 [$(C1OS(=O)(=O)CC1),$(C1OS(=O)(=O)CCC1)] Ring opening SN2
Nitrosos SN2 [CX4][NX3]([#6])[NX2]=O Nitrosation
Epoxides SN2 C1OC1 Direct acting
epoxides and
related
Aziridines SN2 C1[NX3]C1 Direct acting
epoxides and
related
Sulfaranes SN2 C1[SX2]C1 Direct acting
epoxides and
related
Halogenated polarised
alkenes SN2
[CH2,$([CH](=[CH])[#6,F,Cl,Br,I])]= 
[CH][F,Cl,Br,I,$(O(C=C)[a])]
Epoxidation of
aliphatic alkenes
N-acyloxy-N-
alkoxyamides SN2
[a]C(=O)N(O[#6])OC(=O)[#6] SN2 at a nitrogen
atom
Thioureas SN2 [#6][NH]C(=S)[NH][#6] P450 mediated
sulfoxidation
Mono-aldehydes SB [CH2,$([CH](=O)[CX4])]=O Direct acting
Schiff base
formers
a,b-Dicarbonyl SB [CH,$(C(=O)[#6]);!$(C(=O)C=C)](=O)[CH,$(C(=O) 
[#6]);!$(C(=O)C=C)]=O
Direct acting
Schiff base
formers
Ethylenediamines SB [$([NH2,$([NH]([CH2])[CX4])][CH2][CH2] 
[NH2]),$([NH]1[CH2][CH2][NH][CH2][CH2]1)]
Chemicals
activated by P450
to glyoxal
Ethanolamines SB [$([NH2,$([NH]([CH2])[CX4])][CH2][CH2] 
[OH]),$([NH]1[CH2][CH2]O[CH2][CH2]1)]
Chemicals
activated by P450
to glyoxal
N-methylol derivatives
SB
[NH2,$([NH]([CH2])[#6]),$(N([CH2])([#6])[#6])][CH2][OH] Chemicals
activated by P450
to mono
aldehydes
Thiazoles SB [cH]1ncs[cH]1 Chemicals
activated by P450
to mono
aldehydes
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Benzylamines SB c1ccccc1[CH2][NH2] Chemicals
activated by P450
to mono
aldehydes
Acetates AC [#6]C(=[O,SX2])[O,SX2][$([a;r6]),$([a; 
r5]),$(C([O,SX2])=C),$(C([O,SX2])#C)]
Direct acylation
Acetohydroxamic acids
and related AC
[#6,#7]C(=O)[NX3H,$([NX3](C=O)([OH])[#6])][OH] Activated to N
hydroxy
Alkyl carbamates and
related AC
[#6][OX2,NX3]C(=O)[NX3H2,$([NX3H][CX4])] Activated to N
hydroxy
Aromatic and aliphatic
diazoniums AC
[$([#6][NX2+]#[NX1]),$([#6][NX2]=[NX2][OH])] Azo coupling
Ceracemides AC [NH2,$([NH](C=O)[#6]),$(N(C=O)([#6])[#6])]C(=O)O[NX3] 
([$([CH]=O),$(C([NX3])(=O)[#6])])C(=O)[NH2,$([NH] 
(C=O)[CH3]),$(N(C=O)([CH3])[CH3])]
Activated to N
hydroxy
Nitrones AC [CH3,CH2,CH][CX3]=[NX2][OH] Nitrones and
related
Phosphinic halides
esters AC
[PX4](=O)[F,Cl,Br,I,$(Oa)] Acylation at a P
atom
Sulphonyl halides AC [#6]S(=O)(=O)[F,Cl,Br,I] Direct acylation
Cyclohexadiene 1,2
diols MA
C1([OH])[#6]=,:[#6]C=CC1[OH] Pre-quinones
and quinone type
chemicals
Napthalenes and
related MA
[c;R1]1[c;R1][c;R2]2[a;R1][a;R1][a;R1][a;R1] 
[c;R2]2[cH][cH]1
Pre-quinones
and quinone type
chemicals
Polarised alkene cyano
MA
[CH2,CH]=CC#N Polarised alkenes
Pyranones MA [$([cH]1cc(=[O,NH])cc[o,n]1),$([cH]1cc(=[O,NH]) 
[o,n]cc1),$(c1cc(=[O,NH])[o,n][cH]c1)]
Quinones and
quinone type
chemicals
Quinolines MA [$([cH]1[n;R1][c;R2]2[c;R1][c;R1][c;R1][c;R1][c;R2]2[c;R1] 
[cH]1),$([c;R1]1[n;R1][c;R2]2[c;R1][c;R1][c;R1][c;R1] 
[c;R2]2[cH][cH]1)]
Pre quinones and
quinone type
chemicals
Quinone diimine MA [$([CH]1=C[$(C=[NX2H]),$(C=[NX2][#6,#7])][#6]=,: 
[#6][$(C=[NX2H]),$(C=[NX2][#6,#7])]1),$([CH]1=C[$(C= 
[NX2H]),$(C=[NX2][#6,#7])][$(C=[NX2H]),$(C= 
[NX2][#6,#7])][#6]=,:[#6]1)]
Quinones and
quinone type
chemicals
Quinone dioximes MA [$(C1(=[NX2][OH])[#6]=,:[#6]C(=[NX2][OH]) 
[CH]=C1),$(C1(=[NX2][OH])C(=[NX2][OH])[#6]=,: 
[#6][CH]=C1)]
Quinones and
quinone type
chemicals
1,3-Dithianes SB C1S[CH2,$([CH][#6])]SCC1 Activated to di
carbonyl
Aromatic and related
triazenes SN1
[c;r6][NX2]=[NX2][NX3H2,$([NX3H][#6]),$([NX3]([CH3]) 
[CH3])]
Nitrenium ion
formation
N-Acetyl phenyl
hydrazines SN1
c[NH][NH][CX3](=O)[CX4] Carbenium ion
formation
1,1-Dihalos SN2 [CH2,$([CH]([F,Cl,Br,I])([F,Cl,Br,I])[#6])]([F,Cl,Br,I])[F,Cl,Br,I] SN2 at an sp3
carbon atom
Activated haloalkyls SN2 [CX4]([F,Cl,Br,I])[$([NX3+](=O)[O-]),$([CX3]([CX4]) 
(=O)[#6]),$([CH]([CX4])=O),$(a[CX4])]
SN2 at an sp3
carbon atom
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Aliphatic nitros SN2 [$([CH]([NX3+](=O)[O-])([#6])[#6]),$(C([NX3+](=O)[O-]) 
([#6])([#6])[#6])][NX3+](=O)[O-]
SN2 at an sp3
carbon atom
Allyl acetates and
related SN2
[#6]C(=[O,SX1])[O,SX2][CH2,$([CH]([O,SX2])[#6])] 
[c,CX3,CX2]
SN2 at an sp3
carbon atom
Haloalkenes SN2 C=C[F,Cl,Br,I] SN2 reaction at a
sp2 carbon
N-halos SN2 [c;r6][NH][F,Cl,Br,I] SN2 reaction at a
halo atom
Peroxides RD [$([#6][OX2][OX2][#6]),$([#6][OX2][OX2H]),$([OX2H] 
[OX2H])]
Radical
Quindioxin and related
RD
[O-][n+]1cc[n+]([O-])c2ccccc12 Radical
Procedure Description
Biological Endpoint and Measurement:
This method is an in silico model, which provides information on the following, biologically relevant,
endpoints:
DNA damage: formation of covalent adducts
Endpoint Value:
Qualitative: Structural alert
Experimental System:
In silico profiler for covalent DNA binding
3. Method Performance
Robustness of the Method
General performance measures:
Enoch and Cronin reported in 2012 an extensive evaluation and new structural alerts for chemical
category formation including covalent and non-covalent mechanisms of DNA binding.
A total of 2983 chemicals with positive Ames-test results from Kazius et al. (2005) were profiled with the
first set of structural alerts for covalent DNA binding developed by Enoch and Cronin (2010). At least one
electrophilic mechanism could be assigned to 2484 chemicals (83%).
A detailed mechanistic study of the remaining 498 chemicals with positive Ames-test results identified 26
new structural alerts for covalent-binding mechanisms, two for radical-mediated mechanisms and 12
structural alerts related to chemical classes of polycyclic aromatic hydrocarbons with common structural
motifs that could explain mutagenicity by a non-covalent intercalation mechanism.
Only for 150 chemicals with positive Ames-test data (5%) no clear mechanism could be hypothesised
from the available literature. 
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4. Discussion
The formation of a covalent bond between nucleophile (DNA) and electrophile (chemical) is one of the
fundamental steps for both mutagenicity and carcinogenicity. The chemical adducts can lead to
mutations, steric hindrance or strand breaks either directly by altering DNA sequence at the adduct site
or causing failure of the attempted DNA repair (see e.g. Yauk C et al., 2016).
The mechanistic importance of this chemical reaction makes the mechanistic alert approach the natural
choice for developing the profiler for covalent DNA binding. Moreover, the mechanistic domain overlap
between corresponding structural alerts in the literature compilations has been thoroughly assessed, so
that at least for the for the Ames test positive chemicals, only a very small minority could not be
explained by the covalent or non-covalent interaction with DNA. The analysis by Enoch and Cronin
(2012) ensured that for a given structural alert the maximum mechanistic information (and thus domain)
was extracted.
The use of mechanistic chemistry based alerts enables transparent category formation. Moreover, the
use of mechanistic classes (usually as defined by the presence of common reactive functional groups)
can help to develop a number of (quantitative) structure- activity relationship ((Q)SAR) models for
mutagenicity and carcinogenicity (see Passerini 2003; Benigni et al., 2008). These approaches play an
important role in contributing towards reducing the use of animals in regulatory toxicology. Applying
read-across to predict the toxicity of chemicals for which no toxicological data may exist, but might be
available for other members of the same category, is already an accepted practice in REACH dossiers for
genotoxicicty and carcinogenicity endpoints. For more information consult the "Analysis of
carcinogenicity testing for regulatory purposes in the European Union" (Madia et al., 2016).
5. Contact Details
Dr Steve Enoch
School of Pharmacy and Biomolecular Sciences
Liverpool John Moores University
Corresponding author, Method developer / user
Byrom Street
Liverpool L3 3AF
email: s.j.enoch@ljmu.ac.uk
telephone: +44(0)151 231 2164
Ver n° Date Name Type of change
1 12 November 2015 Dr Steve Enoch Data sheet created
6. Abbreviations & Definitions
AC Acylation
AOP Adverse Outcome Pathway
COSMOS EU Integrated Project: COSMOS developed an integrated suite of
computational tools to predict the effects of long-term exposure to chemicals in
humans based on in silico calculation and estimation techniques.
Website: http://www.cosmostox.eu .
ITS Integrated Testing Strategy
IATA Integrated Approach to Testing and Assessment
KNIME KoNstanz Information MinEr
MA Michael Addition
MIE Molecular Initiating Event
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MIE Molecular Initiating Event
RD Radical Mechanism
SB Schiff Base formation
SEURAT Safety Evaluation Ultimately Replacing Animal Testing
SMARTS SMiles ARbitrary Target Specification
SMILES Simplified Molecular-Input Line-Entry System
SN1 Unimolecular Aliphatic Nucleophilic Substitution
SN2 Bimolecular Aliphatic Nucleophilic Substitution
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DB-ALM Method summary n° 179 : In silico profiler for hepatotoxicity
Systemic Toxicity
The in silico profiler for hepatotoxicity consists of 16 structural alerts coded into SMARTS patterns. The
alerts can be used in the further screening of compounds to highlight potential hepatotoxicity. The
profiler is envisaged to be used to develop chemical categories based upon similar mechanisms as part of
the adverse outcome pathway paradigm. 
1. General Information
Corresponding author(s):
Prof. Mark Cronin, Liverpool John Moores University 
Date of data sheet creation: 12 November 2015
Last version number: 1
Last update: 12 November 2015
Proprietary and/or Confidentiality Issues:
None. The model is publicly available.
Status
Development
Development completed. Work carried out at Liverpool John
Moores University with support from the FP7 COSMOS Project
(Integrated In Silico Models for the Prediction of Human Repeated
Dose Toxicity of Cosmetics to Optimise Safety), within the
SEURAT-1 (Safety Evaluation Ultimately Replacing Animal Testing
1) cluster (2011-2015). More information on the COSMOS project is
available on its dedicated website:
http://www.cosmostox.eu
The in silico profiler for hepatotoxicity has a number of structural alerts coded into SMARTS patterns and
translated into KNIME (http://www.knime.org/) automated workflows as part of the COSMOS project.
The KNIME workflow is available via COSMOS Space:
http://cosmosspace.cosmostox.eu
A web version of the model was also implemented, allowing to execute the model via a web browser. It is
available through the COSMOS KNIME WebPortal:
http://knimewebportal.cosmostox.eu
2. Method Definition
Purpose of the Method
TYPE OF TESTING : Screening, Part of an integrated testing strategy
LEVEL OF TOXICITY ASSESSMENT : Toxic potential
Context of use
Liver is exposed to the xenobiotics taken up via the oral exposure route or injection. Many undergo
biotransformation in the liver and may cause hepatotoxicity before or after metabolism, which is a major
concern for the safety of chemical and pharmaceutical products.
The main goal of the in silico profiler is grouping chemicals into mechanism based categories centred on
the knowledge of a number of key molecular initiating events (MIEs) for hepatotoxicity as part of the
adverse outcome pathway (AOP) paradigm (e.g. AOP 38 "Protein alkylation leading to liver fibrosis";
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adverse outcome pathway (AOP) paradigm (e.g. AOP 38 "Protein alkylation leading to liver fibrosis";
Landesmann, 2012 and 2016). Such categories allow for read-across and data gap filling to be applied.
The premise behind these structurally developed categories is that similar chemicals should have similar
biological activities and therefore should have the same MIE.
Furthermore, the categories produced using in silico profilers can be supported by, and - screening large
data sets in order to identify chemicals with potential hepatotoxicity - used to prioritise additional testing
using in vitro and/or in chemico methods, within an integrated testing strategy (ITS) or an integrated
approach to testing and assessment (IATA). Such strategies can be used in hazard identification and risk
assessment for regulatory purposes such as REACH (EU, 2006) or the Cosmetics Directive (EU, 2009) and
could be incorporated into in silico decision-supporting software tools such as the OECD QSAR Toolbox.
Scientific Principle of the Method
Within the AOP paradigm, in silico methods contribute to identifying the key features of a chemical
(structural alerts) that induce a MIE. A collection of structural alerts that induce the same MIE are
considered to be an in silico profiler.
There are two types of profilers: mechanism-based profilers and chemistry-based profilers. The first type
is comprised of structural alerts relating to MIE that are supported by experimental data illustrating how
the alerts initiate the MIE, for example the i n silico profilers for covalent DNA binding (DB-ALM Method
Summary No. 178), covalent protein binding (DB-ALM Method Summary No. 181) or mitochondrial
toxicity (DB-ALM Method Summary No. 180).
In comparison, the chemistry-based profiler, as described here and for example the in silico profiler for
potential nuclear receptor ligands and alerts towards hepatosteatosis (DB-ALM Method Summary No.
177) consists of structural alerts that have been associated with inducing toxicity; thus, in contrast to
mechanism-based profilers, a chemistry-based profiler does not necessarily contain mechanistic
information relating to how the observed toxicity is initiated.
Due to these intrinsic differences, the two types of profiler should be used for different purposes;
mechanistic profilers should be used for category formation and read-across, whilst chemistry-based
profilers should be used to screen an inventory to prioritise chemicals to undergo (non-animal) testing. A
category developed utilising a mechanism-based profiler enables missing toxicological data for a
chemical to be filled using available information from analogues within the same category via
read-across predictions (Enoch et al 2011).
Model Description
The structural alerts were developed based on grouping chemicals from a hepatotoxicity dataset
compiled by Fourches et al. (2010) into 16 categories, investigating the mechanism(s) by which these
compounds cause hepatotoxicity and proposing a mechanistic rationale, where possible, to obtain
mechanistically supported structural alerts for potential hepatotoxins.
This was achieved by grouping chemicals based upon their structural similarity, followed by a literature
search to elucidate mechanistic information for the chemicals in categories associated with liver toxicity.
The identified structural alerts were defined as SMARTS (SMiles ARbitrary Target Specification, based on
SMILES - Simplified Molecular-Input Line-Entry System) patterns. SMARTS pattern allows for a
definition of a sub-structure within a molecule, which is then used to check whether a chemical structure
contains any of the pre-defined fragments.
The in silico profiler was implemented as KNIME workflow, and additionally as web version, allowing to
execute the model via a web browser. It is available through the COSMOS KNIME WebPortal:
http://knimewebportal.cosmostox.eu
Hepatotoxicity Dataset
One of the largest hepatotoxicity datasets available within the open literature was used to develop the
structural alerts. This dataset was compiled by Fourches et al. (2010), who mined the open literature and
got approximately 650,000 MEDLINE titles and abstracts containing one or more predetermined terms
relating to drug-induced liver injury (DILI). A combination of lexical and linguistic tools was used by
Fourches et al. to extract relationships between therapeutic compounds and a range of liver pathologies
(including hepatitis and focal necrosis, hepatic physiological observations such as gluconeogenesis and
cell growth). The data mining procedure considered data from in vivo and in vitro sources relating to
observed hepatotoxicity. Following a data curation process (removal of inorganics, duplicates and
mixtures), a final dataset of 951 substances was obtained. Each of the 951 compounds is accompanied
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mixtures), a final dataset of 951 substances was obtained. Each of the 951 compounds is accompanied
with data for three species groupings: human, rodent (rat, mouse, hamster, and guinea pig) and
non-rodent (dog, cat, pig, monkey, etc.). To develop the in silico profiler described by Hewitt et al.
(2013), only the human toxicity data were used for 650 compounds classified as positive for
hepatotoxicity in humans by Fourches et al. (2010).
Strategy for category formation and structural alert development as defined by Hewitt et al. (2013)
Step 1: Acquire appropriate training data
The first step in any modelling process is to gather appropriate chemical and toxicological data. In
terms of structural alert development this must consist of chemical structure and toxicological data
relevant to the endpoint of interest. Then, all chemical structures were encoded into SMILES strings,
neutralised, and salts were removed.
Step 2: Initial structural similarity-based category formation
The structural similarity of each compound to the remaining dataset members was calculated by
means of an atom environment / Tanimoto coefficient approach using the freely available Toxmatch
structural similarity tool (version 1.07) (Ideaconsult Ltd., 2012). The resulting similarity matrix was
assessed manually and valid categories were highlighted if an active (hepatotoxic) query compound
was matched with five or more compounds with a similarity index of 0.6 or greater (yielding
categories of six or more compounds). The choice of similarity threshold was important as this
directly influenced the level of structural restriction/diversity allowed within resulting categories.
Step 3: Manual validation of initial categories
Despite structural similarity methods often yield a significant number of categories, and a number of
these categories contain members which are not truly similar to the query compound. In such
instances, the observed structural diversity would likely lead to further diversity in the observed
mechanisms of hepatotoxicity making such categories meaningless. In order to eliminate such
categories from the analysis and ensure those remaining are valid, a simple three-tiered manual
inspection process was applied:
Noisy categories containing unsuitable (structurally heterogeneous) category members
were removed.
1.
Duplicate categories (containing identical members but using different initiating
compounds) were removed.
2.
Finally, upon inspection, a small number of additional structural alerts were suggested
based on the well-known hepatotoxicity of certain compound classes (e.g. the nitrogen
mustards). These were not identified using structural similarity alone.
3.
As a result of this process, 16 manually validated structural categories for human hepatotoxicity were
developed.
Step 4: Elucidation of structural alerts
Following the generation of validated structural categories, the next step was to use these to develop
structural alerts for hepatotoxicity. In order to do this, the common structural feature of each
validated category was found via manual inspection of chemical structures and the corresponding
structural alert was created in the form of a SMARTS notation (see Table 1).
Step 5: Using structural alerts to regenerate mechanistic categories
In this step, the original dataset was re-screened using the resulting structural alerts to re-populate
each category. In this way, all compounds containing a given structural fragment will enter the
corresponding category, showing the full scope of the proposed structural alert and maximising the
utilisation of the available toxicological data. In some cases, this alert returns fewer compounds than
were present in the initial category. This was a result of these categories being further restricted in
terms of structural criteria. This stage could also be seen as an action to correct for setting a similarity
threshold too high during the formation of initial categories. This could, therefore, allow for the use
of higher levels of structural similarity without any resultant reduction in the number of category
members.
Step 6: Examine regenerated categories (alert verification) and propose mechanistic rationale 
page 3 / 9
© EURL ECVAM DB-ALM: Method Summary
SEURAT-1 TOOLS & METHODS CATALOGUE PAGE 179
At this point, each of the regenerated categories was taken in turn and a detailed examination of all
category members was undertaken in order to firstly verify the performance of each alert and,
secondly, to derive a mechanistic hypothesis for the observed hepatotoxicity. This verification
element is in place to ensure each alert was developed (coded) correctly and returns categories
containing the structural feature of interest. This step is also beneficial for the identification and
assessment of possible false positive and negative compounds. Of course, given the lack of current
knowledge into the mechanisms of hepatotoxicity, and the often idiosyncratic nature of the effects, it
was accepted from the outset that a mechanistic rationale may not be possible in all cases. Moreover,
it is also probable that some hepatotoxic compounds may elicit their toxicities via multiple
mechanisms, making this process tougher still.
The name, structure and SMARTS notification of each structural alert are presented in Table 1 below.
The full description of the hepatotoxicity profiler is available in Hewitt et al (2013).
Table 1. Summary of the 16 structural alerts identified for hepatotoxicity
Name of structural alert Structural alert SMARTS pattern
Tamoxifen-like
antioestrogen
[#6]N([#6])CCOc1ccc(cc1)C(=C\c1ccccc1)
\c1ccccc1
Adenosine-Based
Reverse Transcriptase
Inhibitors
[H]N([H])c1ncnc2ncnc12
Retinoids C=CC=CC=CC=O
b-Lactam substructure O=C1CCN1
Barbitals O=C1CC(=O)NC(=O)N1
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Phenothiazines [#6]N([#6])CCCN1c2ccccc2Sc2ccccc12
Cytidine-Based Reverse
Transcriptase Inhibitors
c1cc([N])nc(=O)n1
Catechols [H]Oc1ccccc1O[H]
Angiotensin-converting
enzyme (ACE) inhibitors
[H]N(CC=O)CC([#7])=O
Oestrogen Steroids [H]Oc1ccc2C3CCC4CCCC4C3CCc2c1
Thiol [H]S[CX4]
Nitrogen mustards ClCCNCCCl
Anabolic Steroids O=C1CCC2C3CCC4CCCC4C3CCC2=C1
Glucocorticoid steroids O=C1C=CC2C3CCC4CCCC4C3CCC2=C1
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Disulfide bridges [#6]SS[#6]
Para-aminophenyl-
sulphonamides
[H]NS(=O)(=O)c1ccc(cc1)N([H])[H]
Procedure Description
Biological Endpoint and Measurement:
This method is an in silico model, which provides information on the following, biologically relevant,
endpoint:
Hepatotoxicity
Endpoint Value:
Qualitative: Structural alert
Experimental System:
In silico profiler for hepatotoxicity
3. Method Performance
Robustness of the Method
General performance measures:
The performance of each alert was verified by re-screening the original dataset and populating each
category. Detailed examination of all category members was undertaken in order to evaluate the
performance and to derive a mechanistic hypothesis for the observed hepatotoxicity for each category.
Notably, 15 out to 16 categories contained at least one member classified by Fourches et al. (2010) as
negative for human hepatotoxicity.
Given the lack of current knowledge into the mechanisms of hepatotoxicity, and the often idiosyncratic
nature of the effects, it was accepted from the outset that a mechanistic rationale may not be possible in
all cases and some unknown mitigating factors may be responsible for the false positives. Moreover, it is
also probable that some hepatotoxic compounds may elicit their toxicities via multiple mechanisms,
making the analysis even more difficult (Hewitt et al., 2013).
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4. Discussion
The ability of a compound to cause adverse effects to the liver is one of the most common reasons for
drug development failures and the withdrawal of drugs from the market. However, the complexity and
diversity of hepatotoxicity, the limited (if any) mechanistic insight, the lack of large high quality liver
toxicity datasets and the role of metabolism, ensure that hepatotoxicity is one of the most difficult
toxicological endpoints to model. The In silico profiler for hepatotoxicity of Hewitt et al. (2013) is one of
the first attempts undertaken to develop structural alerts or chemical classes for identifying hazardous
substances. The study has been followed by other research groups using publicly available
hepatotoxicity databases such as Hazard Evaluation Support System (HESS) (Pizzo et al., 2015), Fourches
et al. dataset (Fourchess et al., 2010; Zhang et al., 2016) or LiverTox human liver injury database (Liu et
al., 2015) in development of structural alerts and liver toxicity predictions.
The in silico profiler based on mechanistically supported structural alerts provides a useful tool in the
screening of compounds during the early stages of their development. Such profiler can be used to
identify and group chemicals acting via proposed mechanisms of hepatotoxicity. It also allows for
read-across methods to be performed for untested category members if sufficient toxicological data are
available.
Alerts of this type are also useful in further exploring the mechanistic basis of hepatotoxicity and have
been further corroborated and extended with additional categories developed in subsequent studies of
human and rodent hepatotoxicity (eg. Pizzo et al., 2015; Liu et al., 2015; Zhang et al., 2016). A known
limitation of the profiler is that some alerts are more specific than others and some may be
over-predictive. For example: among 11 barbiturates hepatotoxic in rodents (positive in the structural
alert Barbitals) only 3 were classified as hepatotoxic in humans (Hewitt et al., 2013). This might be due to
species differences or ambiguity in hepatotoxicity definition in the training dataset, as Fourches et al. did
not take the exposure into account. Rodent studies typically use higher concentrations than those used
in the human clinical applications. Authors caution that the aim of the model is not a stand alone
prediction of hepatotoxicity, but to provide a scheme capable of generating mechanistically supported
structural alerts suitable for identifying chemicals with hepatotoxicity potential in a weight of evidence
approach (Hewitt et al., 2013).
Implemented into an expert system (or weight-of-evidence approach supported by additional data),
mechanistically supported structural alerts can be a powerful tool in aiding the identification of
hepatotoxic potential. However, taking into account the complexity of hepatotoxicity, the structural
alerts are not limited to a single mechanism of action. Indeed, it is probable that many hepatotoxic
compounds elicit their toxicities via multiple mechanisms of action. Therefore, it is also possible that the
alerts within this profiler may possess the ability to initiate multiple adverse outcome pathways leading
to hepatotoxicity and other adverse outcomes.
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6. Abbreviations & Definitions
AOP Adverse Outcome Pathway
COSMOS EU Integrated Project COSMOS developed an integrated suite of
computational tools to predict the effects of long-term exposure to chemicals in
humans based on in silico calculation and estimation techniques.
Website: http://www.cosmostox.eu 
DILI Drug-induced liver injury
ITS Integrated Testing Strategy
IATA Integrated Approach to Testing and Assessment
KNIME KoNstanz Information MinEr
MIE Molecular Initiating Event
OECD Organisation for Economic Cooperation and Development
(Q)SAR (Quantitative) Structure-Activity Relationships
SEURAT Safety Evaluation Ultimately Replacing Animal Testing
SMARTS SMiles ARbitrary Target Specification
SMILES Simplified Molecular-Input Line-Entry System
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DB-ALM Method summary n° 180 : In silico profiler for mitochondrial toxicity
Systemic Toxicity
The in silico profiler for mitochondrial toxicity consists of 21 structural alerts coded into SMARTS
patterns. This profiler is envisaged to be used to develop chemical categories based upon similar
mechanisms as part of the adverse outcome pathway paradigm (AOP). Additionally, the profiler could be
utilised in screening large data sets in order to identify chemicals with the potential to induce
mitochondrial toxicity.
1. General Information
Corresponding author(s):
Dr Steve Enoch, Liverpool John Moores University 
Date of data sheet creation: 12 November 2015
Last version number: 1
Last update: 12 November 2015
Proprietary and/or Confidentiality Issues:
None. The model is publicly available.
Status
Development
Work carried out at Liverpool John Moores University with support
from the FP7 COSMOS Project (Integrated In Silico Models for the
Prediction of Human Repeated Dose Toxicity of Cosmetics to
Optimise Safety), within the SEURAT-1 Research Initiative (Safety
Evaluation Ultimately Replacing Animal Testing 1) cluster
(2011-2015).
The in silico profiler for mitochondrial toxicity has a number of structural alerts coded into SMARTS
patterns and translated into KNIME (http://www.knime.org/) automated workflows as part of the
COSMOS project. The KNIME workflow is available via COSMOS Space 
http://cosmosspace.cosmostox.eu
A web version of the model was also implemented, allowing to execute the model via a web browser. It is
available through the COSMOS KNIME WebPortal:
http://knimewebportal.cosmostox.eu
2. Method Definition
Purpose of the Method
TYPE OF TESTING : Screening, Part of an integrated testing strategy
LEVEL OF TOXICITY ASSESSMENT : Toxic potential
Context of use
The ability to predict organ-level toxicity is becoming increasingly important to the long term goal of
replacing animal use or chemical safety assessment. Many organ-specific and systemic toxicity
pathways can be traced back to mitochondrial function as initial target (Dykens and Will, 2007).
Therefore, there is an urgent need to develop models able to early detect potential mitochondria toxicants.
The main goal of the in silico profiler is grouping chemicals into mechanism based categories centred on
the knowledge of a number of key molecular initiating events (MIEs) for mitochondrial toxicity as part of
the adverse outcome pathway (AOP) paradigm (e.g. Event 177: "Mitochondrial dysfunction"; AOP-Wiki,
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the adverse outcome pathway (AOP) paradigm (e.g. Event 177: "Mitochondrial dysfunction"; AOP-Wiki,
2016). Such categories allow for read-across and data gap filling to be applied. The premise behind these
structurally developed categories is that similar chemicals should have similar biological activities and
therefore should have the same MIE.
Furthermore, the categories produced using in silico profilers can be supported by, and - screening large
data sets in order to identify chemicals with potential mitochondrial toxicity - used to prioritise,
additional testing using in vitro and/or in chemico methods, within an integrated testing strategy (ITS)
or an integrated approach to testing and assessment (IATA) (Tollefsen et al., 2014). Such strategies can
be used in hazard identification and risk assessment for regulatory purposes such as REACH (EU, 2006)
or Cosmetics Regulation (EU, 2009) and could be incorporated into in silico decision-supporting software
tools such as the OECD QSAR Toolbox.
Scientific Principle of the Method
One of the most ubiquitous and yet less studied targets of systemic toxicity is mitochondrial dysfunction,
which has been linked to a variety of organ toxicities within kidney, liver and nervous tissues (Dykens
and Will 2007).
The molecular mechanism of mitochondrial toxicity is complex: disruption of mitochondrial DNA
replication, protein synthesis, fatty acid metabolism or Krebs cycle, inhibition of electron transport,
uncoupling of electron transport from ATP synthesis, membrane permeability transition and production
of reactive oxygen species are among possible mechanisms which can be related to mitochondrial
dysfunction (Dykens and Will 2007). In addition, mode of action studies reveal that xenobiotics may
cause mitochondrial disruption through several mechanisms simultaniously (Nelms et al., 2015).
Within the AOP paradigm, in silico methods contribute to identifying the key features of a chemical
(structural alerts) that induce a MIE. A collection of structural alerts that induce the same MIE are
considered to be an in silico profiler. There are two types of profilers: mechanism-based profilers and
chemistry-based profilers. The first type is comprised of structural alerts relating to MIE that are
supported by experimental data illustrating how the alerts initiate the MIE, for example the i n silico
profilers for covalent protein binding (DB-ALM Method Summary No. 181), covalent DNA binding
(DB-ALM Method Summary No. 178) or mitochondrial toxicity described in this Method Summary.
In comparison, the chemistry-based profiler consists of structural alerts that have been associated with
inducing toxicity; thus, in contrast to mechanism-based profilers, a chemistry-based profiler does not
contain mechanistic information relating to how the observed toxicity is initiated. Examples are:
the in silico profilers for hepatotoxicity (DB-ALM Method Summary No. 179) and for potential nuclear
receptor ligands and alerts towards hepatosteatosis (DB-ALM Method Summary No. 177).
Due to these intrinsic differences, the two types of profiler should be used for different purposes;
mechanistic profilers should be used for category formation and read-across, whilst chemistry-based
profilers should be used to screen an inventory to prioritise chemicals to undergo (non-animal) testing. A
category developed utilising a mechanism-based profiler enables missing toxicological data for a
chemical to be filled using available information from analogues within the same category via
read-across predictions (Enoch et al., 2011).
Model Description
The in silico profiler for mitochondrial toxicity was developed based around clearly defined mechanistic
information. This was achieved by grouping chemicals based upon their structural similarity, followed
by a literature search to elucidate mechanistic information for a number of key molecular initiating
events that disrupt the normal functioning of mitochondria.
The identified structural alerts were defined as SMARTS (SMiles ARbitrary Target Specification, based on
SMILES - Simplified Molecular-Input Line-Entry System) patterns. SMARTS pattern allows for a
definition of a sub-structure within a molecule, which is then used to check whether a chemical structure
contains any of the pre-defined fragments.
The in silico profiler was implemented as KNIME workflow, and additionally as web version, allowing to
execute the model via a web browser. It is available through the COSMOS KNIME WebPortal:
http://knimewebportal.cosmostox.eu 
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Datasets
Two datasets were used for the development of structural alerts associated with mitochondrial toxicity:
288 chemicals reported by Zhang et al (2009). This article was chosen as it provides one of the largest
freely available datasets, for which the chemical list has qualitative mitochondrial toxicity data
associated with it. Within this data set 171 chemicals have been reported within the literature as
inducing mitochondrial toxicity and were therefore considered to be mitochondrial toxicants. The
chemicals with a negative result for mitochondrial toxicity were selected from the FDA-approved
drug list, whereby the therapeutic action mechanism, of common and safe oral drugs, was not
associated with a mechanism of drug-induced mitochondrial toxicity. Data for the 288 chemicals,
including SMILES and toxicity towards mitochondria are available in Nelms et al.(2015 bis).
1.
94 hair dyes with NOAEL values from oral 90-day rat studies extracted from the SCC(NF)P/SCCS
‘Opinion On’ reports published between 2000 and 2013. The dataset including SMILES and NOAEL
values is available in Nelms et al. (2015).
2.
Category formation based upon structural similarity
All chemical structures were encoded into SMILES strings and neutralised, and salts were removed.
Similarity calculations were implemented within the freely available Toxmatch software (v1.07) using the
atom environment nearest-neighbour approach, generating a data matrix with a Tanimoto similarity
score for each chemical to all others within the dataset. Subsequently, in-house code was implemented
within Microsoft Excel that identified analogues with a similarity index of 0.6 or greater; this was used to
develop categories for the chemicals within the dataset with two, or more, analogues. Further analysis
was undertaken upon those categories that met the following criteria: they contained three or more
chemicals and at least one mitochondrial toxic chemical.
In total, twelve categories were initially formed:
local anaesthetics, antianginal and antiarrhythmic;1.
anti-diabetic drugs;2.
nonsteroidal anti-inflammatory drugs;3.
anthracycline antibiotics;4.
hypolipodemic drugs;5.
bile acids;6.
antihistaminic, antipsychotic and antiemetic drugs;7.
β-blockers;8.
2-nitroaminobenzenes;9.
4-nitroaminobenzenes;10.
aromatic azos and11.
anthraquinones.12.
Mechanistic hypothesis and development of alerts
Once categories had been developed using structural similarity, a detailed search of the available
literature was undertaken to elucidate the mechanistic information behind the molecular initiating
event, along with other downstream key events, leading to the disruption of the mitochondria. This
mechanistic information was subsequently utilised to support the definition of a structural alert suitable
for grouping chemicals. These structural alerts were defined by identifying the common fragment
present within each of the chemicals found to have positive mitochondrial toxicity according to literature
information associated with them. Any additional information regarding the limits of the fragment found
during the literature search, such as the requirement for an electron-withdrawing group or the type of
bond needed (e.g., a tertiary amine), was used to further refine the structural alert.
As a result, 21 structural alerts were developed (nine of them were earlier identified by Naven et al.
(2013)) and subsequently defined as SMARTS patterns.
Table 1 presents the list of 21 structural alerts together with the underlying mechanism and their
graphical representation. The SMARTS pattern are available in Table 2. The full description of this
profiler and the mechanistic rationale behind each alert is available in Nelms et al. (2015 and 2015 bis).
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Table 1. Summary of the structural alerts identified for mitochondrial toxicity.
Structural alert Mechanism Structural Alert
2-(Dialkylamino)-N-(2,6-
dimethylphenylacetamides
Protonophore
R = alkyl carbon
Thiazolinediones Protonophore
2-Anilinobenzoic acids Protonophore
Salicylates Protonophore
Anthranilic acids Protonophore
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Anthracene-9,10-diones Redox cycling
Naphthoquinones Redox cycling
Perfluorinated-carboxcylic-acids Protonophore
n = 5-11
Perfluorinated-sulphonamides Protonophore
n = 5-11
Bile acids Unclear
R = alkyl carbon
Phenothiazines Inhibition of
Complexes I-IV
R1 = CH2, CH3
R2 = Cl, CF3
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Fluoromethylsulphanilides Protonophore
Nitrophenols Protonophore
Nitrosulphonanilides Protonophore
Phenylhydrazones Protonophore
R = any carbon
Thiadiazinedione dioxides Protonophore
Acylindolones Protonophore
R = alkyl carbon
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Quinones (X = NH, O) Inhibition of the
electron transport
chain and
uncoupling of
oxidative
phosphorylation
Pro-quinones 
(R = OH, NH2, NH, NO2)
Inhibition of the
electron transport
chain and
uncoupling of
oxidative
phosphorylation
Aromatic azos
(R = NH2, NH, OH)
Inhibition of the
electron transport
chain
Meta-substituted benzenes
(R = NH2, OH)
Inhibition of the
electron transport
chain
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Table 2. Structural alerts for mitochondrial toxicity defined as SMARTS patterns.
Name Structural alert
2-(Dialkylamino)-N-(2,6-
dimethylphenylacetamides
c1([CH3])cccc([CH3])c1[NX3H][CX3](=[OX1])[CH2][NX3]
([CH2,CH3])[CH2,CH3]
Thiazolinediones [SX2]1[CX3](=[OX1])[NX3H][CX3](=[OX1])[CX4]1
2-Anilinobenzoic acids c1cccc([CX3](=[OX1])[OH])c1[NX3H]c1ccccc1
Salicylates c1cccc([CX3](=[OX1])[OH])c1[OH]
Anthranilic acids c1cccc([CX3](=[OX1])[OH])c1[NH2]
Anthracene-9,10-diones [OX1]=C1c2ccccc2C(=[OX1])c2ccccc12
Naphthoquinones c1ccc2c(c1)C(=[OX1])C=CC2=[OX1]
Perfluorinated-carboxcylic-acids [$([CX4](F)(F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4]
(F)(F)[CX4](F)(F)[CX4](F)(F)[CX3](=[OX1])[OH]),
$([CX4](F)(F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4]
(F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX3](=[OX1])[OH]),
$([CX4](F)(F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4]
(F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX3](=[OX1])[OH]),
$([CX4](F)(F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)
[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX3](=[OX1])[OH]),
$([CX4](F)(F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4]
(F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)
[CX3](=[OX1])[OH])]
Perfluorinated-sulphonamides [$([CX4](F)(F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4]
(F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[SX4](=[OX1])(=[OX1])([NH2])),
$([CX4](F)(F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4]
(F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[SX4](=[OX1])(=[OX1])([NH2])),
$([CX4](F)(F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)
[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[SX4](=[OX1])(=[OX1])([NH2])),
$([CX4](F)(F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)
[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[SX4](=[OX1])
(=[OX1])([NH2])),
$([CX4](F)(F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)
[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[CX4](F)(F)[SX4]
(=[OX1])(=[OX1])([NH2]))]
Bile acids [OH]C1CCC2C(CCC3C4CCC([CH2][CH2][CH2][CX3](=[OX1])
[OH,NX3H])C4CCC23)C1
Phenothiazines [NX3]([CH2,CH3])([CH2,CH3])[CX4][CX4]
[CX4]N1c2ccccc2Sc2ccc([$(C(F)(F)(F)),Cl])cc12
Fluoromethylsulphanilides c1ccccc1[NX3H][SX4](=[OX1])(=[OX1])[CX4](F)(F)F
Nitrophenols c1cccc([NX3+]([OX1-])=O)c1[CX3](=[OX1])[OH]
Nitrosulphonanilides c1ccccc1[NX3H][SX4](=[OX1])(=[OX1])[CX4]
Phenylhydrazones c1ccccc1[NX3H][NX2]=[CX3]([#6])[#6]
Thiadiazinedione dioxides [NX3]1([CX4])[CX3](=O)[CH]([CX3](=O)[CX4])[CX3](=O)[NX3]([CX4])
[SX4]1(=O)=O
Acylindolones c1ccc2c(c1)[CH]([CX3](=O)[NX3]2)[CX3](=O)[CX4]
Pro-quinones (R = OH, NH2,
NH, NO2)
[$(c1cc([$([N+](=O)[O-]),$([NH2,NH,OH])])ccc1[$([N+]
(=O)[O-]),$([NH2,NH,OH])]),$(c1cccc([$([N+]
(=O)[O-]),$([NH2,NH,OH])])c1[$([N+](=O)[O-]),$([NH2,NH,OH])])]
Quinones (X= NH, O) [$(c1cc([$([N+](=O)[O-]),$([NH2,NH,OH])])ccc1[$([N+]
(=O)[O-]),$([NH2,NH,OH])]),$(c1cccc([$([N+]
(=O)[O-),$([NH2,NH,OH])])c1[$([N+](=O)[O]),
$([NH2,NH,OH])])]
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Aromatic azos
(R = NH2, NH, OH)
[$(a[NX2]=[NX2]c1c([NH2,NH,OH])cccc1),$(a[NX2]=
[NX2]c1ccc([NH2,NH,OH])cc1)]
Meta-substituted benzenes (R =
NH2, OH)
c1ccc([NH2,NH,OH])c([!$([NH2,NH,OH])])c1[NH2,NH,OH]
Procedure Description
Biological Endpoint and Measurement:
This method is an in silico model, which provides information on the following, biologically relevant,
endpoint:
MITOCHONDRIAL TOXICITY: Structure-activity relationships related to protonophores, redox cycling,
complex I-IV inhibition, inhibition of electron transport chain and uncoupling of oxidative
phosphorylation.
Endpoint Value:
Qualitative: Structural alert
Experimental System:
In silico profiler for structural alerts of mitochondrial toxicity
3. Method Performance
Robustness of the Method
General performance measures:
The method detects structure-activity relationships with a well documented mechanistic basis for
mitochondrial toxicity, however the profiler is not exhaustive and no analysis of each alert's performance
has been conducted yet.
An earlier study by Naven et al. (2013) has shown that chemicals which share the same structural alert,
may have different mitochondrial dysfunction potency. Therefore the presence of an alert should be
considered an indication of potential mitochondrial toxicity that can be used for screening and a
guidance for further in vitro studies for mitochondrial dysfunction.
4. Discussion
Strengths and limitations of the method
The ability to predict organ-level toxicity is becoming increasingly important to the long term goal of
replacing animal use for chemical safety assessment. It is generally understood that this goal can only be
achieved by a combination of complementary approaches (e.g. in vitro, ex vivo, in silico, in chemico) that
address functional mechanistic endpoints tied to adverse outcomes of regulatory concern.
Organ toxicities within kidney, liver and nervous tissues have been frequently linked to mitochondrial
dysfunction, causing for example off-target systemic adverse effects in chronic drug exposure (Dykens
and Will, 2007). Such effects are often missed in the pre-clinical drug safety animal studies and may be
driven by metabolic or genetic components present only in specific patient subpolulations. In their
page 9 / 12
© EURL ECVAM DB-ALM: Method Summary
SEURAT-1 TOOLS & METHODS CATALOGUE PAGE 195
review in 2007 Dykens and Will estimated that approximately 50% of drugs with FDA Black Box warning
for hepatotoxicity and cardiovascular toxicity cause mitochondrial dysfunction. Consequently
mitochondrial dysfunction is regarded as MIE in numerous AOPs. This example from drug safety
assessment is also applicable for general chemical safety assessment and shows that there is an urgent
need to develop better models able to early detect potential human mitochondria toxicants.
The structural alerts demonstrate such ability for identifying chemicals which can disrupt the
mitochondrial functionality. The in silico profiler can be utilised to either screen an inventory for
prioritization or to develop chemical categories, from which read-across predictions could be made
regarding to a chemical’s ability to initiate mitochondrial toxicity and for which further in vitro /  i n
chemico testing may be appropriate.
Upon development of structural alerts it is necessary to substantiate that each of the alerts correctly
identifies chemicals with the potential to instigate an MIE. Other alternative techniques, such as in vitro
and/or in chemico assays, can be used to verify the alerts developed are correct. However, it should be
noted that whilst these alerts may be correct, other factors, such as the internal concentration or
metabolism, may prevent the MIE from being induced in vivo.
It is important to mention that a structural alert was developed only if information linking category
members to mitochondrial toxicity was present within the scientific literature. The benefit of undertaking
the analysis for each category is that it enabled the chemical space associated with a known, and tested,
mechanism of mitochondrial toxicity to be identified. The development of chemical categories and
identification of additional mechanistic information from the literature were crucial in addressing the
limitations of the information in the original data set. It should be noted that, due to the limitations of the
data available, the method does not aim to create a profiler that would be used for pharmaceutical risk
assessment. Its development has highlighted the need for more mitochondrial chemical testing and
better understanding of the mitochondrial dysfunction and its role in adverse health effects (Nelms et al.,
2015 bis).
Potential for future development
Additional future work involves utilising experimental information from in vitro / in chemico assays to
verify the mechanism-based alerts and to refine the chemistry-based alerts by discerning mechanistic
information associated with them.
5. Contact Details
Prof. Mark Cronin
Professor of Predictive Toxicology
School of Pharmacy and Biomolecular Sciences
Liverpool John Moores University
Method developer / user
Byrom Street
Liverpool L3 3AF
email: m.t.cronin@ljmu.ac.uk
telephone: + 44 151 231 2402
fax: + 44 151 231 2170
last contact update: 11 May 2016
Dr Mark Nelms
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Method developer / user
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Method developer / user
Byrom Street
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Liverpool John Moores University
Method developer / user
Byrom Street
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Dr Steve Enoch
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Corresponding author, Method developer / user
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email: s.j.enoch@ljmu.ac.uk
telephone: +44(0)151 231 2164
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Department of Toxicology, Center for Pharmaceutical Research (CePhar)
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Department of Toxicology, Center for Pharmaceutical Research (CePhar)
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Ver n° Date Name Type of change
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6. Abbreviations & Definitions
AOP Adverse Outcome Pathway
COSMOS EU Integrated Project: COSMOS developed an integrated suite of
computational tools to predict the effects of long-term exposure to chemicals in
humans based on in silico calculation and estimation techniques.
Project website: http://www.cosmostox.eu .
ITS Integrated Testing Strategy
IATA Integrated Approach to Testing and Assessment
KNIME KoNstanz Information MinEr
LO(A)EL Lowest Observed (Adverse) Effect Level
MIE Molecular Initiating Event
OECD Organisation for Economic Cooperation and Development
(Q)SAR (Quantitative) Structure-Activity Relationships
SCCNFP Scientific Committee on Cosmetic products and Non-Food Products
SCCP Scientific Committee on Consumer Products
SCCS Scientific Committee on Consumer Safety
SEURAT Safety Evaluation Ultimately Replacing Animal Testing
SMARTS SMiles ARbitrary Target Specification
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SMILES Simplified Molecular-Input Line-Entry System
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DB-ALM Method summary n° 181 : In silico profiler for covalent protein binding
Systemic Toxicity
The in silico profiler for covalent protein binding compiles mechanistic organic chemistry fragments (in
the form of structural alerts) for the binding of exogenous chemicals (electrophiles) to proteins
(nucleophiles). The profiler is envisaged to be used to develop chemical categories based upon similar
mechanisms as part of the adverse outcome pathway paradigm. Additionally, the profiler could be
utilised in screening large data sets in order to identify chemicals with the potential to bind to proteins.
1. General Information
Corresponding author(s):
Dr Steve Enoch, Liverpool John Moores University 
Date of data sheet creation: 12 November 2015
Last version number: 1
Last update: 12 November 2015
Proprietary and/or Confidentiality Issues:
None. The model is publicly available.
Status
Development
Development completed. Work carried out at Liverpool John
Moores University with support from the with support from the
European Chemicals Agency (EChA) Service Contract No.
ECHA/2008/20/ECA.203 and the FP7 COSMOS Project (Integrated 
In Silico Models for the Prediction of Human Repeated Dose
Toxicity of Cosmetics to Optimise Safety), within the SEURAT-1
(Safety Evaluation Ultimately Replacing Animal Testing 1) cluster
(2011-2015). More information on the COSMOS project is available
on its dedicated website:
http://www.cosmostox.eu
Most of the structural alerts and associated mechanistic chemistry have been incorporated into the
Organisation for Economic Co-operation and Development (OECD) (Q)SAR Application Toolbox, a
software tool designed to fill data gaps in a regulatory environment without the need for further animal
testing: http://www.qsartoolbox.org 
The in silico profiler for covalent protein binding has a number of structural alerts coded into SMARTS
patterns and translated into KNIME (http://www.knime.org/) automated workflows as part of the
COSMOS project. The KNIME workflow is available via COSMOS Space:
http://cosmosspace.cosmostox.eu
A web version of the model was also implemented, allowing to execute the model via a web browser. It is
available through the COSMOS KNIME WebPortal:
http://knimewebportal.cosmostox.eu
2. Method Definition
Purpose of the Method
TYPE OF TESTING : Screening, Part of an integrated testing strategy
LEVEL OF TOXICITY ASSESSMENT : Toxic potential
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Context of use
The main goal of the in silico profiler is grouping chemicals into mechanism based categories centred on
the knowledge of a number of key molecular initiating events (MIEs) for a number of toxicity endpoints
such as skin sensitisation, respiratory sensitisation, hepatotoxicity and aquatic toxicity, as part of the
adverse outcome pathway (AOP) paradigm.
Such categories allow for read-across and data gap filling to be applied to the chemicals for which no
toxicological data are available. The premise behind these structurally developed categories is that
similar chemicals should have similar biological activities and therefore should have the same MIE.
Covalent binding to extra- and intra-cellular proteins is a well known mechanism of action of chemicals,
leading to impaired physiological functions of the modified proteins and/or immune response to the
haptenated proteins (Zhou et al., 2005; Chipinda et al., 2011). Target organ or systemic adverse effects
may include allergic contact dermatitis, respiratory sensitisation, liver fibrosis, neurotoxicity, cancer,
growth impairment or mortality of aquatic organisms (e.g. AOP 40:"Covalent Protein binding leading to
Skin Sensitisation" and AOP 38:"Protein Alkylation leading to Liver Fibrosis") (Landesmann, 2012 and
2016; Lopachin and Decaprio, 2005). Such effects are of major concern in drug development and for the
environmental, health and safety impact of chemicals.
The categories produced using in silico profilers can be supported by -and screening large data sets in
order to identify chemicals with the potential to bind to proteins, and can be used to prioritise additional
testing using in vitro and/or in chemico methods, within an integrated testing strategy (ITS) or an
integrated approach to testing and assessment (IATA).
Such strategies can be used in hazard identification and risk assessment for regulatory purposes such as
REACH (EU, 2006) or the Cosmetics Regulation (EU, 2009). To facilitate the use in this context the
covalent DNA binding profiler was incorporated into in silico software tools such as the OECD QSAR
Toolbox.
Scientific Principle of the Method
For a number of toxicological endpoints, such as hepatotoxicity (liver fibrosis), skin sensitisation,
respiratory sensitisation or aquatic toxicity, one of the fundamental steps is the formation of a covalent
adduct between a reactive exogenous chemical (electrophile) and biological protein (nucleophile).
Protein binding can thus be a molecular initiating event for a number of adverse outcome pathways (e.g.
AOP 40 and AOP 38, Landesmann, 2016; Cochrane et al., 2015).
Within the AOP paradigm, in silico methods contribute to identifying the key features of a chemical
(structural alerts) that induce a MIE. A collection of structural alerts that induce the same MIE are
considered to be an in silico profiler.
There are two types of profilers: mechanism-based profilers as described here and chemistry-based
profilers. The first type is comprised of structural alerts relating to a MIE that are supported by
experimental data illustrating how the alerts initiate the MIE, as for example also the in silico profilers for
covalent DNA binding (DB-ALM Method Summary No. 178) or mitochondrial toxicity (DB-ALM Method
Summary No. 180). In comparison, the chemistry-based profiler, as for example the in silico profilers for
potential nuclear receptor ligands and alerts towards hepatosteatosis (DB-ALM Method Summary No.
177) or hepatotoxicity (DB-ALM Method Summary No. 179), consists of structural alerts that have been
associated with inducing toxicity; thus, in contrast to mechanism-based profilers, a chemistry-based
profiler does not contain mechanistic information relating to how the observed toxicity is initiated.
Due to these intrinsic differences, the two types of profilers should be used for different purposes;
mechanistic profilers should be used for category formation and read-across, whilst chemistry-based
profilers should be used to screen an inventory to prioritise chemicals to undergo (non-animal) testing. A
category developed utilising a mechanism-based profiler enables missing toxicological data for a
chemical to be filled using available information from analogues within the same category via
read-across predictions (Enoch et al., 2011).
Model Description
The in silico profiler for covalent protein binding was developed based on the review of current scientific
knowledge on structural alerts relating to a number of toxicity endpoints such as skin sensitisation,
respiratory sensitisation and aquatic toxicity. There are several publications in which structural alerts for
direct acting and indirect acting electrophiles have been published (see Enoch et al., 2011 bis).
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The existing structural alerts were mapped in terms of their relationships with mechanistic organic
chemistry, i.e. identifying alerts from the published compilations related to covalent protein binding.
The mapping was performed to achieve maximum overlap and usability whilst restricting redundancy in
the alerts, and to ensure that the alerts related to the molecular initiating event of covalent protein
binding.
As a result, a total of 108 structural alerts, supported by mechanistic information and meta data, have
been created, covering five broad organic chemistry mechanisms (domains) - acylation (AC), Michael
addition (MA), Schiff base formation (SB), bimolecular aliphatic nucleophilic substitution (SN2) and
aromatic nucleophilic substitution (SNAr).
The identified mechanistic structural alerts were further defined as SMARTS (SMiles ARbitrary Target
Specification, based on SMILES - Simplified Molecular-Input Line-Entry System) patterns. SMARTS
pattern allows for a definition of a sub-structure within a molecule, which is then used to check whether
a chemical structure contains any of the pre-defined fragments.
Moreover, the detailed mechanistic chemistry reaction associated with each of the alerts has been
compiled. The mechanistic information is intended to outline how the alert can act as a direct
electrophile or how it can be converted into an electrophile. Therefore, an important consideration
within the mechanistic chemistry framework is the inclusion of potential metabolic activation.
The in silico profiler was implemented as KNIME workflow, and additionally as web version, allowing to
execute the model via a web browser. It is available through the COSMOS KNIME WebPortal: 
http://knimewebportal.cosmostox.eu 
Table 1. Summary of the 108 structural alerts defined for covalent protein binding.
AC - Acylation, MA - Michael addition, SB - Schiff base formation, 
SN2 - nucleophilic substitution 2, SNAr - aromatic nucleophilic substitution
The full description of the protein binding profiler is available in Enoch et al. (2011 bis). 
Structural alert SMARTS Mechanism 
Acyl halides AC [CH,$(C(=[O,SX1])[#6])](=[O,SX1])[F,Cl,Br,I] Direct acylation
involving a
leaving group
Acetates AC [CH,$(C(=[O,SX1])[#6])](=[O,SX1])[O,SX2,NX3]
[$([a;r6]),$([a;r5]),$(C([O,SX2,NX3])=C),
$(C([O,SX2,NX3])#C)]
Direct acylation
involving a
leaving group
Anhydrides AC [CH,$(C([O,SX2])(=[O,SX1])[#6])](=[O,SX1])[O,SX2]
[CH,$(C([O,SX2])(=[O,SX1])[#6])]=[O,SX1]
Direct acylation
involving a
leaving group
Azlactones AC C1=[O,SX2,NX2,CX3]CC(=[O,SX2])[O,SX2,NX3]1 Direct acylation
involving a
leaving group
Sulphonyl halides AC [#6]S(=O)(=O)[F,Cl,Br,I,$(C#N)] Direct acylation
involving a
leaving group
Phosphonic acid halides
AC
[#6]OP(=O)(O[#6])[F,Cl,Br,I,$(C#N)] Direct acylation
involving a
leaving group
Dialkyl carbamyl halides
AC
[NH2,$([NH](C=O)[#6]),$(N(C=O)([#6])
[#6])]C(=O)[F,Cl,Br,I]
Direct acylation
involving a
leaving group
β-Lactones AC C1C(=O)OC1 Ring opening
acylation
Thio lactones AC C1C(=O)SC1 Ring opening
acylation
α-Lactams AC C1C(=O)NC1 Ring opening
acylation
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Cyclopropenones AC [cH,$(c(c)[#6])]1[cH,$(c(c)[#6])]c1=O Ring opening
acylation
Isocyanates AC [NH,$(N(=C=O)[#6])]=C=O Isocyanates and
related
Isothiocyanates AC [NH,$(N(=C=[SX1])[#6])]=C=[SX1] Isocyanates and
related
Dithiocarbonamide acid
esters AC
[#6]N=C(S[#6])S[#6] Isocyanates and
related
Carbodiimides AC [#6]N=C=N[#6] Isocyanates and
related
Ketenes AC [CH2,$([CH](=C=O)[#6]),$(C(=C=O)([#6])
[#6])]=C=O
Isocyanates and
related
Polarised alkene
aldehydes MA
[$([CH2]),$([CH][#6])]=[CH,$(C[#6])][CH]=O Polarised alkenes
Polarised alkene ketones
MA
[$([$([CH2]),$([CH][#6])]=[CH,$(C[#6])]C(=O)
[#6]);!$([CH]1=CC(=O)C=CC1(=O));
!$([CH]1=CC(=O)C(=O)C=C1)]
Polarised alkenes
Polarised alkene esters
MA
[$([CH2]),$([CH][#6])]=[CH,$(C[#6])]C(=O)O[#6] Polarised alkenes
Polarised alkene amides
MA
[$([CH2]),$([CH][#6])]=[CH,$(C[#6])]C(=O)
[NH2,$([NH](C=O)[#6]),$(N(C=O)([#6])[#6])]
Polarised alkenes
Polarised alkene nitros
MA
[$([CH2]),$([CH][#6])]=[CH,$(C[#6])][N+](=O)[O-] Polarised alkenes
Polarised alkene cyano
MA
[$([CH2]),$([CH][#6])]=[CH,$(C[#6])]C#N Polarised alkenes
Polarised alkene
sulfonate MA
[$([CH2]),$([CH][#6])]=[CH,$(C[#6])]S(=O)(=O)O[#6] Polarised alkenes
Polarised alkene sulfone
MA
[$([CH2]),$([CH][#6])]=[CH,$(C[#6])]S(=O)(=O)[#6] Polarised alkenes
Polarised alkene sulfinyl
MA
[$([CH2]),$([CH][#6])]=[CH,$(C[#6])][SX3](=O)[#6] Polarised alkenes
Polarised alkene oximes
MA
[$([CH2]),$([CH][#6])]=[CH,$(C[#6])]C=[NX2][OH] Polarised alkenes
Polarised alkene
pyridines MA
[$([CH2]),$([CH][#6])]=[CH,$(C[#6])][$(c1ncccc1),
$(c1ccncc1)]
Polarised alkenes
Polarised alkene
pyrazines MA
[$([CH2]),$([CH][#6])]=[CH,$(C[#6])]c1nccnc1 Polarised alkenes
Polarised alkene
pyrimidines MA
[$([CH2]),$([CH][#6])]=[CH,$(C[#6])]
[$(c1ncncc1),$(c1ncccn1),$(c1cncnc1)]
Polarised alkenes
Polarised akene triazines
MA
[$([CH2]),$([CH][#6])]=[CH,$(C[#6])]
[$(c1ncncn1),$(c1nncnc1),$(c1nnccn1),
$(c1cnncn1),$(c1nnncc1),$(c1cnnnc1)]
Polarised alkenes
Azocarbonamides MA [NH2,$([NH](C=O)[#6]),$(N(C=O)([#6])[#6])]
C(=O)N=NC(=O)[NH2,$([NH](C=O)[#6]),
$(N(C=O)([#6])[#6])]
Polarised azo
compounds
Polarised alkyne
aldehydes MA
[CH,$(C(#C)[#6])]#C[CH]=O Polarised alkynes
Polarised alkyne ketones
MA
[CH,$(C(#C)[#6])]#CC(=O)[#6] Polarised alkynes
Polarised alkyne esters
MA
[CH,$(C(#C)[#6])]#CC(=O)O[#6] Polarised alkynes
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Polarised alkyne amides
MA
[CH,$(C(#C)[#6])]#CC(=O)[$([NH2]),
$([NH](C=O)[#6]),$(N(C=O)([#6])[#6])]
Polarised alkynes
Polarised alkyne nitros
MA
[CH,$(C(#C)[#6])]#C[N+](=O)[O-] Polarised alkynes
Polarised alkyne cyano
MA
[CH,$(C(#C)[#6])]#CC#N Polarised alkynes
Polarised alkyne
sulfonate MA
[CH,$(C(#C)[#6])]#CS(=O)(=O)O[#6] Polarised alkynes
Polarised alkyne sulfone
MA
[CH,$(C(#C)[#6])]#CS(=O)(=O)[#6] Polarised alkynes
Polarised alkyne sulfinyl
MA
[CH,$(C(#C)[#6])]#C[SX3](=O)[#6] Polarised alkynes
Polarised alkyne
pyridines MA
[CH,$(C(#C)[#6])]#C[$(c1ncccc1),$(c1ccncc1)] Polarised alkynes
Polarised alkyne
pyrazine MA
[CH,$(C(#C)[#6])]#Cc1nccnc1 Polarised alkynes
Polarised alkyne
pyrimidine MA
[CH,$(C(#C)[#6])]#C[$(c1ncccn1),
$(c1cncnc1),$(c1ncncc1)]
Polarised alkynes
Polarised alkyne
triazines MA
[CH,$(C(#C)[#6])]#C[$(c1ncncn1),
$(c1nncnc1),$(c1nnccn1),$(c1cnncn1)]
Polarised alkynes
Quinones MA [$(C1(=O)[#6]=,:[#6]C(=O)[CH]=C1),
$(C1(=O)C(=O)[#6]=,:[#6][CH]=C1)]
Quinones and
quinone type
chemicals
Quinone methides MA [$(C1=CC(=O)[#6]=,:[#6]C1(=[CH][CX4])),
$(C1(=[CH][CX4])C(=O)[#6]=,:[#6]C=C1)]
Quinones and
quinone type
chemicals
Quinone imines MA [$(C1(=O)[#6]=,:[#6][$(C=[NH]),$(C=N[CX4])]
[CH]=C1),$(C1(=O)[$(C=[NH]),$(C=N[CX4])]
[#6]=,:[#6][CH]=C1),$(C1(=O)[$(C=[NH]),
$(C=N[CX4])]C=[CH][#6]=,:[#6]1)]
Quinones and
quinone type
chemicals
Quinone diimines MA [$([CH]1=C[$(C=[NH]),$(C=N[CX4])][#6]=,:[#6]
[$(C=[NH]),$(C=N[CX4])]1),$([CH]1=C[$(C=[NH]),
$(C=N[CX4])][$(C=[NH]),$(C=N[CX4])][#6]=,:[#6]1)]
Quinones and
quinone type
chemicals
Pyranones MA [$([cH]1cc(=[O,NH])cc[o,n]1),
$([cH]1cc(=[O,NH])[o,n]cc1),
$(c1cc(=[O,NH])[o,n][cH]c1)]
Quinones and
quinone type
chemicals
Acid imides MA O=C1[NH,$(N(C=O)(C=O)[#6])]C(=O)
[CH,$(C(C=O)(=C)[#6])]=[CH]1
Acid imides
Hydroquinones MA [$(c1([OH,$(O[CH3])])c[cH]c([OH,$(O[CH3])])cc1),
$(c1([OH,$(O[CH3])])c([OH,$(O[CH3])])cc[cH]c1)]
Pre quinones and
quinone type
chemicals
Alkyl phenols MA [$(c1([OH])ccc([CH3,$([CH2][CX4])])cc1),
$(c1([OH])c([CH3,$([CH2]
[CX4])])cccc1)]
Pre quinones and
quinone type
chemicals
Aminophenols MA [$(c1([OH])c[cH]c([NH2])cc1),
$(c1([OH])c([NH2])cc[cH]c1)]
Pre quinones and
quinone type
chemicals
Benzenediamines MA [$(c1([NH2])c[cH]c([NH2])cc1),
$(c1([NH2])c([NH2])cc[cH]c1)]
Pre quinones and
quinone type
chemicals
page 5 / 12
© EURL ECVAM DB-ALM: Method Summary
SEURAT-1 TOOLS & METHODS CATALOGUE PAGE 203
Pre-polarised alkenes
aldehdyes (allyl
alcohols) MA
[CH2,$([CH](=C)[#6])]=[CH,
$(C(=C)([CH2][OH])[#6])][CH2][OH]
Pre polarised
alkenes
Pre polarised alkynes
aldehdyes (propargyl
alcohols) MA
[CH,$(C(#C)[#6])]#C[CH2][OH] Pre polarised
alkynes
Mono aldehydes SB [CH2,$([CH](=O)[CX4]),
$([CH](=O)c1a(*)caaa1),
$([CH](=O)c1a(*)aaa1)]=O
Direct acting
Schiff base
formers
Disubstituted polarised
aldehydes SB
[$(C(=C)([#6])[#6]);
!$(C(=C)([#6])C=[CH2,CH])]=C[CH]=O
Direct acting
Schiff base
formers
1,2-Dicarbonyl SB [CH,$(C(=O)(C=O)[CX4]),
$(C(=O)(C=O)c1a(*)aaaa1),
$(C(=O)(C=O)c1a(*)aaa1)](=O)[CH,$(C(=O)(C=O)[#6]);
!$(C(=O)(C=O)C=[CH2,CH]);!$(C(=O)(C=O)C#C)]=O
Direct acting
Schiff base
formers
1,3-Dicarbonyl SB [CH,$(C(=O)([CX4]C=O)[CX4]),
$(C(=O)([CX4]C=O)c1a(*)aaaa1),
$(C(=O)([CX4]C=O)c1a(*)aaa1)]
(=O)[CX4][CH,$(C(=O)([CX4]C=O)
[#6]);!$(C(=O)([CX4]C=O)C=[CH2,CH]);
!$(C(=O)([CX4]C=O)C#C)]=O
Direct acting
Schiff base
formers
Ethylenediamines SB [$([NH2,$([NH]([CH2])[CX4])]
[CH2][CH2][NH2]),$([NH]1[CH2]
[CH2][NH][CH2][CH2]1)]
Pro Schiff base
formers (glyoxal)
Ethanolamines SB [$([NH2,$([NH]([CH2])[CX4])]
[CH2][CH2][OH]),$([NH]1[CH2]
[CH2]O[CH2][CH2]1)]
Pro Schiff base
formers (glyoxal)
Pro disubstituted
polarised aldehydes
(disubstituted allyl
alcohols) SB
C([#6])([#6])=[CH,$(C(=C)
([CH2][OH])[#6])][CH2][OH]
Pro Schiff base
formers (mono
aldehydes)
Epoxides SN2 C1OC1 Epoxides and
related
Aziridines SN2 C1[NX3]C1 Epoxides and
related
Sulfaranes SN2 C1[SX2]C1 Epoxides and
related
Epoxypropane SN2 C1[CH2,CH]OC1 Epoxides and
related
Epithiopropane SN2 C1[CH2,CH][SX2]C1 Epoxides and
related
Lactones SN2 C1CC(=O)O1 Ring opening SN2
reaction
Nitrosoureas (nitrogen)
SN2
[NX3]C(=O)[$([NH](C=O)[NX2]=O),
$(N(C=O)([#6])[NX2]=O)]
SN2 reaction at a
nitrogen atom
Nitrosoguanidine
(nitrogen) SN2
[NX3]C(=[NH])[$([NH](C=[NH])[NX2]=O),
$(N(C=[NH])([#6])[NX2]=O)]
SN2 reaction at a
nitrogen atom
N-acetoxy N acetyl
phenyl SN2
[a][NX3](O[$([CH](O)=O),$(C(=O)(O)
[#6])])[$([CH](N)=O),$(C(=O)(N)[#6])]
SN2 reaction at a
nitrogen atom
N-acyloxy N
alkoxyamides SN2
[#6]O[NX3](O[$([CH](O)=O),
$(C(=O)(O)[#6])])[$([CH](N)=O),
$(C(=O)(N)[#6])]
SN2 reaction at a
nitrogen atom
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Isothiazol-3-ones
(sulphur) SN2
[cH,$(c(c)([sX2])[#6])]1[cH,$(c(c)(c=O)
[#6])]c(=O)[nH,$(n(c=O)([sX2])[#6])][sX2]1
Isothiazolin-3-ones
(sulphur) SN2
[CH2,$([CH](C)([SX2])[#6])]1[CH2,
$([CH](C)(C=O)[#6])]C(=O)
[NH,$(N(C=O)([SX2])[#6])][SX2]1
SN2 reaction at a
sulphur atom
aromatic sulphonic
acids SN2
[a][SX3](=O)[OH] SN2 reaction at a
sulphur atom
Thiocyanates SN2 [#6][SX2]C#N SN2 reaction at a
sulphur atom
Thiols SN2 [#6][SH] SN2 reaction at a
sulphur atom
Disulfides SN2 [#6][SX2][SX2][#6] SN2 reaction at a
sulphur atom
Thiosulfonates SN2 [#6][SX2][SX3](=O)[#6] SN2 reaction at a
sulphur atom
Sulfoxides of disulfides
SN2
[#6][SX2][SX4](=O)(=O)[#6] SN2 reaction at a
sulphur atom
Sulfenyl halides SN2 [#6][SX2][F,Cl,Br,I] SN2 reaction at a
sulphur atom
N-chloro
sulphonamides SN2
[#6][SX4](=O)(=O)[NH]Cl SN2 reaction at a
halo atom
N-haloimides SN2 [CH,$(C(=O)(N)[#6])](=O)[NX3]
([F,Cl,Br,I])[CH,$(C(=O)(N)[#6])]=O
SN2 reaction at a
halo atom
Polarised alkenes with a
halogen leaving group
SN2
C=[CH][F,Cl,Br,I] SN2 reaction at a
sp2 carbon
Polarised alkenes with a
sulfonate leaving group
SN2
C=[CH]OS(=O)(=O)[#6] SN2 reaction at a
sp2 carbon
Polarised alkenes with a
sulfate leaving group SN2
C=[CH]OS(=O)(=O)O[#6] SN2 reaction at a
sp2 carbon
Polarised alkenes with a
phosphonate leaving
group S N2
C=[CH]OP(=[O,SX])(O[#6])[#6] SN2 reaction at a
sp2 carbon
Polarised alkenes with a
phosphate leaving group
SN2
C=[CH]OP(=[O,SX])(O[#6])O[#6] SN2 reaction at a
sp2 carbon
Mustards SN2 [NX3,SX2][CH2,$([CH]([NX3,SX2])
([CX4])[CX4])][CH2,$([CH]([CX4])
([Cl,Br,I])[CX4])][Cl,Br,I]
Episulfonium ion
formation
1,2-Dihaloalkanes SN2 [Cl,Br,I][CH2,$([CH]([Cl,Br,I])([CX4])
[CX4])][CH2,$([CH]([Cl,Br,I])([CX4])[CX4])][Cl,Br,I]
Episulfonium ion
formation
Aliphatic halide SN2 [CH3,$([CH2]([F,Cl,Br,I])[#6]),
$([CH]([F,Br,Cl,I])([#6])[#6]);
!$([CH2,CH]C=O);!$([CH2,CH][CX4][NX3,SX2]);
!$([CH2,CH][CX4][F,Cl,Br,I])][F,Cl,Br,I]
SN2 at an sp3
carbon atom
Sulfates SN2 [#6]OS(=O)(=O)O[CH3,$([CH2](O)[#6]),
$([CH](O)([#6])[#6])]
SN2 at an sp3
carbon atom
Sulfonates SN2 [#6]S(=O)(=O)O[CH3,$([CH2](O)[#6]),
$([CH](O)([#6])[#6])]
SN2 at an sp3
carbon atom
Allyl acetates and
related SN2
[#6]C(=[O,SX1])[O,SX2][CH2,
$([CH]([O,SX2])[#6])][c,CX3,CX2]
SN2 at an sp3
carbon atom
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Nitrosoureas (carbon)
SN2
[NH2,$([NH](C=[O,NH])[#6]),
$(N(C=[O,NH])([#6])[#6])]C(=[O,NH])
[NX3]([NX2]=O)[CH3,$([CH2](N)[#6]),
$([CH](N)([#6])[#6])]
SN2 at an sp3
carbon atom
α-Halocarbonyls SN2 [$([CH]=[O,SX1]),$(C([#6])=[O,SX1])]
[CH2,$([CH](C=[O,SX1])[#6])][F,Cl,Br,I]
SN2 at an sp3
carbon atom
Phopshates (inc
thiophosphates) SN2
[#6][O,SX2]P(=[O,SX1])([O,SX2][#6])
[O,SX2][CH3,$([CH2](O)[#6]),$([CH](O)([#6])[#6])]
SN2 at an sp3
carbon atom
Phosphonates (inc
thiophosphonates) SN2
[#6][O,SX2]P(=[O,SX1])([#6])[O,SX2]
[CH3,$([CH2](O)[#6]),$([CH](O)([#6])[#6])]
SN2 at an sp3
carbon atom
α-Haloethers SN2 [CX4]O[CH2,$([CH](O)([F,Cl,Br,I])[#6])][F,Cl,Br,I] SN2 at an sp3
carbon atom
β-Haloethers SN2 [CX4]O[CH2,$([CH](O)([CX4])[CX4]),
$(C(O)([CX4])([CX4])[CX4])][CH2,
$([CH](O)([F,Cl,Br,I])[#6])][F,Cl,Br,I]
SN2 at an sp3
carbon atom
Alkyl diazo SN2 [CH3,$([CH2](N=N)[#6]),$([CH](N=N)
([#6])[#6])][NX2]=[NH,$(N(=N)[#6])]
SN2 at an sp3
carbon atom
α-Haloalkenes SN2 [CH2,$([CH](=C)[#6]),$(C(=C)([#6])
[#6])]=[CH,$(C(=C)[#6])][$([CH2](C=C)
[F,Cl,Br,I,$(C#N),$(OS(=O)(=O)O[#6]),
$(OS(=O)(=O)[#6])]),$([CH](C=C)([#6])
[F,Cl,Br,I,$(C#N),$(OS(=O)(=O)O[#6]),
$(OS(=O)(=O)[#6])])]
SN2 at an sp3
carbon atom
α Haloalkynes SN2 [CH,$(C(#C)[#6])]#C[$([CH2](C#C)
[F,Cl,Br,I,$(C#N),$(OS(=O)(=O)O[#6]),
$(OS(=O)(=O)[#6])]),$([CH](C#C)([#6])
[F,Cl,Br,I,$(C#N),$(OS(=O)(=O)O[#6]),$(OS(=O)(=O)[#6])])]
SN2 at an sp3
carbon atom
α-Halobenzyls SN2 [c][$([CH2]([c])[F,Cl,Br,I,$(C#N),
$(OS(=O)(=O)O[#6]),$(OS(=O)(=O)[#6])]),
$([CH]([a])([#6])[F,Cl,Br,I,$(C#N),
$(OS(=O)(=O)O[#6]),$(OS(=O)(=O)[#6])])]
SN2 at an sp3
carbon atom
Activated benzenes SNAr [$(c1([F,Cl,Br,$(OC(F)(F)F),
$(C#N)])c([N+](=O)[O-])cc([N+](=O)[O-])cc1),$(c1(F)c([N+]
(=O)[O-])cc([$([CH]=O),$(C(=O)[CH3]),$(C(F)
(F)F)])cc1),$(c1(Cl)c([N+]
(=O)[O-])cc([CH]=O)cc1),$(c1(F)c([$(C#N),$([CH]=O)])cc([N+]
(=O)[O-])cc1),$(c1([$(OC(F)(F)F),Br,$(C#N)])c([N+]
(=O)[O-])cc([CH]=O)cc1),$(c1([F,Cl,Br,$(OC(F)
(F)F),$(C#N)])cc([N+](=O)[O-])c([N+]
(=O)[O-])cc1),$(c1([F,Cl,Br,$(OC(F)(F)F),$(C#N)])c([N+]
(=O)[O-])cccc1([N+](=O)[O-]))]
Activated
benzenes
Activated poly
fluorobenzenes SNAr
[$(c1([$([N+](=O)[O-]),$([CH]=O),$(C#N),$(C(=O)
[CH3])])c(F)c(F)c(F)c(F)c1(F)),$(c1([$([N+]
(=O)[O-]),$([CH]=O),$(C#N)])c(F)c(F)c(F)c(F)c1),$(c1([$([N+]
(=O)[O-]),$([CH]=O),$(C#N)])c(F)c(F)c(F)cc1F),$(c1([$([N+]
(=O)[O-]),$([CH]=O),$(C#N)])c(F)c(F)cc(F)c1F),$(c1([N+]
(=O)[O-])c(F)c(F)c(F)cc1),$(c1([N+]
(=O)[O-])c(F)c(F)cc(F)c1),$(c1([N+]
(=O)[O-])c(F)c(F)ccc1F),$(c1([N+](=O)[O-])c(F)cc(F)cc1F)]
Activated poly
fluorobenzenes
Activated pyridines SNAr [$(c1([F,Cl,Br,$(C#N),$(OC(F)
(F)F)])ncc([$(N(=O)=O),$(C#N),$([CH]=O),$(C(=O)
[CH3])])cc1),$(c1([F,Cl,Br,$(C#N),$(OC(F)
(F)F)])ncccc1[$(N(=O)=O),$(C#N),$([CH]=O),$(C(=O)
[CH3])]),$(c1([F,Cl,Br,$(C#N),$(OC(F)
(F)F)])ccncc1[$(N(=O)=O),$(C#N),
$([CH]=O),$(C(=O)[CH3])])]
Activated
pyridines
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Procedure Description
Biological Endpoint and Measurement:
This method is an in silico model, which provides information on the following MIE, biologically
relevant, for several toxicological endpoints:
Covalent binding to proteins
Endpoint Value:
Qualitative: Structural alert
Experimental System:
In silico profiler for covalent protein binding
3. Method Performance
Robustness of the Method
General performance measures:
The applicability domain of the structural alerts obtained with the profilers was investigated for different
groups of chemicals using the glutathione (GSH) reactivity assay and the Tetrahymena pyriformis growth
inhibition assay:
Potential pre-electrophile polyphenolics were evaluated by Bajot et al. (2010)
Epoxides, lactones, nitrosos, nitros, aldehydes, ketones and ring-strained hydrocarbons were
evaluated by Nelms et al. (2013)
Cyclic compounds as potential Michael acceptor were evaluated by Rodriguez-Sanchez et al. (2013)
Sulfur-containing organic chemicals were evaluated by Richarz et al. (2014)
Each of the studies showed significant agreement between the profilers and experimental data, however
several discrepancies were observed, which were explained once additional mechanistic information
was taken into account. Further refinement of the profiler was recommended for each case,
underpinning the importance of using extensive experimental data to further improve the accuracy of the
alerts.
4. Discussion
The formation of a covalent adduct between a reactive pair of exogenous chemical (electrophile) and
biological protein (nucleophile) is one of the fundamental steps for several toxicological endpoints such
as hepatotoxicity (liver fibrosis), skin sensitisation, respiratory sensitisation or aquatic toxicity. The
mechanistic importance of this chemical reaction makes the mechanistic alert approach the natural
choice for developing the profiler for covalent protein binding. Moreover the mechanistic domain
overlap between corresponding structural alerts in the literature compilations has been assessed. This
analysis ensured that for a given structural alert the maximum mechanistic information (and thus
domain) was extracted.
Unlike covalent DNA binding, the covalent protein binding is not distinctly linked to one specific area of
toxicology. Therefore, no established experimental toxicological dataset exists that could be readily used
in the verification of structural alerts and for applicability domain definition. The interpretation of the
alerts will largely depend on the endpoint for which the chemical is being considered and corroborating
information available for that endpoint. The alerts, however, can be verified using in chemico data, e.g.
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reactivity with GSH.
The use of such mechanistic chemistry based alerts enables transparent category formation where all
category members act via the same mechanism of action (OECD 2007; ECHA 2008). Moreover, such
alerts, accompanied by the detailed documentation of the chemistry relevant to covalent protein
binding, make the chemical category methodology acceptable for safety assessment without animal
testing.
5. Contact Details
Dr Steve Enoch
School of Pharmacy and Biomolecular Sciences
Liverpool John Moores University
Corresponding author, Method developer / user
Byrom Street
Liverpool L3 3AF
email: s.j.enoch@ljmu.ac.uk
telephone: +44(0)151 231 2164
Ver n° Date Name Type of change
1 12 November 2015 Dr Steve Enoch Data sheet created
6. Abbreviations & Definitions
AC Acylation
AOP Adverse Outcome Pathway
COSMOS EU Integrated Project: COSMOS developed an integrated suite of
computational tools to predict the effects of long-term exposure to chemicals in
humans based on in silico calculation and estimation techniques.
Website: http://www.cosmostox.eu .
ITS Integrated Testing Strategy
IATA Integrated Approach to Testing and Assessment
KNIME KoNstanz Information MinEr
MA Michael Addition
MIE Molecular Initiating Event
SB Schiff Base formation
SEURAT Safety Evaluation Ultimately Replacing Animal Testing
SMARTS SMiles ARbitrary Target Specification
SMILES Simplified Molecular-Input Line-Entry System
SN2 Bimolecular Aliphatic Nucleophilic Substitution
SNAr Aromatic Nucleophilic Substitution
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DB-ALM Method summary n° 182 : In silico skin permeability estimation
Systemic Toxicity
The purpose of this in silico workflow is to estimate the skin permeability coefficient (kp) for an organic
compound, based on calculated physico-chemical descriptors.
1. General Information
Corresponding author(s):
Prof. Mark Cronin, Liverpool John Moores University 
Date of data sheet creation: 28 October 2015
Last version number: 1
Last update: 28 October 2015
Proprietary and/or Confidentiality Issues:
None. The model is publicly available.
Status
Development
Development completed. Work carried out at Liverpool John
Moores University with support from the FP7 COSMOS Project
(Integrated In Silico Models for the Prediction of Human Repeated
Dose Toxicity of Cosmetics to Optimise Safety), within the
SEURAT-1 Research Initiative (Safety Evaluation Ultimately
Replacing Animal Testing 1) cluster (2011-2015). More information
on the COSMOS project is available on its dedicated website:
http://www.cosmostox.eu
The in silico model has been coded into a KNIME (http://www.knime.org/) automated workflow as part
of the COSMOS project. The web version of the KNIME workflow can be executed via a web browser. It is
available through the COSMOS KNIME WebPortal:
http://knimewebportal.cosmostox.eu
More information is available via COSMOS Space: 
http://cosmosspace.cosmostox.eu
A tutorial is available at:
https://www.youtube.com/watch?v=DtNdwtKuY74
2. Method Definition
Purpose of the Method
TYPE OF TESTING : Screening
Context of use
Dermal absorption is of great importance for safety evaluation of chemicals taken up via dermal route of
exposure regarding the availability of the substance in the organism. Experimental testing of the
multitude of chemical substances for properties such as skin absorption is laborious and expensive, even
with the use of in vitro methods e.g. such as described in the DB-ALM Topic Summary "Percutaneous
Absorption" (DB-ALM, 2010). Therefore, reliable models for a theoretical prediction of dermal
absorption have been sought (Cronin, 2006; Russel and Guy, 2009).
An open-access skin permeability estimation automated model is presented to support risk assessment
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An open-access skin permeability estimation automated model is presented to support risk assessment
and safety evaluation regarding dermal absorption potential. The purpose of this model is to obtain skin
permeability coefficient estimations with an easy and fast but also robust method.
The model was built to support safety evaluation of cosmetics-related substances. The robustness of the
model by incorporating statistical data quality is beneficial for the chemical diversity of cosmetic
ingredients. Furthermore the model might support evaluations in the context of REACH (EU, 2006),
medical devices etc. Principally the model may support other fields as well, e.g. dermal drug delivery, for
example within a consensus approach with known data.
Scientific Principle of the Method
Substances with high octanol/water partition coefficients (a common measure of lipophilicity) and low
molecular volume are associated with greater skin permeability coefficient (kp) and hence greater
dermal absorption.
Many models, most notably the Quantitative Structure-Property Relationship (QSPR) of Potts and Guy
(1992), have been created to predict skin permeability coefficients (kp) or flux (J) of dermally applied
substances.
Similar computational models, i.e. correlating physio-chemical properties with membrane permeability,
are used widely in different scientific fields. These models are developed and used in the investigation
and assessment of pharmaco- and toxicokinetics. They are particularly relevant for oral and dermal drug
development. However, they are also valuable contributions to the safety evaluation of cosmetic
ingredients.
Model description
The Potts and Guy QSPR (1992) to predict skin permeability was modified by incorporating a larger
dataset and a statistical tool to assess data quality (confidence score).
The compilation of skin permeability coefficient values from the literature (see below) resulted in 343
different kp values being compiled for 226 compounds. 55 of these compounds have more than a single
kp value, hence the arithmetic means and the confidence scores (CS) were calculated. Due to the high
variability in most skin permeability datasets, a statistical data quality tool was used (Steinmetz et al.,
2014). The assigned statistical data quality was used to support weighted linear regression. Hence the
QSPR equation is based on CS-weighted multivariate linear regression.
Physico-chemical properties, i.e. molecular volume (MV) and lipophilicity (XLogP) were calculated from
molecular structures, expressed as SMILES (Simplified Molecular-Input Line-Entry System) strings, with
CDK in KNIME 2.9.1. R Studio 0.98.501 was used to model kp with MV and XLogP as descriptors and CS
as weights. The results of the multivariate linear regression is expressed in Equation 1 below.
The model was implemented as KNIME workflow web version, as an easy-to-use user-interface allowing
to execute the model via a web browser. It is available through the COSMOS KNIME WebPortal:
http://knimewebportal.cosmostox.eu 
Dataset
Data was collected from the following literature:
ten Berge (2014)
Chen et al. (2013)
Moss and Cronin (2002)
Chauhan and Shakya (2010).
Model equation
The equation (Eq.1) used within the skin permeability estimation KNIME workflow is as follows:
Log kp = -2.33 + 0.513 XLogP - 0.00611 MV (Eq. 1)
n = 226, SXLogP = 0.035, tXLogP = 14.8, SMV = 0.000685, tMV = -8.91, F = 113.03, R2adj = 0.499
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Procedure Description
Biological Endpoint and Measurement:
This method is an in silico model, which provides information on the following, biologically relevant,
endpoint:
Dermal absorption
Endpoint Value:
Human in vitro skin permeability coefficient (kp)
Experimental System:
In silico workflow to estimate the human skin permeability coefficient
3. Method Performance
Robustness of the Method
General performance measures:
The QSPR model was validated with 10-fold cross validation employing confidence score (CS)-adjusted
root-mean-square error (RMSE) (Eq.2), which led to a value of 0.79 ± 0.25. Further details on method
validation can be found in Steinmetz et al. (2015).
(Eq.2)
Test Compounds
Applicability:
The model is only applicable for simple organic molecules, i.e. no mixtures, salts or polymers are
supported.
4. Discussion
The robust estimation of human in vitro kp values may support regulatory decision making. It is
however not recommended to use this value as single rationale/argument in safety evaluations based on
dermal absorption.
Ethical issues and considerations for 3R’s impact 
There is an indirect positive impact on 3Rs due to the development of a new methodology (implementing
statistical data quality into QSAR/QSPR modelling). Furthermore this model supports integrated testing
strategies and non-testing approaches.
 Strengths and limitations of the method
It must be emphasised that the modelling approach used here is rather simple and hence can be
repeated with appropriate data and descriptors. Performance has been compromised by using freeware
tools from CDK within KNIME. A very similar model with slightly better performance using different
descriptors has been published in Steinmetz et al. (2015).
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Since the predictivity of the model is only moderate, the model should be used for support or estimation
only. However, based on its transparency and implementation of data quality, the model can be
regarded as more robust than many overpredicted models (for example due to defined chemical
categories). EPI Suite’s Dermwin, just to mention one of many models, predicts kp values as well. For
well-studied chemical classes, i.e. where many kp data is available, models such as Dermwin are likely to
perform better. However, for new chemical classes, the described model is assumed to perform better,
based on its robustness over different chemical classes with a pure focus on physico-chemical properties.
Potential for future development
The implementation of new data (if available) is recommended. Building models with other descriptors
and/or only specific chemical compounds is possible. If such models are desired, please refer to current
QSAR guidelines.
5. Contact Details
Dr Fabian Steinmetz
School of Pharmacy and Biomolecular Sciences
Liverpool John Moores University
Method developer / user
Byrom Street
Liverpool L3 3AF
Prof. Mark Cronin
Professor of Predictive Toxicology
School of Pharmacy and Biomolecular Sciences
Liverpool John Moores University
Corresponding author
Byrom Street
Liverpool L3 3AF
email: m.t.cronin@ljmu.ac.uk
telephone: + 44 151 231 2402
fax: + 44 151 231 2170
last contact update: 11 May 2016
Ver n° Date Name Type of change
1 28 October 2015 Prof. Mark Cronin Datasheet created
6. Abbreviations & Definitions
CDK: Chemical Development Kit
COSMOS: EU Integrated Project: COSMOS developed an integrated suite of computational tools to
predict the effects of long-term exposure to chemicals in humans based on in silico calculation and
estimation techniques. 
Website: http://www.cosmostox.eu
CS: Confidence Score
MV: Molecular Volume (in Å3)
QSAR: Quantitative Structure-Activity Relationship
QSPR: Quantitative Structure-Property/-Permeability Relationship
RMSE: Root-Mean-Square Error
SEURAT-1: Safety Evaluation Ultimately Replacing Animal Testing
SMILES: Simplified Molecule Input Line Entry System
XLogP: CDK’s calculated octanol/water partition coefficient
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